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Salomon saith: There is no new thing upon the earth.  
So that as Plato had an imagination, that all knowledge was but remembrance;  
so Salomon giveth his sentence, that all novelty is but oblivion.  
Francis Bacon, Essays, LVIII 
 
 
The certainty that everything has already been written annuls us,  
or renders us phantasmal.   
Jorge Luis Borges, The Library of Babel 
 
 
SEPTIMUS: We shed as we pick up, like travellers who must carry everything in their 
arms, and what we let fall will be picked up by those behind. The procession is very long 
and life is very short. We die on the march. But there is nothing outside the march so 
nothing can be lost to it. The missing plays of Sophocles will turn up piece by piece, or be 
written again in another language. Ancient cures for disease will reveal themselves once 
more. Mathematical discoveries glimpsed and lost to view will have their time again. You 
do not suppose, my lady, that if all of Archimedes had been hiding in the great library of 
Alexandria, we would be at a loss for a corkscrew?  
Tom Stoppard, Arcadia 
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ABSTRACT 
Synthetic biology promises to transform organic synthesis by enabling artificial catalysis in 
living cells. I start by reviewing the state of the art in this young field and recognizing that 
new approaches are required for designing enzymes that catalyze nonnatural reactions, in 
order to expand the scope of biocatalytic transformations. Carbene and nitrene transfers to 
C=C and C-H bonds are reactions of tremendous synthetic utility that lack biological 
counterparts. I show that various heme proteins, including cytochrome P450BM3, will 
catalyze promiscuous levels of olefin cyclopropanation when provided with the appropriate 
synthetic reagents (e.g., diazoesters and styrene). Only a few amino acid substitutions are 
required to install synthetically useful levels of stereoselective cyclopropanation activity in 
P450BM3. Understanding that the ferrous-heme is the active species for catalysis and that 
the artificial reagents are unable to induce a spin-shift-dependent increase in the redox 
potential of the ferric P450, I design a high-potential serine-heme ligated P450 (P411) that 
can efficiently catalyze cyclopropanation using NAD(P)H. Intact E. coli whole-cells 
expressing P411 are highly efficient asymmetric catalysts for olefin cyclopropanation. I 
also show that engineered P450s can catalyze intramolecular amination of benzylic C-H 
bonds from arylsulfonyl azides. Finally, I review other examples of where synthetic 
reagents have been used to drive the evolution of novel enzymatic activity in the 
environment and in the laboratory. I invoke preadaptation to explain these observations and 
propose that other man-invented reactions may also be transferrable to natural enzymes by 
using a mechanism-based approach for choosing the enzymes and the reagents. Overall, 
this work shows that existing enzymes can be readily adapted for catalysis of synthetically 
important reactions not previously observed in nature.  
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NOMENCLATURE 
Bioinformatics: the study of methods for storing, retrieving, and analyzing biological data 
such as DNA, RNA, and protein sequence, structure, function, pathways, and genetic 
interactions 
Directed evolution: a systematic algorithm of mutation and selection for improvements in 
the properties of a biological entity, such as an enzyme, a metabolic pathway, or a whole 
organism 
Heterologous protein expression: expression of a gene coding for a protein not natively 
produced by the production host  
Metabolic engineering: genetic alteration of metabolism to produce molecules of interest 
Metagenomics: the study of genetic material recovered directly from environmental 
samples 
Operon: a functioning unit of genomic DNA containing a cluster of genes under the 
control of a single promoter   
Recombinant (metabolic) pathway: an artificial (metabolic) pathway created by 
combining one or more enzymes foreign to the host organism 
Synthetic biology: forward engineering of genetic material (genes, promoters, operons, 
genomes) encoding an artificial function  
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ABBREVIATIONS 
BM3 Cytochrome P450 BM3 from Bacillus megaterium (CYP102A1) 
DMSO Dimethyl sulfoxide 
KM Michaelis-Menten constant 
kcat Catalytic rate constant 
LB Luria-Bertani medium 
M9Y M9 minimal medium with 1.5% yeast extract 
NADH Reduced nicotinamide adenine dinucleotide 
NADPH Reduced nicotinamide adenine dinucleotide phosphate 
P411 Serine-heme ligated cytochrome P450s 
P450 Cysteine-heme ligated cytochrome P450s 
TB Terrific-broth medium 
TTN Total turnover number 
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Abstract. The development of new catalytic methods to functionalize carbon-hydrogen 
(C−H) bonds continues to progress at a rapid pace due to the significant economic and 
environmental benefits of these transformations over traditional synthetic methods. In 
nature, enzymes catalyze regio- and stereoselective C−H bond functionalization using 
transformations ranging from hydroxylation to hydroalkylation under ambient reaction 
conditions. The efficiency of these enzymes relative to analogous chemical processes has 
led to their increased use as biocatalysts in preparative and industrial applications. 
Furthermore, unlike small molecule catalysts, enzymes can be systematically optimized 
via directed evolution for a particular application and can be expressed in vivo to augment 
the biosynthetic capability of living organisms. While a variety of technical challenges 
must still be overcome for practical application of many enzymes for C−H bond 
functionalization, continued research on natural enzymes and on novel artificial 
metalloenzymes will lead to improved synthetic processes for efficient synthesis of 
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complex molecules. In this critical review, we discuss the most prevalent mechanistic 
strategies used by enzymes to functionalize nonacidic C−H bonds, the application and 
evolution of these enzymes for chemical synthesis, and a number of potential 
biosynthetic capabilities uniquely enabled by these powerful catalysts. 
 
M. M. Chen, P. S. Coelho, F. H. Arnold, Utilizing terminal oxidants to achieve P450-
catalyzed oxidation of methane. Advanced Synthesis & Catalysis 354, 964–968 (2012). 
Abstract. Terminal oxidant-supported P450 reactions alleviate the need for substrate 
binding to initiate catalysis by chemically generating “compound I.” This allows 
investigation of the innate substrate range of the enzyme active site. Using 
iodosylbenzene as the oxidant, CYP153A6, a medium-chain terminal alkane hydroxylase, 
exhibits methanol formation in the presence of methane demonstrating that P450-
mediated methane hydroxylation is possible. 
Comment. Hydroxylations using iodosylbene are isoelectronic to C−H aminations using 
sulfonylazides and C=C cyclopropanations using diazoesters. An important difference is 
that iodozylbenzene can react directly with the resting state ferric form of cytochrome 
P450, whereas the N and C transfer reagents only react with the ferrous form of the 
enzyme (as shown in chapters 2, 3 and 4). This difference in reactivity requires that P450 
aminations and cyclopropanations be conducted in the presence of a reductant [e.g., 
dithionite or NAD(P)H]. 
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C h a p t e r  1  
SYNTHETIC BIOLOGY APPROACHES FOR ORGANIC SYNTHESIS 
 
 
 
 
“Organic chemistry just now is enough to drive one mad.  
It gives me the impression of a primeval forest  
full of the most remarkable things,  
a monstrous and boundless thicket,  
with no way of escape,  
into which one may well dread to enter.”  
– Friedrich Wöhler (1835) 
 
 
Synthetic biology is to the 21st century chemist  
what organic chemistry was to the 19th century inorganic chemist 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published as P. S. Coelho, J. C. Lewis, F. H. Arnold “Synthetic biology 
approaches for organic synthesis” in Comprehensive Organic Synthesis II, G. Molander, 
P. Knochel, eds. (Oxford, UK: Elsevier Ltd, 2014)    
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Key Words. Synthetic Biology | Enzyme Engineering | Directed Evolution | Metabolic 
Engineering | Microbial Cell Factories | Metagenomics | Biocatalysis  
 
Abstract. Advances in DNA technologies, metagenomics, and bioinformatics have 
enabled the use of biological systems (i.e., enzymes, metabolic pathways, and cells) for 
chemical synthesis and production of chemicals from renewable resources such as plant 
sugars. We review these basic technologies, illustrate their connection to synthetic 
chemistry, and provide examples of enzyme and metabolic engineering for synthesis of 
organic molecules with high efficiency and selectivity. Finally, we anticipate the 
potential for increased integration of engineered enzymes in metabolic pathways as well 
as the creation of enzymes with completely novel activities to expand our biosynthetic 
capabilities.  
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1. Introduction 
  
 As the volumes of this collection illustrate, synthetic chemists have devised a 
powerful arsenal of chemical reactions—one that is often, if colloquially, claimed to 
enable the synthesis of any desired molecule given enough time.  This factor, time, along 
with measures of material and energy economy, largely determines the efficiency, and 
thus utility, of chemical syntheses. Developing new catalysts, reactions, and functional 
molecules remains a time-intensive endeavor, and the costs of energy and material inputs 
along with waste from syntheses continue to increase as the global population swells and 
resources become more limited.  Barring the removal of these pressures, advances in our 
ability to assemble molecules are essential. 
 Systematic and highly efficient approaches to the construction of molecular 
complexity have evolved in response to analogous supply and demand challenges over 
four billions years of natural selection.  The emergence of myriad biocatalysts ultimately 
enabled the generation of the seemingly infinite array of natural products that inspire 
chemists (and provide immense human benefits).  The efficiency of these evolved 
catalytic systems is typically far greater than any synthetic systems we have generated in 
the short 200 years of modern chemistry.  This has driven extensive efforts to mimic 
these systems for synthetic applications—but stripping systems down to their simplest 
forms rarely replicates the levels of efficiency and selectivity that are hallmarks of 
biology. 
 More recently, increased understanding of biology has allowed researchers to begin 
to harness the capabilities of biological catalysts, including enormous catalyst diversity, 
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molecular recognition, selection, and evolution, for chemical synthesis.  Furthermore, 
we are no longer limited to whole-cell or enzyme catalysts isolated from nature or 
cultured in the laboratory, but can readily modify these systems to suit our purposes.  
Efforts toward this end have taken many names over the course of their development, but 
are now encompassed by the umbrella term “synthetic biology”. This review summarizes 
some key technologies and examples from this field, with the goal of illustrating how 
synthetic biology is already a powerful tool that can be used alongside and, increasingly, 
in place of conventional synthetic methods.  
 
2. Enabling Technologies  
2.1 DNA Sequencing and Synthesis 
 Since chemical function in biocatalysts is encoded and engineered at the DNA 
level, our ability to build systems for chemical synthesis is greatly influenced by 
technologies that enable efficient manipulation and analysis of genetic information. 
Reductions in the cost of DNA sequencing have outpaced Moore’s law (a doubling in 
microprocessor computing power every two years), especially following the transition 
from Sanger-based (dideoxy chain termination sequencing) capillary electrophoresis 
sequencing to second-generation (“massively parallel”) technologies in the mid 2000s.1 
Several competing massively parallel sequencing technologies have been brought to 
market, including but not limited to pyrosequencing (Roche/454, Basel, Switzerland), 
sequencing-by-ligation (Life Technologies, Carlsbad, USA), sequencing-by-synthesis 
(Illumina, San Diego, USA), optical single-molecule sequencing (Pacific Biosciences, 
Menlo Park, USA) and nanopore technology (Oxford Nanopore, Oxford, UK). All the 
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massively parallel technologies differ significantly from Sanger capillary sequencing in 
that they occur in a nucleotide-by-nucleotide stepwise fashion, eliminating the need for 
discrete separation and detection of Sanger sequencing reaction products on a capillary 
instrument. An entire human genome can now be sequenced in a matter of hours for less 
than US$1,000 (a dramatic reduction from US$70,000,000 in 2002).2 This revolution in 
genomics has now made whole-genome sequencing experiments routine and has enabled 
initiatives to sequence entire ecosystems. 3 
 The ability to chemically synthesize sequences of DNA greatly facilitates 
production and optimization of genetically encoded products. DNA synthesis capabilities 
have also improved at an exponential pace.4 Synthetic oligonucleotides have been 
available for 20 years, and synthetic genes built commercially from those “oligos” for the 
last 10. The ability to synthesize increasingly longer stretches of DNA is improving 
rapidly as evidenced from the following milestone “firsts”: a synthetic gene in 1979 (207 
base pairs, bp), a synthetic plasmid in 1990 (2,100 bp), and a synthetic genome in 2008 
(583,000 bp).5 Because total chemical synthesis remains limited to relatively short DNA 
molecules (<200 nucleotides), novel enzymatic methods have been developed to 
assemble synthetic oligos into the desired DNA duplex length.6 These methods can be 
broadly categorized as restriction enzyme-dependent or sequence-independent overlap 
techniques, either of which may be employed depending on the gene of interest.7 De novo 
synthesis of entire genomes requires assembly at the chromosomal scale, which can be 
achieved by in vivo recombination in yeast or Bacillus by making use of native 
recombination mechanisms.8 For example, in the 580 kb synthesis for the genome of 
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Mycoplasma genitalium, in vitro recombination was used to assemble 101 overlapping 
cassettes each 5–7 kb in length into 4 DNA fragments of 144 kb, which were 
subsequently assembled into the complete genome by in vivo recombination in yeast.5c 
De novo DNA synthesis is a key enabling technology for synthetic biology because it 
permits access to arbitrary genes and even whole biosynthetic pathways directly from 
digital information (DNA sequences from databases), thus bypassing the need to clone 
genetic material from biological samples.  
  
2.2. Metagenomics and Bioinformatics 
 Nature presents an immense collection of genes encoding biocatalysts that can be 
directly applied in chemical syntheses. The most diverse source of biocatalysts in nature 
is arguably the prokaryotes (archaea and bacteria), comprising millions of species that 
display an extraordinary diversity of niche, habitat range, and metabolisms.9 However, 
genomic information for only around 6,000 prokaryotic species is available in 
commercial culture collections, and it is estimated that 99% of all microorganisms may 
be recalcitrant to cultivation. Although it is not possible to characterize the enzymes and 
small molecules produced by uncultured bacteria using traditional microbiological 
methods, it is possible to extract microbial DNA directly from an environmental sample 
and clone this DNA into easily cultured bacteria. The utility of this approach for the 
discovery of novel biocatalysts and small molecules has been extensively reviewed.10 In 
short, these “metagenomic” libraries can be analyzed by two general strategies: (i) 
functional screening, which requires the heterologous expression of environmental DNA 
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in a model cultured host to yield a phenotype of interest, and (ii) homology screening, 
which relies on DNA sequence similarity to identify genes of interest.  
 The first approach typically uses one of three classes of functional screens: (i) 
direct readout assays, (ii) reporter genes, and (iii) complementation. Direct readout assays 
are applicable when the enzyme reaction product can be coupled to a spectroscopic signal 
or to the formation of a halo around the clone encoding the gene for the desired enzyme. 
For example, halo formation resulting from tributyrin ester hydrolysis in agar plates was 
used to screen a metagenomic library from the Antarctic desert soil, which led to the 
discovery of a cold-active alkaliphilic esterase only distantly related to reported lipases.11 
Reporter genes may be used in special cases where the enzymatic product is known to 
elicit a response from a transcription factor. For example, a benzoate-sensitive 
transcription factor controlling green fluorescent protein expression was used to identify 
11 amidases distantly related to known amidases from a wastewater sludge metagenomic 
library based on their activity on benzamide.12 Genetic complementation assays may also 
be used, with very high throughput. Genencor-DuPont screened metagenomic libraries 
for a novel glycerol dehydratase that catalyzes the bottleneck reaction in the heterologous 
fermentation pathway to make 1,3-propanediol from sugars (see section 3.6).13 The 
complementation screen was based on an E. coli strain that contained and expressed all 
genes necessary for anaerobic glycerol breakdown except the genes coding for glycerol 
dehydratase. The only way for such a strain to survive under anaerobic conditions with 
glycerol as the sole carbon and energy source is complementation by a gene that confers 
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the glycerol or diol dehydratase activity. Two out of 560,000 E. coli clones tested 
contained active dehydratases with superior properties.13  
 Novel enzymes can also be identified from their sequence similarity to enzymes 
that possess the desired activity. This homology-based screening can be carried out in 
vitro, using polymerase chain reaction (PCR) and colony hybridization, or in silico, using 
bioinformatics. This approach is particularly suited for studying the production of 
secondary metabolites in prokaryotes, since the genes involved are typically clustered on 
the chromosomes. For example, homology screening was used to identify gene clusters 
associated with the biosynthesis of natural products derived from bacteria that exist in 
symbiosis with animals, including medicinally important pederins and patellamides.14 
Ultimately, heterologous expression of the gene clusters provides a renewable source of 
these compounds, which could not otherwise be isolated in sufficient quantities to permit 
extensive biological testing.  
 “Synthetic metagenomics” is another form of sequence-based screening that 
builds on advances in gene synthesis and bioinformatics. Several free web-based 
bioinformatics tools are available for aiding experimental design (table 1). For example, 
the NCBI sequence database, which comprises both cultured and uncultured genomes, 
can be used to identify genes that are similar to a given enzyme gene. These genes can be 
optimized for expression in a particular heterologous host, chemically synthesized, 
cloned, and expressed in the selected host. This approach was used for the discovery and 
characterization of methyl halide transferases, which catalyze the transfer of a methyl 
group from the ubiquitous metabolite S-adenosyl methionine (SAM) to a halide ion.15 A 
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BLAST search of the NCBI database using known methyl chloride transferases yielded 
89 putative methyl halide transferases from sources spanning the biological kingdoms, 
with a remarkable degree of sequence diversity (average of 28% amino acid identity 
between sequences). These genes were codon-optimized, expressed in E. coli, and 
analyzed for methyl halide synthesis. More than half were active on halides (X− = Cl−, 
Br− and I−), and subsequent engineering of the most active methyl halide transferase in S. 
cerevisiae resulted in fermentative production of methyl halides from glucose with a 
volumetric productivity of 190 mg L−1 h−1.15 
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Table 1. A compilation of generally useful publicly available bioinformatic tools and 
resources 
Database URL Description 
Genbank—National Center 
for Biotechnology 
Information (NCBI) 
http://www.ncbi.nlm.nih.go
v/genbank/ 
Annotated collection of all 
publicly available DNA 
sequences 
BLAST (Basic Local 
Alignment Search Tool)—
NCBI 
http://blast.ncbi.nlm.nih.go
v/Blast.cgi 
Compares a query sequence 
with a database of 
nucleotide or amino acid 
sequences  
BRENDA Enzyme Database http://www.brenda-
enzymes.info/ 
Kinetic, thermodynamic, 
structural and reaction 
information for enzymes  
KEGG (Kyoto Encyclopedia 
of Genes and Genomes) 
http://www.genome.jp/keg
g/ 
Searchable metabolic 
pathway maps for various 
organisms 
DR Nelson Cytochrome 
P450  
http://drnelson.uthsc.edu/C
ytochromeP450.html 
Reference for over 11,500 
CYPs 
eQuilibrator http://equilibrator.weizman
n.ac.il/ 
Computation of 
thermodynamic parameters 
for enzymatic reactions and 
metabolic pathways 
Genome News Network 
(GNN)  
http://www.genomenewsne
twork.org/ 
Updates on developments in 
genomics research 
American Type Culture 
Collection (ATCC) 
http://www.atcc.org/ Source of microbial strains, 
vectors, genomic and cDNA 
libraries  
FoldX http://foldx.crg.es/ Estimates the contributions 
of mutations/interactions to 
the stabilities of proteins 
and protein complexes 
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EcoCyc (Encyclopedia of E. 
coli K-12 genes and 
metabolism)  
http://ecocyc.org/ Transcriptional regulators, 
transporters, metabolic 
pathways; flux balance 
metabolic model 
YeastCyc http://pathway.yeastgenom
e.org/ 
152 metabolic pathways 
from S. cerevisiae  
MetaCyc http://biocyc.org/metacyc/i
ndex.shtml 
1,877 metabolic pathways 
from 2,263 organisms 
GLAMM http://glamm.lbl.gov/ Regulation of metabolic 
pathways under a range of 
environmental conditions 
Gene Designer (DNA 2.0) https://www.dna20.com/ge
nedesigner2/ 
Codon optimization of 
genes for heterologous 
expression 
 
2.3 Protein Expression 
 Once a gene encoding an enzyme of interest is identified, it must be expressed by 
some organism in a functional form. Expression level targets differ depending on whether 
the enzyme is used to catalyze a reaction in isolation or in the context of a well-balanced 
metabolic pathway. For example, metabolic engineering requires precise relative control 
of the expression of several enzymes (as opposed to the overexpression of a single 
enzyme) to prevent the accumulation of potentially toxic intracellular intermediates and 
to prevent the diversion of carbon and energy to other products. Expression levels must 
be carefully tuned rather than simply maximized to ensure high flux through the target 
pathway.  This has been accomplished by varying the gene copy number, altering 
promoter sequences, and utilizing designer transcription factors.16     
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On the other hand, production of isolated enzymes for single reactions is 
largely an exercise in maximizing expression of functional enzyme.  This is often 
accomplished by optimizing culture conditions (e.g., time, temperature, media, aeration, 
etc.), but more recently gene modification has also been used to improve enzyme 
expression levels.17 Modified leader sequences and optimization of codon choices have 
improved transcription and translation, respectively, but solubility (if dealing with a 
cytosolic enzyme) cannot generally be improved using these methods.  This can be 
addressed in some cases by lowering the expression temperature, fusing a solubility-
inducing protein to the target enzyme, or even by expressing truncated soluble versions of 
the target enzyme.18 Coexpressing target enzymes with chaperones has also been 
effective.19 These are largely empirical techniques, and their mode of action remains the 
subject of active investigation, but they can be useful tools in the preparation of soluble 
enzymes. 
The most important factor influencing protein expression is the host organism 
used.  E. coli is often chosen due to the expansive set of genetic tools and relatively 
simple culturing requirements for this organism.  However, E. coli is by no means 
appropriate for all enzymes and biosynthetic pathways, and one may choose from a wide 
range of organisms for a given application.20 In general, a host organism must possess the 
ability not only to synthesize the gene product, which requires appropriate codon usage 
and GC content, but also to incorporate cofactors, form disulfide bonds, and perform any 
required posttranslational modifications. Many industrial enzymes are expressed in hosts 
with good secretion capabilities (e.g., filamentous fungi and Bacillus sp.), so that the 
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enzyme can be precipitated or filtered directly from the supernatant, or even used 
without purification.    
 
3. Enzyme Engineering 
Enzymes produced using the methods outlined above are valuable catalysts for a 
range of chemical reactions.  Extensive reviews on the utility of such catalysts21 and the 
engineering of substrates22 to suit those catalysts have been published.  In many cases, 
however, enzymes themselves are not ideally suited to the task for which they are 
charged, and properties such as thermal stability, organic cosolvent and pH tolerance, 
substrate scope, or selectivity may require improvement.  Although some of these factors 
may be addressed through the use of specialized bioreactors, enzyme immobilization, or 
other process optimization,23 modification of the enzyme itself has proven to be a 
powerful means of improving biocatalytic processes.24 Indeed, the ability to engineer 
enzymes gives them a significant advantage over small molecule catalysts. For example, 
enzymes may be tuned for specific applications using a systematic process of mutation 
and selection known as directed evolution.25 
We provide some examples of directed evolution of synthetically relevant 
enzymes,24 to illustrate the types of improvements that have been made. We specifically 
focus on the use of directed evolution to alter substrate scope or reaction selectivity, 
rather than process-related properties such as thermal stability, solvent tolerance, or pH.26 
The choice of sequence modification approach depends on the problem; for example, 
how much is known about that enzyme?  Is a crystal structure available or can a 
homology model be generated?  Practical constraints also exist.  Can libraries of mutant 
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enzymes be generated readily, and is a high throughput assay possible?  Thus, the 
examples presented illustrate the results of various approaches and are grouped based on 
the type of reaction catalyzed rather than the methods employed.24 We avoid discussion 
of specific technologies and strategies for introducing sequence modifications (EP-PCR, 
DNA shuffling, site-directed recombination, ISM, circular permutation, etc.), as they 
have been thoroughly discussed elsewhere.27 
 
3.1. Oxygenation 
Given the importance of oxygenation in synthetic organic chemistry, it is not 
surprising that several different classes of oxygenases have been engineered.28 Of these, 
the cytochromes P450 (P450s) have been the subject of a particularly large volume of 
work due to their ability to hydroxylate unactivated C-H bonds and epoxidize olefins 
(figure 1).29 Several recent examples highlight the power of engineered P450s to 
hydroxylate a wide range of substrates whose structures differ significantly from the 
native substrates of these enzymes. The applications of engineered P450s in biocatalysis 
have been reviewed.29-30 
 
Figure 1. General scheme for oxygenase-catalyzed C-H hydroxylation and olefin 
epoxidation.  
R1 H
R1
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P450 or 
FAD 
oxygenase R
1
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H
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Cytochrome P450BM3 from Bacillus megaterium (BM3) has been the subject of 
a large number of engineering efforts.31 In this enzyme, the heme and diflavin reductase 
domains (FMN and FAD) are fused in a single polypeptide chain, rendering BM3 self-
sufficient in generating the active oxidant from dioxygen and NAD(P)H.  BM3 is soluble, 
readily overexpressed in a variety of heterologous hosts, and requires only atmospheric 
oxygen and a supply of nicotinamide adenine dinucleotide phosphate (NADPH) for 
monooxygenase activity.  Arnold and Lewis have used directed evolution to alter the 
substrate scope of BM3, from long chain fatty acids to gaseous alkanes, including 
propane and ethane.32 Some of the intermediate mutants along the evolutionary lineage of 
the so-called BM3 propane monooxygenase (PMO) were found to have activity on a 
wide range of small organic molecules. These enzymes commonly catalyze both olefin 
epoxidation and C-H hydroxylation, and hydroxylation of secondary C-H bonds or those 
alpha to heteroatom substitution is particularly efficient.  This activity has been enhanced 
to provide catalysts suitable for preparative scale hydroxylation of drugs, protected 
sugars, steroids, alkaloids, and other small molecules (figure 2).  Other research groups, 
including those of Reetz, Schmid, and Fasan, have described the directed evolution of 
BM3 for hydroxylation of substrates ranging from methane to aromatic heterocycles to 
steroids and terpenes.29 
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Figure 2. A native substrate for cytochrome P450BM3 and representative substrates 
accepted by BM3 variants.32 Arrows denote sites of hydroxylation. Block arrow denotes 
engineered activity on unnatural substrates. 
 
Cytochrome P450 CAM from Pseudomonas putida has also been engineered as 
an oxygenation catalyst.  Hydroxylations of substrates similar to those outlined above for 
BM3, including terpenes, arenes, polychlorinated arenes, and even ethane, have been 
accomplished using CAM variants.29  Both cytochrome P450 CAM and BM3 accept 
small molecules (camphor and dodecanoic acid) as substrates, but significant sequence 
engineering effort is typically required to achieve high activity on larger substrates. In 
contrast, PikC, a P450 from Streptomyces venezuelae that catalyzes hydroxylation of an 
intermediate in the biosynthesis of the macrolactone YC-17 (22 carbon atoms),33 can also 
hydroxylate a range of other macrocyclic compounds. Efforts are underway to expand 
this reactivity and enable hydroxylation of large substrates.  
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FAD-dependent oxygenases use an FAD hydroperoxide oxidant to catalyze 
oxygenation of activated substrates. Directed evolution of 2-hydroxybiphenyl 3-
monooxygenase led to variants with improved activity on several substrates, including 2-
sec-butylphenol, 2-methoxyphenol, and 2-tert-butylphenol (figure 3A).34 Similar efforts 
improved the hydroxylase activity of vanillyl-alcohol hydroxylase on cresol35 and 
epoxidation activity of styrene monoxygenase from Pseudomonas putida CA-3 on 
styrene, indene, and indole36 (figure 3B, C).  
 
Figure 3. Native substrates and representative substrates accepted by variants of (A) 2-
hydroxybiphenyl 3-monooxygenase,34  (B) vanillyl-alcohol hydroxylase,35 and (C) 
styrene monoxygenase from Pseudomonas putida CA-3.36 
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Extensive evolution of FAD-dependent Baeyer-Villiger monooxygenases,37 
which catalyze the eponymous chemical reaction on a range of native carbonyl and 
thiocarbonyl containing substrates (figure 4A), has been reported.  This work focused on 
improving activity and enantioselectivity on unnatural substrates, typically involving 
desymmetrization of prochiral ketones or kinetic resolution of racemic ketones.38 For 
example, cyclohexanone monooxygenase (CHMO) was engineered to oxidize 4-
hydroxycyclohexanone to either enantiomer of the corresponding lactone (figure 4B), and 
related variants have been found to accept a wide range of substrates (figure 4C).  Many 
of these enzymes have been employed on large scales (e.g., 200 L), including the 
reactions of rac-bicyclo-[3.2.0]-hept-2-en-6-one and rac-2-phenylcyclohexanone, which 
provide near-quantitative conversion and high enantioselectivities (E-values >100).  
Similarly high enantioselectivities are possible for the resolution of a range of substituted 
cyclohexanones using variants of phenylacetone monooxygenase (PAMO) (figure 4D). 
 
	  	  
19	  
 
Figure 4. (A) General scheme for Baeyer-Villiger monooxygenase-catalyzed oxidation 
of carbonyl compounds. (B) Enantioselective oxidation of a meso ketone. (C) Native 
substrate and representative substrates accepted by variants of cyclohexanone 
monooxygenase. (D) Native substrate and representative substrates accepted by variants 
of phenylacetone monooxygenase.37-38 
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dioxygenated (and in some cases monooxygenated) products of a wide range of 
heterocycles and arenes (figure 5B).40 
 
 
Figure 5.  (A) General scheme for dioxygenase catalyzed arene oxidation.39   (B) Native 
substrate and representative substrates accepted by variants of biphenyl dioxygenase. 40 
 
Wood and others have made extensive efforts to expand the scope of toluene and 
xylene monooxygenases.  Variants with improved activity and altered regioselectivity on 
indole41 and naphthalene42 have been reported (figure 6A).  Furthermore, variants of 
toluene p-monooxygenase from R. pickettii PKO1 are capable of hydroxylating toluene at 
the ortho, meta, and para positions (figure 6B).43 
H
N
R R
OH
OH
dioxygenase
A
H
H
H
N
O
CO2H
H H
H
H
monohydroxylation
dihydroxylationNHt-Bu
O H
H
or
R
OH
N
S
H H
B
dihydroxylation monohydroxylation
	  	  
21	  
 
Figure 6.  (A) Native substrate and representative substrates accepted by variants of 
toluene and xylene monooxygenases.41-42 Sites of hydroxylation are denoted with arrows.  
(B) Hydroxylation of ortho, meta, and para positions of toluene using variants of a 
toluene monooxygenase.43 
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3.2. Halogenation 
Enzymatic halogenations typically involve oxidation of halide anion to an X+ (X 
= halogen) equivalent that can react with electron-rich substrates.  Directed evolution of 
heme-44 and vanadium-dependent45 haloperoxidases has improved the scope of 
biocatalytic halogenation.  The site selectivity of halogenation reactions catalyzed by 
haloperoxidases has been questioned due to their release of free HOCl into solution.46 On 
the other hand, FAD-dependent halogenases are known to catalyze site-specific 
halogenation of their native substrates.  Thus, Van Pee and co-workers utilized site 
directed mutagenesis to alter the site selectivity of tryptophan chlorination and 
bromination by the halogenase PrnA.47 More recently, O’Connor and co-workers 
engineered the halogenase RebH to act on tryptamine, rather than its native substrate, 
tryptophan.48 
 
3.3. Dehydrogenation 
Dehydrogenases and a variety of oxidases catalyze the oxidation of organic 
substrates, including amines, alcohols, and sugars, via dehydrogenation (figure 7A).  The 
activities of these enzymes can also be reversed under suitable conditions to enable 
hydrogenation of unsaturated compounds (vide infra).  The utility of the products of both 
modes of operation has motivated many successful examples of engineering these 
enzymes for synthetic applications. 
Amino acid dehydrogenases have been engineered to convert unnatural amino 
acids to the corresponding imines, which subsequently undergo hydrolysis to generate 
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alpha-keto acids (figure 7B).49 Although not directly relevant to organic synthesis, 
much work has also focused on improving alcohol, sugar, and other dehydrogenases for 
producing reducing equivalents needed by other redox enzymes.50 Several oxidases also 
catalyze dehydrogenation of C-O and C-N bonds.  Amino acids are also substrates for 
these enzymes, and directed evolution has been used to expand the range of amino acids 
that these enzymes accept.51 Monoamine oxidase from Aspergillus niger has been studied 
as a catalyst for chemo-enzymatic deracemization of amines.  In this process, the oxidase 
converts a single enantiomer of the racemic amine to an imine, which is subsequently 
reduced by a nonspecific reducing agent (figure 7C).52 Directed evolution has been used 
to expand the scope of this enzyme from several simple primary amines to a very large 
range of secondary amines (figure 7D).52 In a similar fashion, galactose oxidase, which 
naturally oxidizes the primary alcohol of galactose to the corresponding aldehyde has 
been used to catalyze oxidation of secondary alcohols to the corresponding ketones, 
enabling kinetic resolution of the alcohol enantiomers (figure 7E).53 Directed evolution of 
several other pyranose oxidase enzymes has also been described.54 
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Figure 7. (A) General scheme for oxidase and dehydrogenase catalyzed reactions.  (B) 
Native substrate and representative substrate accepted by a variant of phenylalanine 
dehydrogenase.  The site of dehydrogenation is denoted by an arrow.49   (C) General 
scheme for oxidase catalyzed deracemization of amines.52   (D) Native substrate and 
representative substrates accepted by variants of a monoamine oxidase from Aspergillus 
niger.  (E) Native substrate and representative substrates accepted by variants of a 
galactose oxidase. 53 
 
3.4. Hydrogenation 
As noted above, dehydrogenases can operate in “reverse” to catalyze 
hydrogenation of unsaturated carbon-heteroatom bonds (i.e., the reverse of figure 7A).  
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broad substrate scope.  For example, the S-selective dehydrogenase from Rhodococcus 
erythropolis and the R-selective dehydrogenase from Lactobacillus kefir have been used 
extensively as ketoreductases.55 These enzymes accept a wide range of simple aldehydes 
and ketones as substrates for reduction and the corresponding alcohols as substrates for 
oxidation. In most cases a specific cognate substrate for the wild-type enzyme is not 
known.  Despite the utility of these enzymes, the desired selectivity is not always 
achieved, and directed evolution has been used to achieve highly selective reduction of a 
wide range of ketones, including aryl ketones, α-amino ketones, cyclic ketones, and β-
dicarbonyl compounds, many on a commercial scale (figure 8).55 Importantly, both 
product enantiomers typically can be obtained using variants of one of the two 
aforementioned ketoreductases.  Enolate reductases have also attracted much attention 
due to their ability to effect stereoselective hydrogenation of β-substituted α,β-
unsaturated ketones.56 
Figure 8.  Representative substrates accepted by ketoreductase variants.  The site of 
reduction is denoted by an arrow.55 
F3C
CF3
O
O
F3C
O
Cl
O
CO2Et
O
NHMe
O
CO2Me
NHBz
EtO2C
EtO2C
O
F
O N
O
O
CO2R
N
O
CO2Me
NO
OEt
O
O
simple
aldehydes
and
ketones
	  	  
26	  
3.5. Group Transfers 
Several different enzyme classes transfer functional groups and even entire 
molecular fragments from donor substrates to target substrates.  Particularly notable in 
this regard are the pyridoxyl phosphate dependent amino transferases, also known as 
transaminases, which enable synthesis of chiral amines by exchanging amine and ketone 
functional groups on donor (typically amino acids or simple short chain alkyl amines) 
and acceptor substrates, respectively (figure 9A).  The ω-transaminases have been the 
subject of the most engineering efforts due to the fact that they can accept a wide range of 
amine (rather than amino acid) donor substrates.  These have been engineered to utilize 
simple amines as donor substrates with high efficiency.  The reaction scope of the ketone 
acceptor substrate has been greatly expanded to enable the amination of a wide range of 
acyclic and cyclic ketones bearing a variety of functional groups (figure 9B).57 Variants 
capable of providing either enantiomer of the amine product have also been generated.  
Perhaps most impressively, as highlighted in another section of this volume, researchers 
at Merck and Codexis engineered a transaminase capable of installing a chiral amine in 
the final step of the synthesis of the drug Sitagliptin.58 
 
	  	  
27	  
 
Figure 9.  (A) General scheme for transaminase-catalyzed reductive amination.  (B)  
Representative substrates accepted by transaminase variants.57-58 
 
Glycotransferases have also benefited from directed evolution.59 These enzymes 
transfer single sugar moieties to a range of aglycone (i.e., small molecule) substrates 
(figure 10 A), and directed evolution has been used to expand the scope of aglycones that 
may be utilized (figure 10B/C).  Glycosidases have also been used as glycotransferase 
catalysts. These enzymes possess transglycosidase activity in addition to hydrolytic 
activity, and the former has been improved through rational design of variants lacking a 
nucleophilic active site residue required for hydrolytic activity.60 The resulting artificial 
transglycosidases enable glycosylation of a range of substrates, including sugars (to 
generate oligosaccharides) as well as aglycones (figure 10D).   
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Figure 10.  (A) General scheme for glycotransferase coupling of a nucleotide 
diphosphate (NDP) glycosyl donor and a glycosyl acceptor (R-OH).  (B) Native glycosyl 
acceptor and acceptors accepted by glycotransferase variants.59   (C) Native glycosyl 
donor and glycosyl donors accepted by glycotransferase variants.59   (D) Representative 
glycosylation reaction catalyzed by an artificial transglycosidase.60 
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with biologically important functional groups that are highly challenging to install 
using conventional synthetic methods. 
 
3.6. Hydrolysis and Condensation 
Hydrolases remain among the most commonly used enzymes in organic synthesis.  
In the forward direction, these enzymes hydrolyze a range of functional groups, including 
esters, amides, and nitriles, and many of these enzymes can be conveniently operated in 
the reverse direction to enable formation of these same functional groups.  Directed 
evolution has been applied extensively to optimize hydrolase activity in both directions.  
While not all of these can be covered here, the examples presented should provide 
readers with an idea of how these enzymes are typically used for chemical synthesis. 
Lipases, which catalyze ester hydrolysis or formation (figure 11A), were among 
the first enzymes to be evolved for improved organic solvent tolerance and 
enantioselectivity, and have received extensive attention since these early efforts.27 
Engineered lipases enable efficient kinetic resolution of racemic esters and 
desymmetrization of meso diesters that are dramatically different, in many cases, from 
those accepted by the wild type enzymes.  Carboxyl esterases possess very similar 
hydrolytic activities64 and have been engineered to improve enantioselectivity toward a 
range of substrates.  Hydrolysis of carboxylic acid esters, including ibuprofen esters, 2-
phenylalkanoic acid esters, and allene esters, has been achieved, and various alcohol 
leaving groups ranging from phenols to primary alcohols to tertiary alcohols can be used 
(figure 11B).  Among the most commonly used enzymes are those from Pseudomonas 
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aeruginosa (PAL), Bacillus subtilis (BSLA), Candida antarctica (CALA/CALB),65 
and Burkholderia cepacia (BCL).   
 
 
Figure 11.  (A) General scheme for lipase- and esterase-catalyzed hydrolysis reactions.  
(B) Representative substrates accepted by lipase and esterase variants for either kinetic 
resolution or desymmetrization.64-65 
 
Epoxides have long been recognized as valuable synthetic intermediates, and 
epoxide hydrolases convert these compounds to enantio-enriched diols (figure 12A).  
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engineering efforts (figure 12B).66 Halohydrin dehalogenases can also catalyze 
epoxide hydrolysis; however, these enzymes possess the added ability to resolve racemic 
halohydrins via epoxide formation prior to catalyzing epoxide opening with water 
(hydrolysis) and a range of additional nucleophiles, including azide, cyanide, and halide 
(figure 12C).  In a particularly notable example, directed evolution improved a 
halohydrin dehalogenase for production of the side chain of the commercial drug 
atorvastatin (figure 12C, Nu = CN, R = CH2CO2Et).67 Several examples of similar efforts 
have been described, including engineering the halohydrin dehalogenase from 
Agrobacterium radiobacter for greater enantioselectivity on 2-chloro-1-phenethyl 
alcohol.24 
 
 
 
 
Figure 12.  (A) General scheme for epoxide hydrolase catalyzed reaction.  (B) 
Representative substrates accepted by epoxide hydrolase variants.66   (C) General scheme 
for halohydrin dehalogenase-catalyzed addition of nucleophiles to 2-haloalcohols.68 
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3.7. Nonoxidative, Nonhydrolytic Bond Formation 
 Lyases catalyze nonoxidative, nonhydrolytic bond cleavage; when catalyzing the 
reverse direction (bond formation), these enzymes are called synthases.  Perhaps among 
the most recognizable members of this class of enzymes to the synthetic chemist are the 
aldolases.  Given the importance of the aldol reaction in synthetic organic chemistry, it is 
hardly surprising that enzymes capable of catalyzing this reaction on highly 
functionalized, unprotected substrates have received considerable attention.  These 
enzymes utilize either an active site lysine (Class I aldolases) or zinc ion (Class II 
aldolases) to catalyze the cross aldol reaction between two carbonyl compounds (figure 
13A).  Directed evolution has improved the utility of these enzymes, which typically 
have stricter requirements on at least one of the aldol partner substrates than many of the 
enzymes outlined above.69 
For example, many aldolases require phosphorylated substrates, which are not 
typically desired by synthetic chemists. Reymond and co-workers removed this 
requirement by evolving a L-ramulose-1-phosphate (RhaD) aldolase to accept 
dihydroxyacetone as a substrate, which greatly improves the enzyme’s utility (figure 
13B).70 Similarly, 2-deoxyribose-5-phosphate aldolase (DERA), which naturally 
catalyzes the aldol reaction of acetaldehyde with D-glyceraldehyde 3-phosphate, was 
evolved to accept nonphosphorylated aldol acceptors.71 Because this enzyme catalyzes 
the aldol reaction of two aldehydes, the product can in turn function as a substrate for a 
second aldol reaction (figure 13C). Of course, not all aldolases require phosphorylated 
substrates, but expanding the substrate scope of these enzymes to include unnatural 
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substrates remains highly desirable.  For example, N-acetyl neuraminic acid lyase 
(NAL) catalyzes the aldol reaction between pyruvate and N-acetyl mannosamine and a 
variety of additional 5- and 6-carbon sugars. This scope has been extended by directed 
evolution to generate biologically relevant sialic acid derivatives (figure 13D).72 
 
Figure 13.  (A) General scheme for aldolase-catalyzed aldol reactions.  (B) Native 
phosphorylated substrates and nonphosphorylated substrates accepted by DHAP and 
DERA aldolase variants.70   (C) Native substrate and representative substrate accepted by 
an NAL aldolase variant.  Different variants can be used to generate either the 4R or 4S 
product enantiomer.72-73   (D) Native substrate and representative substrates accepted by 
KDPG aldolase variants to generate diastereomeric products.74 
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As these examples highlight, aldolases can generate products containing a high 
degree of stereochemical information.  Control of both the enantioselectivity and 
diastereoselectivity of these reactions is therefore crucial.  For example, building upon 
the NAL-catalyzed reaction outlined above, researchers used directed evolution to 
generate variants capable of providing either the (4S)- or (4R)-enantiomer of the aldol 
product (figure 13D).73 Control over the diastereoselectivity of the aldol reaction requires 
that either enantiomer of the aldol acceptor function as a substrate for the aldolase.  
Indeed, D-2-keto-3-deoxy-6-phosphogluconate aldolase was evolved not only to accept 
non-phosphorylated substrates, including glyceraldehyde, but also to enable the reaction 
of either enantiomer of glyceraldehyde with pyruvate to provide diastereomeric products 
(figure 13E).74  
Hydroxynitrile lyases catalyze the addition of cyanide to aldehydes to generate 
synthetically valuable cyanohydrins.  These enzymes have been the targets of several 
engineering efforts, including that of Glieder and co-workers, who were able to 
significantly improve the activity and enantioselectivity of a hydroxynitrile lyase from 
Prunus amygdalus to (R)-pantolactone (figure 14A).75 Amino acid lyases catalyze 
nonoxidative, reversible deamination of amino acids and hydroamination of a,b-
unsaturated acids in the reverse direction.  Altering the substrate scope of these enzymes 
has enabled the synthesis of unnatural amino acids (figure 14B).76 Directed evolution has 
been used to expand the scope of a number of naturally occurring synthase complexes, 
including those responsible for the biosynthesis of terpenes,77 polyketides,78 and 
nonribosomal peptides.79 
	  	  
35	  
 
 
 
Figure 14.  (A) General scheme for hydrocyanation of aldehydes using a hydroxynitrile 
lyase and representative substrates accepted by hydroxynitrile lyase variants.75   (B) 
General scheme for hydroamination of a,b-unsaturated acids using an amino acid lyase 
and representative substrates accepted by amino acid lyase variants.76 
 
 
3.8. Summary 
 Given that efforts to alter the properties of enzymes using directed evolution have 
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appreciated.32 This renders enzymes similar to the “general” catalysts typically 
employed by chemists.  And, unlike those small molecule catalysts, which may be more 
or less applicable to a given target, enzymes can be systematically improved using 
directed evolution.   
The examples outlined above show that changes in enzyme activity achieved 
using directed evolution can range from relatively minor, for example, increasing activity 
toward a known substrate, to surprisingly large, as exemplified by the commercial 
synthesis of Sitagliptin using an enzyme evolved from a completely inactive parent 
enzyme.58 While the extent to which any given enzyme can be tuned appears to vary on a 
case-to-case basis, it is clear that for many enzymes, very large improvements can be 
realized.  It should also be appreciated that in the course of evolving an enzyme for a 
given target, many additional enzymes with improved fitness on substrates not directly 
selected for are also obtained, which greatly expands the pool of catalysts available for 
synthesis.32 This also provides starting points for rapid evolution of enzymes for new 
targets.  Finally, while most work in this area has focused on improving enzymes for 
single reactions either in vivo or in vitro, the optimization of enzymes of inclusion in 
metabolic pathways, either natural or synthetic, holds great promise for the synthesis of a 
wide range of compounds.  This will ultimately enable completely novel metabolic 
pathways to be developed for chemical production inside a cell. 
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4. Metabolic Engineering   
 Living organisms create molecular complexity under stringent limitations where 
cofactors are recycled and multiple catalysts coexist in the same medium without 
compromising efficiency and selectivity. This ability to catalyze multiple steps in vivo 
without the need to isolate intermediates and change conditions (solvent, temperature, 
pH, etc.)83 underscores the tremendous potential of using metabolically engineered cells 
for efficient chemical synthesis.  Natural selection has rarely acted to channel valuable 
energy and carbon towards production of a single compound. Thus most organisms are 
suboptimally designed to convert a feedstock (i.e., glucose) to a desired product. 
Engineering organisms to become high performance living factories is the ultimate goal 
of metabolic engineering.  
 Contemporary metabolic engineering utilizes various technologies (enzyme 
engineering, modeling, network analysis, manipulation of regulation, DNA synthesis, and 
careful analysis of genes, transcripts, and metabolites) to engineer organisms to 
synthesize chemical compounds of both native and heterologous origin.84 This field has 
attracted intense industrial interest over the last decade, particularly to provide alternate, 
microbial sources of scarce compounds that are extracted from biological materials and 
cannot be synthesized economically by purely chemical means. Additionally, there is 
strong interest in fermentative processes to replace petrochemicals as a strategy to 
mitigate volatility in the price and supply of petroleum. We illustrate the state of the art 
by summarizing selected efforts directed at biomanufacturing commodities and specialty 
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chemicals. The examples were selected based on diversity of methodology and are 
organized below according to natural product class.        
 
4.1 Isoprenoids 
 Isoprenoids make up the most numerous and structurally diverse family of natural 
products, with more than 50,000 different compounds identified to date from all forms of 
life. Commonly isolated from plants (in which case they are also referred to as 
terpenoids), microbes, and marine organisms, these valuable compounds are used as 
flavors, fragrances, nutraceuticals, biodegradable pesticides, as well as potent anticancer 
and antimalarial drugs. Representative examples include limonene (responsible for the 
strong smell in oranges and used in many fragrances and artificial flavors), the anticancer 
drug taxol, the antimalarial agent artemisinin, and lycopene (the red pigment in tomatoes 
that is used as a nutraceutical). Due to their structural complexity, isoprenoids are 
difficult, expensive, and inefficient to synthesize chemically and have to be sourced from 
biological materials. However, these compounds are produced only in small quantities, 
and extraction and purification is costly as well. The biosynthesis of these complex 
targets directly from inexpensive carbon sources such as glucose by metabolic 
engineering in microbial hosts has provided an elegant alternative to chemical synthesis 
and extraction from natural sources.   
 All isoprenoids are biosynthesized from two precursors, isopentenyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which undergo 
isomeric conversion catalyzed by the enzyme IPP isomerase. Elimination of 
	  	  
39	  
pyrophosphate from DMAPP catalyzed by isoprene synthase forms isoprene, the 
simplest terpene (figure 15). On the other hand, the nucleophilic methylene group of IPP 
can attack the electrophilic allylic CH2 group of DMAPP to condense in a head-to-tail 
fashion to form geranyl pyrophosphate (GPP), the common precursor to all monoterpenes 
(C10H16, e.g., limonene). Chain elongation of GPP by addition of another IPP unit forms 
farnesyl pyrophosphate (FPP), the common precursors to all sesquiterpenes (C15H24, e.g., 
amorphadiene). Addition of yet another IPP unit to FPP gives geranylgeranyl 
pyrophosphate (GGPP), from which all diterpenes are made (C20H32, e.g., taxadiene). The 
head-to-head condensation of two FPP molecules makes pre-squalene (C30H48) which is 
reduced to give squalene, the precursor to steroids (section 4.2). The tail-to-tail linkage of 
two GGPP molecules makes the tetraterpene phytoene (C40H64, i.e., lycopene), which 
serves as the precursor to carotenoids. This collection of precursors provides starting 
points for a wide range of molecules of interest to chemists, some of which are shown in 
figure 15.    
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Figure 15. Terpene synthases make isoprenoids from pyrophosphate precursors derived 
from IPP and DMAPP.85    
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 Given the importance of IPP and DMAPP in terpene biosynthesis, 
understanding the biosynthesis of these precursors is essential for any terpenoid 
engineering effort. In fact, IPP and DMAPP are produced by two distinct pathways that 
differ in their cofactor requirements and theoretical yields from glucose. The mevalonate 
(MVA) pathway converts the ubiquitous intermediate acetyl-coenzyme A (A-CoA) to 
IPP, whereas the 1-deoxy-D-xylulose-5-phosphate/2-C-methyl-D-erythritol-4-phosphate 
(DXP/MEP) pathway produces IPP and DMAPP from pyruvate and glyceraldehyde-3-
phosphate derived from glycolysis. The MVA pathway offers a lower theoretical yield of 
conversion of glucose to isoprenoids (0.252 g g-1) compared to the DXP/MEP pathway 
(0.302 g g-1) due to its cofactor imbalance.86 The choice of which pathway to engineer for 
maximizing flux toward IPP and DMAPP depends on the regulatory elements present in 
the host organism. It is important to note that accumulation of prenyl pyrophosphates has 
been found to be toxic to the host,87 such that the metabolic engineering experiment has 
to go one step further and include the terpene synthase that will produce the hydrocarbon 
product. 
 
4.1.1 Isoprene 
 Isoprene (2-methyl-1,3-butadiene) is an important commodity chemical used in a 
wide range of industrial applications, from production of synthetic rubber for tires and 
coatings to use in adhesives and specialty elastomers. Global industrial production of 
synthetic isoprene from petrochemical feedstocks is approximately 1 million tons per 
year.86 Isoprene is naturally produced by bacteria, animals, and plants, which are 
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estimated to collectively release approximately 600 million tons per year into the 
atmosphere. Despite isoprene’s pervasiveness in the environment, genetic approaches to 
identifying the genes encoding isoprene synthesis in prokaryotes have been pursued with 
limited success.88 Thus far, only plant-derived isoprene synthases have been well 
characterized, and sequence data for isoprene synthases exist for only two plant families. 
Because the catalytic efficiencies of these enzymes are suboptimal for industrial 
applications (KM ~ 1–10 mM and kcat ~ 1 s−1),86, 89 protein engineering for superior kinetic 
parameters has been pursued by industrial groups.89-90 As a proof of concept, recombinant 
production of isoprene in  microbial hosts has been achieved by expressing plant isoprene 
synthases in E. coli, S. cerevisiae, and photosynthetic bacteria.91     
 Genencor-DuPont and The Goodyear Tire & Rubber Co. are developing a high 
efficiency fermentative route for polymer-grade isoprene via heterologous expression of 
the MVA pathway and plant derived isoprene synthases in E. coli.86 The mevalonate 
pathway was chosen over the DXP/MEP pathway because it was better characterized and 
has been exploited industrially for production of isoprenoids in both yeast and 
bacteria.87,92 The volatile nature of isoprene (b.p. 34 °C) allows gas phase recovery, 
simplifying purification and eliminating potential feedback inhibition by virtue of product 
accumulation. This process is reported to have an isoprene yield of 0.11 g g−1, volumetric 
productivity of 2.0 g L−1 h−1, and a titer of 60 g L−1.86 
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4.1.2 Artemisinin 
 Artemisinin, an endoperoxide sesquiterpene lactone, is an antimalarial drug 
produced in the leaves of Artemisia annua. Its biosynthesis comprises at least four 
enzymatic steps starting from FPP, the common precursor to sesquiterpenes. The first 
committed step is the cyclization of FPP to amorpha-4,11-diene, catalyzed by 
amorphadiene synthase (ADS). The cyctochrome P450 CYP71AV1 then oxidizes 
amorphadiene to artemisinic aldehyde and also makes artemisinic acid as a by-product. 
Reduction to dihydroartemisinic aldehyde is catalyzed by artemisinic aldehyde ∆11 
reductase, BDR2, and a specific aldehyde dehydrogenase is likely involved in the 
oxidation step to form hydroartemisinic acid, but the remaining steps in the pathway may 
be nonenzymatic.93  
 The semisynthesis of artemisinin via metabolic engineering is based on the in vivo 
overproduction of amorphadiene or artemisinic acid and their subsequent conversion to 
artemisinin through chemical reactions (figure 16). Initial experiments aimed at 
improving the isoprenoid flux in E. coli focused on introducing the heterologous MVA 
pathway from S. cerevisiae to circumvent the regulatory elements found in E. coli’s 
native MEP pathway.87 The recombinant eight-gene biosynthetic pathway was divided 
into two operons: a “top” operon (MevT) that encodes the three enzymes required to 
convert the ubiquitous precursor acetyl-CoA to (R)-mevalonate and a “bottom” operon 
(MBIS) that converts (R)-mevalonate to FPP (figure 16). Coexpression of these operons 
with a synthetic ADS gene, optimized for expression in E. coli, resulted in the production 
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of amorphadiene from glucose and glycerol with a final concentration of 0.5 g L−1 
following optimization of process conditions.87, 94 
 
 
Figure 16. Semisynthetic scheme for artemisinin production. Enzymes encoded by the 
genes shown are: atoB, acetoacetyl-CoA thiolase; HMGS, HMG-CoA synthase; tHMGR, 
truncated HMG-CoA reductase (expressing only the C-terminal catalytic domain); MK, 
mevalonate kinase; PMK, phosphomevalonate kinase; MPD, mevalonate diphosphate 
decarboxylase; idi, IPP isomerase; ispA, farnesyl diphosphate synthase; ADS, 
amorphadiene synthase; CPR, cytochrome P450 reductase; P450, CYP71AV1.95  
 
 
 Mevalonate supplementation studies suggested that the production of 
amorphadiene in this system was limited by the conversion of acetyl-CoA to 
mevalonate.96 However, increased expression of the three enzymes in the top operon 
(MevT) ⎯ by increasing plasmid copy number and by replacing the promoter ⎯ resulted 
in cell growth inhibition. Gene titration studies and metabolite profiling using LCMS 
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linked growth inhibition with the intracellular accumulation of the heterologous 
metabolite 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA), suggesting that low 
activity of a single enzyme, HMG-CoA reductase (tHMGR), encoded in MevT, was the 
major bottleneck. This flux imbalance was alleviated by coexpressing the MevT operon 
with an additional medium-copy-number plasmid carrying an extra copy of tHMGR, 
effectively increasing the concentration of the catalyst in the bottleneck step and thereby 
achieving a 3-fold increase in mevalonate production. Further optimizations included 
replacing the yeast genes for HMG-CoA synthase and HMG-CoA reductase with 
equivalent genes from Staphylococcus aureus, and improving the fermentation process 
under the restriction of carbon and nitrogen, so as to maximize flux toward the desired 
metabolic pathway, yielding commercially relevant titers of 27.4 g L-1 amorphadiene.97 
 The membrane-associated cytochrome P450 monooxygenase from A. annua 
(CYP71AV1) catalyzes the three-step oxidation of amorphadiene to artemisinic acid, 
producing the alcohol and aldehyde congeners of artemisinic acid as intermediates. To 
achieve the in vivo oxidation of amorphadiene to artemisinic acid, CYP71AV1 and its 
redox partner cytochrome P450 reductase (CPR), were codon-optimized for E. coli and 
coexpressed in the aforementioned strains. By engineering the N-terminal transmembrane 
sequence and using an expression plasmid suitable for P450 expression, artemisinic acid 
titers of 105 mg L-1 were achieved, when conducting the fermentation in the absence of a 
n-dodecane overlay.98  Conversion of artemisinic acid to the drug aremisinin can be 
accomplished in just two in vitro chemical reactions, namely reduction to 
hydroartemisinic acid followed by a photooxidation cyclization reaction (figure 16).99 
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 Biosynthesis of artemisinic acid has also been achieved in the yeast S. 
cerevisiae, by up-regulating the expression of several genes from the native MVA 
pathway and by heterologous expression, through chromosomal integration, of 
amorphadiene synthase (ADS), amorphadiene monooxygenase (CYP71AV1) and the 
reductase (CPR).100  Since steroid biosynthesis in yeast competes with ADS for FPP 
availability, it was necessary to down-regulate expression of squalene synthase, which 
catalyzes the first step downstream of FPP in the sterol pathway. Just as for E. coli, 
integration of an additional copy of tHMGR into the chromosome increased 
amorphadiene production, altogether producing >100 mg L-1 artemisinic acid. 
Interestingly, artemisinic acid was found to accumulate on the outer side of the cell 
membrane, allowing for a one-step purification following its “total” synthesis in yeast. 
Artemisinic acid removed from the cell pellet by washing with alkaline buffer was 
extracted into ether and purified by silica gel chromatography to achieve more than 95% 
purity.100  Further strain engineering could not improve titers beyond 0.2 g L-1 for 
glucose-fed fermentations.95b However, strains that had been cloned with the pathway 
only up to amorphadiene achieved titers of more than 1.2 g L-1. Subsequent 
improvements in the fermentation process for amorphadiene were able to significantly 
increase product titers up to the commercially relevant target of 37 g L-1.95b Key 
developments included restricting phosphate in fed-batch fermentations—this is thought 
to limit growth and channel greater carbon flux to product—and replacing the restricted 
glucose feed with a restricted ethanol feed, which is thought to increase intracellular 
acetyl-CoA levels for the MVA pathway. Deletion of GAL1 GAL10 GAL7 and Gal80p, a 
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gene cluster required for the utilization of galactose, altogether eliminated the need to 
add expensive galactose for induction of amorphadiene production. The S. cerevisiae–
based process has considerable advantages over the aforementioned E. coli process, most 
notably the absence of an expensive inducer such as IPTG and the lower oxygen uptake 
rate required for the restricted ethanol process, which reduces costs associated with 
aerating large fermentors.  
 The more facile biosynthesis of amorphadiene compared to artemisinic acid led to 
an alternative semisynthetic strategy where yeast fermentation converts sugars to 
amorphadiene and in vitro chemical reactions subsequently convert amorphadiene to 
dihydroartemisinic acid en route to artemisinin (figure 16).95b Industrial production of 
semisynthetic artemisinin is being pursued by Amyris Biotechnologies in collaboration 
with Sanofi-Aventis.    
 
4.1.3 Taxol 
 Taxol (paclitaxel) and its structural analogs are among the most potent and 
commercially successful anticancer drugs. Taxol comprises a highly oxygenated 6-8-6 
tricyclic ring system, featuring a total of 11 stereogenic centers, an ester side chain, and a 
distinctive oxetane ring. Six independent total syntheses have been reported involving 
elaborate routes that require 37 to 51 steps, with yields too low for practical synthesis 
(highest yield of 0.4%).83 Taxol was first isolated from the bark of Taxus brevifolia 
(Pacific Yew tree), and its biosynthetic pathway consists of approximately 20 enzymatic 
steps from the primary intermediate geranylgeranyl diphosphate (GGPP).93 Taxadiene 
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synthase catalyzes the cyclization of GGPP to taxa-4(5),11(12)-diene (figure 15), the 
first committed step of the pathway, with remarkable fidelity generating the 6-8-6 tricycle 
with the correct chirality for the first three stereogenic centers. The diterpenoid core is 
further decorated by 8 cytochrome P450-mediated oxygenations, four coenzyme A-
dependent acylations, and a C13 side chain assembly and attachment en route to taxol. 
Metabolic engineering has been applied successfully to overproduce taxol 
precursors in E. coli.101 Since the MEP pathway for making IPP and DMAPP (figure 17, 
upstream module) is endogenous to E. coli, heterologous expression of only GGPP 
synthase and taxadiene synthase (figure 17, downstream module) allows for the 
production of taxa-4(5), 11(12)-diene. The pathway was partitioned into two modules 
separated at IPP, the key intermediate in terpenoid biosynthesis. A total of 32 strains were 
constructed wherein 8 native enzymes identified as bottlenecks in the upstream MEP 
pathway were expressed in one module and the two heterologous downstream enzymes 
were expressed in the other module. By systematically varying expression of each 
module, a nonlinear effect on taxadiene titers was observed for the relative dosage of the 
two pathways. Further optimizations such as chromosomal integration of the upstream 
operon, minimizing pathway inhibition by indole (a by-product), and a two-phase 
fermentation to avoid air-stripping of taxadiene resulted in titers as high as 1.02 g L−1.101  
Finally, the plant-derived cytochrome P450, taxadiene 5α hydroxylase, an unusual 
monooxygenase that catalyzes hydroxylation along with double bond migration, was 
included in the pathway to generate taxadien-5α-ol (though this resulted in a much lower 
product titer of 50 mg L−1).   
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Figure 17. Biosynthesis of taxol precursors in E. coli via the DXP/MEP pathway 
(upstream module). Enzymes encoded by the genes shown are dxs, 1-deoxy-D-xylulose-
5-phosphate synthase; ispC, 1-deoxy-D-xylulose-5-phosphate reductoisomerase; ispD, 4-
diphosphocytidyl-2-C-methyl-D-erythritol-2,4-cyclodiphosphate synthase; ispE, 4-
diphosphocytidyl-2-C-methyl- D-erythritol kinase; ispF, 2-C-Methyl-D-erythritol-2,4-
cyclodiphosphate synthase; ispG, 1-hydroxy-2-methyl-2-(E)-butenyl-4- diphosphate 
synthase; ispH, 4-hydroxy-3-methyl-2-(E)-butenyl-4-diphosphate reductase; idi, IPP 
isomerase.101   
 
4.1.4 Levopimaradiene 
 Levopimaradiene is the diterpenoid gateway precursor of the pharmaceutically 
important plant-derived ginkgolides. Heterologous production has been achieved in E. 
coli with a maximum titer of 700 mg L−1 using a combination of metabolic and protein 
engineering methods.102 Introduction of plant-derived geranylgeranyl diphosphate 
synthase (GGPPS) and levopimaradiene synthase (LPS) codon-optimized for E. coli led 
to only marginal production of levopimaradiene (0.15 mg L−1). Overexpression of the 
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upstream MEP/DXP pathway for increasing the intracellular concentration of the 
isoprenoid precursors IPP and DMAPP led to a titer of 92 mg L−1. However, further 
product amplification could not be achieved by continuing to increase the concentration 
of the bottleneck enzymes in the MEP/DXP pathway. This suggested that the inherently 
low enzyme activity and specificity of the downstream steps had become rate limiting 
under high isoprenoid precursor flux. Thus, enzyme engineering at the key metabolic 
nodes was pursued in order to achieve substantial overproduction of the target diterpene.     
 LPS from Ginkgo biloba converts GGPP to levopimaradiene with about 87% 
selectivity, while also forming the isomers abietadiene (11%), sandaracopimaradiene 
(2%), and neoabietadiene (trace) (figure 18).102  This product mixture results from initial 
isomerization of GGPP in the first active site of LPS to form the intermediate copalyl 
diphosphate, which subsequently undergoes a poorly selective diphosphate-ionization 
cyclization in the second active site of LPS. This example illustrates how the poor 
selectivity of some terpene synthases can result in unwanted product formation, which 
leads to low metabolic fluxes and large product losses.  
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Figure 18. Levopimaradiene synthase (LPS) catalyzes the cyclization of geranylgeranyl 
diphosphate (GGPP) to levopimaradiene in two distinct active sites. In the first active 
site, deprotonation drives the formation of (+)-copalyl diphosphate (CPP). Reaction in a 
second active site leads to the formation of multiple products from GGPP with poor 
selectivity for levopimaradiene. CPP undergoes diphosphate-ionization cyclization to 
form the C8-sandaracopimarenyl cation, which can be deprotonated to release 
sandaracopimaradiene or undergo intramolecular proton transfer and 1,2-methyl 
migration to yield the abietenyl cation.  Subsequent deprotonation of abietenyl cation at 
four possible sites produces abietadiene, levopimaradiene, neoabietadiene, and 
palustradiene (not shown).102  
  
 E. coli overexpressing the genes for the MEP/DXP pathway and expressing wild-
type GGPPS was used to screen a library of LPS variants with mutations focused in the 
troublesome second active site. Mutations were selected to increase diterpene 
productivity and retain or improve the selectivity for levopimaradiene. Saturation 
mutagenesis at key residues and recombination of the top mutations improved 
productivity by 10-fold without significant changes in product distribution. Finally, the 
activity of GGPPS was improved 1.7-fold via random mutagenesis and an in vivo screen 
that utilized a lycopene biosynthetic pathway as a colorimetric reporter.102 This example 
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illustrates the utility of protein engineering in manipulating secondary metabolic 
pathways with poor selectivity to optimize microbial overproduction of desired 
chemicals.   
 
4.2 Steroids 
 Sterols are essential structural and regulatory components of eukaryotic cell 
membranes.  Thus far, only a couple of members of this important class of natural 
products have been produced by engineered microbial hosts, most notably ergosterol and 
hydrocortisone. Ergosterol is the main sterol in yeast and is responsible for structural 
membrane features such as fluidity and permeability, similar to cholesterol in mammalian 
cells. Additionally, ergosterol is a precursor to vitamin D2 and cortisone. Overproduction 
of ergosterol has been achieved in S. cerevisiae by overexpressing endogenous genes that 
are bottlenecks in the native ergosterol biosynthetic pathway (figure 19).103 
Transformation of squalene, the polyisoprene precursor, to ergosterol requires the action 
of 12 different enzymes. Deregulated expression of HMG-CoA reductase leads to 
accumulation of squalene (due to higher isoprenoid flux via the MVA pathway) but not 
of ergosterol, suggesting that the steps downstream of squalene become rate limiting. 
Simultaneous overexpression of two genes along the ERG pathway led to a significant 
decrease of the squalene pool and concomitant increase in the amount of ergosterol.103 
With optimization in fermentation conditions the final ergosterol titer has been reported 
to reach 1.98 g L−1.104  
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Figure 19. Endogenous biosynthesis of ergosterol in yeast and recombinant production of 
hydrocortisone involving mammalian and plant enzymes. Enzymes: matCYP11A1, 
mature form of CYP11A1 (P450 side chain cleaving); 3β-HSD, 3β-hydroxysteroid 
dehydrogenase-isomerase; ADX, bovine adrenodoxin (electron carrier); ADR, bovine 
adrenodoxin reductase; Δ7 reductase, Δ7 sterol reductase; Ncp1p, NADPH P450 
reductase; Arh1p, adrenodoxin reductase homolog.105 
 
 Total biosynthesis of heterologous steroids in genetically programmed 
microorganisms has been pursued with limited success, with only modest titers reported. 
Notable advances include the overproduction of progesterone and hydrocortisone in 
yeast.105-106 Hydrocortisone is the major steroid in mammals and an important 
intermediate of steroidal drug synthesis. Total biosynthesis of hydrocortisone in yeast 
involves 25 steps from acetyl-CoA (figure 19), of which the first 19 are endogenous to S. 
cerevisiae. Conversion of ergosterol to hydrocortisone requires the introduction of one 
plant enzyme and five additional enzymatic steps catalyzed by eight mammalian proteins 
(figure 19).105 The heterologous genes were introduced by a combination of plasmid and 
genomic integration techniques. Elimination of competing pathways and balanced 
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expression of the key enzymes resulted in the production of hydrocortisone as the 
major sterol (70% selectivity), albeit at low titers (<20 mg L−1), reflecting the challenges 
in transferring a highly complex and mainly membrane-bound mammalian pathway into 
a microbial host.     
 
 4.3 Amino Acids 
Amino acids are major industrial products of microbial fermentations, with a 
global market of over three million tons per year and applications ranging from animal 
feed to food and pharmaceutical products. The microbial hosts used in industry typically 
do not require foreign DNA for overproduction, and engineering efforts are instead 
directed toward bypassing native regulation mechanisms (i.e., feedback inhibition) that 
limit titer and productivity. Metabolic engineering applied to amino acid fermentation has 
been reviewed elsewhere.107 Here we limit discussion to a summary of efforts to produce 
L-lysine and L-alanine in bacteria to illustrate approaches of genomic reconstruction and 
metabolic evolution.  
 More than 1,000,000 tons of L-lysine per year are produced from the Gram-
positive bacterium Corynebacterium glutamicum.108 Industrial strains of C. glutamicum 
have been developed by classical methods of whole-cell mutagenesis and selection. This 
technique generated many industrial fermentation strains, but has the serious 
disadvantage of accumulating uncharacterized secondary mutations that are detrimental 
to important properties such as growth, sugar consumption, and stress tolerance. For 
instance, C. glutamicum B-6 was constructed from the wild-type strain (ATCC 13032) by 
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iterations of random mutation and selection, and is able to produce L-lysine to high 
titers (95 g L−1) but with suboptimal rate (1.9 g L−1 h−1), due to poor growth and sugar 
consumption.109 It had been known for decades that the wild-type strain cannot 
accumulate L-lysine unless it is deficient in L-homoserine dehydrogenase, since this 
enzyme will divert flux toward the production of L-threonine, L-methionine, and L-
isoleucine.110 Comparative genomics of B-6 and the wild-type strain along the 16 
proteins involved in the terminal pathway and the L-lysine efflux step revealed that only 
three enzymes had suffered amino acid mutations, with each differing from the wild-type 
copy by a single amino acid substitution.109 Recombining the three evolved genes in the 
wild-type background leads to faster production of L-lysine (3.0 g L−1 h−1) than in B-6, 
while retaining a high titer (80 g L−1). This example of genome-based strain 
reconstruction shows how dissecting the genetic modifications responsible for phenotypic 
selection at the macroscopic level can lead to an industrially useful, genetically defined 
mutant without any foreign DNA.  
In another effort to understand microbial metabolism at a systems biology level, 
in-depth profiling of intracellular metabolite concentrations, metabolic fluxes, and gene 
expression of lysine-producing C. glutamicum revealed that the phase shift from growth 
to lysine production is accompanied by a decrease in glucose uptake flux and the 
redirection of flux from the tricarboxylic acid (TCA) cycle toward lysine biosynthesis.111 
Additionally, metabolic engineering created an L-lysine hyper-producing C. glutamicum 
with impressive fermentation metrics: 120 g L−1 titer, 4.0 g L−1 h−1 volumetric 
productivity and 0.55 g g−1 yield on glucose.112 The engineered strain contained only 12 
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mutations, which were integrated into the genome without introducing foreign DNA 
and without requiring selection markers.       
 Production of L-alanine has been achieved in E. coli with industrially relevant 
parameters.113  An E. coli strain that makes L-alanine as the major product was created by 
replacing the genomic lactic acid dehydrogenase gene in a strain already optimized for 
lactic acid fermentation with a heterologous alanine dehydrogenase (figure 20). Alanine 
dehydrogenase produces alanine from pyruvate and ammonia using one equivalent of 
NADH (i.e., the biological equivalent of reductive amination, see section 3.4). The 
engineered pathway is redox-balanced such that NADH oxidation (required for alanine 
biosynthesis) is coupled to ATP production and cell growth (figure 20). This linkage 
provides a basis for metabolic evolution (i.e., serial or continuous cultivation) where 
selection for improvements in growth coselect for increased glycolytic flux and alanine 
production. Cells with increased growth rate due to spontaneous mutations will 
outcompete their parent strains and have increased alanine productivity. Deletion of other 
genes that divert metabolic flux away from the target pathway, optimizing fermentation 
conditions, and successive rounds of metabolic evolution achieved a final product titer of 
114 g L−1, 96% mass yield (with respect to glucose), 2.4 g L−1 h−1 average volumetric 
productivity, and product purity greater than 99.5%. In this example, chromosomal 
integration of a single heterologous gene provided sufficient levels of expression to 
support high levels of growth and product flux without the need for multicopy plasmids 
and selection agents for plasmid retention (thus obviating the need for expensive inducers 
and antibiotics). Impressively, the dried broth from batch fermentation in glucose mineral 
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salts medium afforded, after cell removal, approximately 95% (w/w) L-alanine without 
further purification.      
 
 
 
Figure 20. Fermentation of glucose to L-alanine generates a surplus of ATP allowing the 
pathway to be optimized by metabolic evolution.113  
 
4.4 Diamines 
 Diamines have many industrial applications as components of polyamides, 
pharmaceuticals, agrochemicals, surfactants, and other materials. For example, putrescine 
(1,4-diaminobutane) is currently used to synthesize nylon-4,6 by polycondensation with 
adipic acid. Putrescine is naturally biosynthesized in E. coli and is thought to play a role 
in cell proliferation and normal cell growth; however, its intracellular concentration in E. 
coli is reported to be only ~30 mM, as it is elaborately regulated by biosynthesis, 
degradation, uptake and excretion.114  Accordingly, overproduction of putrescine in E. 
coli requires the concerted overexpression of bottleneck enzymes, deletion of competing 
degradation pathways, enhancing excretion, and hindering uptake back into cells. 
Amplification of putrescine biosynthesis in E. coli is based on seven enzymatic steps 
from the TCA cycle intermediate α-ketoglutarate (figure 21).115  The key step is 
decarboxylation of ornithine, a common precursor in arginine biosynthesis, to directly 
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form putrescine. The putrescine importer (puuP) was deleted to prevent the cells from 
importing extracellular putrescine at the end of batch fermentations under conditions of 
carbon starvation. Arginine biosynthesis from ornithine requires the action of one of two 
ornithine carbamoyltransferases (argI and argF). The argI argF double knock-out is 
auxotrophic with respect to arginine, but arginine supplementation is undesirable since 
the pathway is feedback-inhibited by arginine at the level of N-acetylglutamate synthase. 
Deletion of just the argI gene, encoding the major carbamoyltransferase, results in 
increased production of putrescine and eliminates the requirement for arginine 
supplementation. Constitutive overexpression of the antiporter potE, responsible for 
putrescine excretion, was achieved by replacing its native promoter by a stronger 
promoter. Finally, high cell density fed-batch fermentations in glucose mineral salts 
medium allowed for a putrescine accumulation of 24.2 g L−1 at 0.75 g L−1 h−1, with 
0.168 g g−1 yield on glucose.115  
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Figure 21. Putrescine biosynthesis in E. coli. Enzymes encoded by the genes shown 
are gdhA, glutamate dehydrogenase; argA, N-acetylglutamate synthase; argB, N-
acetylglutamate kinase; argC, N-acetylglutamyl phosphate reductase; argD, 
acetylornithine transaminase; argE, acetylornithine deacetylase; speC/speF, 
biosynthetic/degradative ornithine decarboxylase; potE putrescine/ornithine antiporter; 
puuP, putrescine importer. TCA cycle, tricarboxylic acid cycle. Overall 
biotransformation: 1.03 glucose + 2 NH3 → putrescine + 2.18 CO2 + NADH.115 
  
 Unlike putrescine, cadaverine is a minor polyamine found only in a few 
microorganisms.116 In E. coli, cadaverine (1,5-pentanediamine) is biosynthesized from 
lysine in a single enzymatic step by the action of lysine decarboxylase. Accordingly, 
previously derived lysine-producing strains of C. glutamicum offer an excellent starting 
point for overproduction of this diamine. Toray Industries demonstrated that cadaverine 
accumulation can be achieved by chromosomal substitution of the native homoserine 
dehydrogenase gene (hom) in C. glutamicum for the lysine decarboxylase from E. coli 
(cadA).117  Homoserine dehydrogenase deficiency is required for lysine accumulation 
(section 4.3) and thus is also important for improving flux toward cadaverine. 
Simultaneous hom removal and cadA expression resulted in a titer of 2.6 g L-1 cadaverine, 
with 0.052 g g−1 yield from glucose. Efficient secretion of cadaverine is important as its 
in vivo accumulation can inhibit lysine decarboxylase. Most cadaverine formed inside C. 
glutamicum is ionized (pKa = 9.13) such that its secretion requires active transport across 
the cell membrane. Genome-wide transcription analysis of cadaverine-producing C. 
glutamicum was used to identify the key exporter, a permease with an undefined 
physiological role, which when overexpressed resulted in improved yields of cadaverine 
(0.136 g g−1 on glucose).118  E. coli has also been engineered to overproduce cadaverine 
by overexpressing cadA and dihydrodipicolinate synthetase.119 Deletion of genes 
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involved in the utilization, degradation, and import of both putrascine and cadaverine 
was also required. Altogether, the engineered E. coli fermented sugars in mineral salts to 
a final cadaverine concentration of 9.61 g L−1, at a volumetric productivity of 
0.32 g L−1 h−1, and a yield of 0.12 g g−1 on glucose.119  
 
4.5 Alcohols 
 Alcoholic fermentation in S. cerevisiae is the largest scale biotechnology process 
in operation (>70 million tons per year). Strains of S. cerevisiae have been developed 
over millennia of artificial selection for ethanol production, which is the end product of 
anaerobic fermentation in yeast. Intense academic and industrial research has been 
directed toward novel fermentation routes for higher chain alcohols with superior fuel 
properties and more versatile chemical applications. Isobutanol (2-methylpropan-1-ol), 
for example, is a precursor to C4 petrochemical building blocks as well as an excellent 
gasoline blend. Glucose to isobutanol conversion has been demonstrated in E. coli via a 
modified amino acid pathway that requires only two nonnative steps (KDC and ADH) 
and uses keto-isovalerate as a precursor (figure 22).120 Isobutanol titers of >20 g L−1 have 
been reached by using engineered strains with deletions in pathways competing for 
carbon and using cofactors that are available aerobically or microaerobically.120 
Anaerobic conditions are preferred, however, for lower operating costs, higher yields, 
and compatibility with existing ethanol plants. An anaerobic pathway that operates at 
nearly theoretical yield was achieved by engineering the KARI to switch cofactor 
	  	  
62	  
preference (i.e., to use NADH instead of NADPH) and thereby consume NADH 
produced during glycolysis (figure 22).121 
 
Figure 22. Glucose to isobutanol conversion via 2-ketoisovalerate. Enzymes: ALS, 
acetolactate synthase; KARI, ketol-acid reducto-isomerase; DHAD, dihydroxy-acid 
dehydratase; KDC, 2-ketoacid decarboxylase; ADH, alcohol dehydrogenase.120 
 
4.6 Diols 
 Propane-1,3-diol (PDO) is used in fiber polymers prepared from terephthalic acid 
and PDO that are produced in large volumes (e.g., for apparel and carpeting). PDO is 
naturally produced by a large number of bacteria, such as Citrobacter, Clostridium, 
Enterobacter, Klebsiella, and Lactobacillus, as the result of anaerobic growth on 
glycerol.122  In these systems, glycerol is converted to PDO in just two steps, namely 
dehydration to 3-hydroxypropionaldehyde (3-HPA) followed by NAD(P)H-dependent 
reduction to PDO (figure 23).  The first reaction, which is rate limiting, proceeds via a 
free radical H-abstraction/rearrangement mechanism followed by spontaneous 
dehydration and is catalyzed by the coenzyme B12-dependent glycerol dehydratase. This 
enzyme is eventually inactivated by a suicide reaction with glycerol, such that an ATP-
dependent auxilliary reactivase (a chaperone-like protein) is required to reestablish 
dehydratase activity. The high cost of supplementing vitamin B12 to the growth medium 
is an additional drawback of relying on a B12-dependent enzyme in a metabolic pathway 
to PDO. Dehydratases with higher resistance to inactivation by glycerol and inhibition by 
PDO were identified in a metagenomics study, as described in section 2.2.13  
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Alternatively, B12-independent glycerol dehydratases have been described and may 
find application in PDO bioproduction.123 
 
 
 
Figure 23. Recombinant pathways for the production of propanediols in E. coli. Enzymes 
encoded by the genes shown are dar1, glycerol 3-phosphate dehydrogenase (S. 
cerevisiae); gpp2, glycerol 3-phosphate phosphatase (S. cerevisiae); dhaB1, glycerol 
dehydratase (K. pneumoniae); dhaBX, orfX, reactivating factors for glycerol dehydratase 
(K. pneumoniae); yqhD, oxidoreductase (E. coli); mgsA, methylglyoxal synthase (E. 
coli); tpi, triosephosphate isomerase (E. coli); gap, glyceraldehyde 3-phosphate 
dehydrogenase (E. coli). Calculations assumed that cellular respiration of 1 mol of 
glucose yields 12 mol NAD(P)H equivalents and 34 mol ATP.124     
  
 No naturally occurring microbe has been reported to directly ferment glucose to 
PDO.  In  a landmark success of industrial metabolic engineering, Genencor-DuPont 
engineered E. coli to directly produce high levels of PDO from glucose.122  The 
heterologous pathway imports two genes from S. cerevisiae (DAR1 and GPP2, figure 23) 
to convert the glycolytic intermediate dihydroxyacetone phosphate (DHAP) to glycerol 
and the K. pneumoniae glycerol dehydratase  (dhaB1) and its reactivating factors (dhaBX, 
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orfX) that subsequently convert glycerol to 3-HPA. Reduction of 3-HPA to PDO is 
catalyzed by an oxidoreductase (yqhD) that is endogenous to E. coli. Since biosynthesis 
of the highly reduced product PDO from glucose requires additional inputs of NAD(P)H 
and ATP (figure 23), some glucose substrate needs to be oxidized through glycolysis and 
the TCA cycle to provide the necessary reducing equivalents and energy (figure 23). This 
creates a branch point at triose phosphate isomerase (tpi), which interconverts DHAP and 
glyceraldehyde-3-phosphate (G3P). G3P is fed into the TCA cycle to produce reducing 
equivalents and energy required for the PDO pathway and cell growth. Down-regulation 
of glyceraldehyde 3-phosphate dehydrogenase (gap) provides an improved flux control 
point while maximizing PDO yields. With additional modifications in the E. coli strain, 
the metabolically engineered organism provides PDO at a rate of 3.5 g L−1 h−1, a titer of 
135 g L−1, and a yield of 0.51 g g−1 in glucose fed-batch aerobic fermentations.122  
 Fermentation of glucose to 1,2-propanediol (propylene glycol) in both 
homologous and heterologous hosts has also been investigated by various groups.124-125  
Major uses of propylene glycol are in unsaturated polyester resins, liquid laundry 
detergents, pharmaceuticals, cosmetics, antifreeze, and deicing formulations. Some 
microbes such as Clostridium sphenoides and Thermoanaerobacterium 
thermosaccharolyticum naturally ferment sugars to propylene glycol.124  The pathways 
employed by these two organisms are very similar and have identical ATP and NAD(P)H 
cofactor requirements to the aforementioned PDO pathway (figure 23). DHAP is first 
dephosphorylated to methylglyoxal by the action of methylglyoxal synthase (an enzyme 
which is also native to E. coli). In C. sphenoides, the methylglyoxal is reduced to (R)-
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lactaldehyde, whereas in T. thermosaccharolyticum the methylglyoxal is reduced to 
hydroxyacetone. Both of these intermediates are then reduced to (R)-1,2-propanediol. 
Propylene glycol production in these hosts is limited by low yields, a lack of genetic tools 
for rational biocatalyst improvement and, in the case of C. sphenoides, by the 
requirement for phosphate-free media (it is both difficult and expensive to obtain 
commercial-grade medium components that are free of phosphate). Since E. coli 
naturally produces methylglyoxal, recombinant production of propylene glycol can be 
readily achieved by providing the appropriate reductase activities.124  
 1,4-Butanediol (BDO) is an important commodity chemical used to manufacture 
more than 2.5 million tons annually of valuable polymers. Current production is based on 
feedstocks of fossil origin such as acetylene, propane, butane, and butadiene. Because 
BDO is not produced naturally in any known organism, its production in E. coli required 
the establishment of a novel heterologous biochemical pathway.126  Computational design 
was used to screen reaction classes (rather than actual enzyme-catalyzed reactions) that 
could intercept common metabolites in E. coli and convert those to BDO. This broader 
approach identified more than 10,000 putative pathways capable of converting common 
metabolites (i.e., acetyl-CoA, succinyl-CoA, α-ketoglutarate, and glutamate) to BDO in 
just 4–6 steps. Computational methods were used to rank the pathways according to 
maximum theoretical BDO yield, pathway length, number of nonnative steps, number of 
novel steps, and thermodynamic feasibility. Constraint-based modeling was then used to 
eliminate pathways that displayed unfavorable thermodynamics or low theoretical yield. 
The remaining 1,000 pathways were ranked again according to the number of steps 
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catalyzed by uncharacterized enzymes (based on KEGG and EcoCyc databases, see 
section 2), the number of nonnative steps, and the total number of steps from central 
metabolism. 
This process led to the selection of two artificial routes for BDO production from 
succinyl-CoA and α-ketoglutarate proceeding via 4-hydroxybutyrate as a common 
intermediate (figure 24). The pathway was divided into an upstream module (succinyl-
CoA / α-ketoglutarate to 4-hydroxybutyrate) and a downstream module (4-
hydroxybutyrate to BDO) for experimental validation and metabolic engineering. Only 
two out of the seven enzymes are native to E. coli; the remaining enzymes have to be 
imported from other organisms, as shown in figure 24. All enzymes act on their native 
substrates, with the exception of the aldehyde and alcohol dehydrogenases. A 
computational algorithm was used to predict gene knock-outs that couple BDO 
production to growth while preserving the maximum BDO theoretical yield. Knocking-
out those genes eliminated E. coli’s ability to produce the usual fermentation products 
(ethanol, formate, lactate, succinate) thereby forcing production toward BDO to achieve 
redox balance. This led to improved BDO titers, but other intermediates were still formed 
preferentially, such as 4-hydroxybutyrate, succinate, and notably butyrolactone (likely 
formed spontaneously from 4-hydroxybutyrate-CoA, figure 24). Finally, improvements 
in expression of TCA cycle enzymes under microaerobic conditions by lifting 
transcriptional repression and NADH inhibition of citrate synthase, as well as selecting 
an aldehyde dehydrogenase that acts on 4-hydroxybutyraldehyde but not on acetyl-CoA, 
led to formation of BDO as the main product with a final titer of 18 g L−1.126  
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Figure 24. Computationally designed pathway for 1,4-butanediol production in E. coli. 
Enzymes encoded by the genes shown are: sucCD, succinyl-CoA synthetase (E. coli); 
sucD, semialdehyde dehydrogenase (Porphyromonas gingivalis); 4HBd, 4-
hydroxybutyrate dehydrogenase (P. gingivalis); sucA, alpha-keto acid decarboxylase 
(Mycobacterium bovis); cat2, 4-hydroxybutyryl-CoA transferase; ald025B, aldehyde 
dehydrogenase (Clostridium beijerinckii); adh, alcohol dehydrogenase (E. coli).126 
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4.7 Summary 
 Designing new synthetic pathways into microbial hosts demands careful 
consideration of redox balance, ATP balance, product toxicity, feedback inhibition, and 
host selection, the last factor accounting for growth rate and ability to grow on simple 
media. There is no universal approach for engineering microbial metabolism, and 
successful efforts necessarily employ a range of technologies as outlined above. It is 
noteworthy that most case studies thus far have not involved extensive use of enzyme 
engineering, but focused instead on optimizing and balancing expression of naturally 
occurring enzymes in a convenient host. Notable exceptions include the engineered 
levopimaradiene and isobutanol pathways listed above (sections 4.1.4 and 4.5). Fine-
tuning of many recombinant pathways will likely involve more enzyme engineering to 
deliver enhanced kinetic parameters and substrate and product specificities at each 
catalytic node.  However, the very possibility of such sensitive modulation should 
provide chemists with clear appreciation of the potential utility of biological catalysts 
relative to small molecule catalysts. 
 The three key metrics used to assess the utility of microbial processes—yield, 
volumetric productivity, and titer—are listed in table 2 for some of the pathways 
discussed in this section. These examples developed over the last decade affirm our 
ability to manipulate microbial metabolism for industrial production of chemicals. 
However, most of these processes do not yet match the thermodynamic and kinetic 
efficiencies of yeast ethanol fermentations, adapted and improved over millennia by 
artificial selection. Process robustness is also an important consideration for large-scale 
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implementation of these technologies. Ideally, the recombinant pathway should not 
require expensive inducers and selection markers (antibiotics), and the engineered strain 
should not require complex nutrients or ideally even sterile conditions for growth and 
should be tolerant to high product concentrations.  This field is still in its infancy, and as 
our techniques grow in sophistication and our understanding of metabolic control 
deepens, we can look forward to enabling the vision of living factories for sustainable 
chemical production.  
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Table 2. Summary of key metrics for the pathways described in this section 
Target product Host Theoretical 
yield  
(gpdt  
gCsource−1) 
Practical 
yield  
(gpdt 
gCsource−1) 
Titer 
 (g L−1) 
Volumetric 
productivity 
(g L−1 h−1)c 
Isoprene86 E. coli 0.25a 0.11 (44%) >60 2.0 
Amorphadiene95b S. cerevisiae 0.25 N/A 37 N/A 
Taxadiene101 E. coli 0.30b 0.025 (7%) 1.00 N/A 
L-Alanine113 E. coli 0.989 0.950 (96%) 114 2.37 
L-Lysine112 C. glutamicum 0.75 0.55 (73%) 120 4.0 
Putrescine115 E. coli 0.475 0.168 (35%) 24.2 0.75 
Cadaverine119 E. coli 0.524 0.12 (23%) 9.61 0.32 
Isobutanol S. cerevisiae 0.41 0.41 (>95%) N/A 2.0 
1,3-Propanediol122 E. coli 0.607 0.51 (84%) 135 3.5 
1,4-Butanediol 126 E. coli 0.55 N/A 18.0 0.15 
Ethanol S. cerevisiae 0.51 ~0.49 (96%) ~ 95 ~ 8.0 
a Based on MVA pathway utilizing glucose as the carbon source. b Based on MEP 
pathway utilizing glycerol as the carbon source. c Average volumetric productivity was 
calculated based on total product produced per total fermentation time. 
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5. Beyond Nature: Design and Evolution of Artificial 
Function/Catalysis 
Given the rate at which the biotechnologies outlined above are being applied to 
chemical synthesis, it is reasonable to consider more recent advances that might soon 
have a similar impact. While directed evolution of enzymes has clearly provided an 
extremely powerful tool to generate efficient catalysts, this process is only reliable once 
some initial activity is identified. Accordingly, researchers are starting to design enzymes 
de novo in order to reap the benefits of enzyme catalysis for reactions not found in nature; 
notable examples include designed enzymes for the Diels-Alder and retro-aldol 
reactions.127 A range of nonnatural transition metal-catalyzed reactions have also been 
enabled by incorporating metal catalysts into protein scaffolds.128 The several different 
systems that have been devised can be classified generally according to how the metal 
catalyst is anchored into the protein, namely covalent, supramolecular, or dative 
attachment.  Among the most well-studied systems are the (strep)avidin-biotin 
metalloenzymes (supramolecular anchoring) devised by Whitesides and greatly improved 
by Ward, which have been used for a range of transition-metal-catalyzed reactions.129  
Covalently linking a catalyst precursor (e.g., bisdiphenylphosphino rhodium) to a 
biotin anchor ensures that upon stoichiometric addition of (strept)avidin, the metal 
cofactor is quantitatively incorporated within the host protein. The resulting hybrid 
catalyst exhibits features of both homogenous and enzyme catalysis. For example, 
features reminiscent of homogeneous catalysis include straightforward access to both 
enantiomers of the product, broad substrate scope, organic solvent tolerance, whereas 
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acquired enzyme-like properties include access to genetic optimization, aqueous 
solubility and activity, and Michaelis-Menten behavior. This strategy has been used to 
create asymmetric systems for catalyzing rhodium-diphosphine hydrogenation of N-
protected dehydroaminoacids (figure 25, up to 95% ee), palladium-diphosphine allylic 
alkylation (up to 95% ee), and vanadyl oxidation of sulfides (up to 93% ee).129  
 
Figure 25. Reduction of N-acetamidoacrylic acid and N-acetamidocinnamic acid by 
artificial hydrogenases based on the biotin-avidin technology. The hybrid catalyst can be 
improved by chemogenetic optimization by varying the spacer (oval) or the chelating 
ligand, or by amino acid substitutions in the host protein [(strept)avidin].129  
 
Nonnatural activities can also be installed into naturally occurring enzymes 
without the addition of synthetic cofactors. Taking advantage of the catalytic promiscuity 
of enzymes, panels of enzymes can be screened against synthetic reagents to discover 
abiological reactions. For example, Purkarthofer et al. screened a hydroxynitrile lyase for 
nitro-aldol (Henry reaction) activity on nitromethane and various aldehydes and found 
that the wild-type enzyme could catalyze the carboligation of nitromethane to 
benzaldehyde with high enantioselectivity (92% ee).130 Similarly, a panel of engineered 
cytochrome P450s was screened against diazoester and azide reagents for C=C and C-H 
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functionalization by carbenoid and nitrenoid insertions.131 P450 variants (with as few 
as one mutation from the wild-type) could catalyze the cyclopropanation of styrene from 
ethyl diazoacetate with high enantioselectivity and exquisite diastereocontrol (figure 
26A) as well as the intramolecular C-H amination from arylsulfonyl azides (figure 
26B).131 
 
Figure 26. (A) P450BM3-catalyzed cyclopropanation of styrene utilizing ethyl 
diazoacetate as a carbene precursor. Variant C3C-T438S has 14 mutations with respect to 
P450BM3. (B) P450BM3-catalyzed intramolecular C-H amination from an arylsulfonyl 
azide. Variant B1SYN has 23 mutations with respect to P450BM3. 131  
 
Evolution of de novo designed enzymes and artificial metalloenzymes will be 
useful for their optimization for synthetic applications.132   As illustrated in the previous 
section, most metabolic engineering projects have aimed at establishing heterologous 
production of molecules with well-understood natural pathways. As protein engineering 
advances in installing nonnatural activities into enzymes, we can expect that entirely 
artificial pathways will emerge for producing compounds of industrial relevance that are 
not synthesized naturally. 
Of course both the catalysts and the format in which they are used can have a 
large impact on the utility and efficiency of a process.  For example, some of the 
challenges associated with conducting reactions in vivo for metabolic engineering efforts 
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were outlined above.  Due to these challenges, researchers have sought to design cells 
with minimal genomes that might simplify metabolic networks to minimize undesired 
reactivity, divert more energy and materials toward target products, and simplify 
downstream bioprocessing.133 Further simplifications have also been realized using cell-
free biosynthetic systems in which cells are grown to provide the necessary cofactors and 
catalysts for a target process, then lysed to release these materials in a reactor. Substrates, 
cosolvents, and other reagents that may be detrimental to cell survival can then be 
utilized, and the concentration of these species in the reaction medium can be precisely 
controlled.134 The relative concentrations of enzymes can be controlled by combining 
isolated enzymes in a single reactor to enable selective sequential reactions on a substrate 
via in vitro cascades.135  Thus, in all of these cases, chemists are given increasing control 
over the complex milieu in living cells.  As these processes are improved, chemists will 
thus have an increasing palette of systems to draw on to carry out target reactions with 
increased efficiency. 
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C h a p t e r  2  
OLEFIN CYCLOPROPANATION VIA CARBENE TRANSFER CATALYZED BY 
ENGINEERED CYTOCHROME P450 ENZYMES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published as P. S. Coelho, E. M. Brustad, A. Kannan, F. H. Arnold, 
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Abstract  
Transition metal-catalyzed transfers of carbenes, nitrenes and oxenes are powerful 
methods for functionalizing C=C and C–H bonds. Nature has evolved a diverse toolbox 
for oxene transfers, as exemplified by the myriad monooxygenation reactions catalyzed 
by cytochrome P450 enzymes. The isoelectronic carbene transfer to olefins, a widely 
used C–C bond forming reaction in organic synthesis, has no biological counterpart. 
Here, we report engineered variants of cytochrome P450BM3 that catalyze highly 
diastereo- and enantioselective cyclopropanation of styrenes from diazoester reagents via 
putative carbene transfer.  This work highlights the capacity to adapt existing enzymes 
for the catalysis of synthetically important reactions not previously observed in nature.  
 
One sentence summary. A bacterial cytochrome P450 has been readily engineered to 
catalyze highly stereoselective carbene transfers to aryl-substituted olefins, enabling 
cyclopropanation through a route not observed in Nature. 
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The many strategies for functionalizing C=C and C–H bonds that have evolved in 
nature have captivated the imaginations of chemists and form the foundation of 
biomimetic chemistry (1, 2). The reverse of this, using inspiration from synthetic 
chemistry to discover and develop new biocatalysts, is a nascent frontier in molecular 
engineering, whose recent highlights include C–H activation by artificial rhodium 
enzymes (3) and the de novo design of Diels-Alderases (3, 4). Synthetic chemists have 
developed powerful methods for direct C=C and C–H functionalization based on 
transition metal-catalyzed carbenoid and nitrenoid transfers, reactions that are widely 
used to synthesize natural product intermediates and pharmaceuticals (5). The 
asymmetric cyclopropanation of olefins with high-energy carbene precursors (e.g., 
acceptor-substituted diazo reagents) is a hallmark reaction that generates up to three 
stereogenic centers in a single step to make the important cyclopropane motif, featured in 
many natural products and therapeutic agents (6). Limited to using physiologically 
accessible reagents, nature catalyzes intermolecular cyclopropane formation through 
wholly different strategies, typically involving olefin addition to the methyl cation of S-
adenosyl methionine or through cyclization of dimethylallyl pyrophosphate-derived 
allylic carbenium ions (7). As a result, the diverse cyclopropanation products that can be 
formed by metallocarbene chemistry cannot be readily accessed by engineering natural 
cyclopropanation enzymes. We hypothesized that a natural metalloenzyme, the iron-
heme-containing cytochrome P450, could be engineered to catalyze formal carbenoid 
transfers, thereby combining the high levels of regio- and stereoselectivity of enzymes 
with the synthetic versatility of carbene-based strategies.  
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Members of the cytochrome P450 enzyme family catalyze myriad oxidative 
transformations, including hydroxylation, epoxidation, oxidative ring coupling, 
heteroatom release, and heteroatom oxygenation (8). Most transformations encompassed 
by this broad catalytic scope manifest the reactivity of the same high-valent iron-oxene 
intermediate, compound I (figure 1). Inspired by the impressive chemo-, regio- and 
stereoselectivities with which cytochrome P450s can insert O atoms into C–H and C=C 
bonds, we investigated whether these enzymes could be engineered to mimic this 
chemistry for isoelectronic carbene transfer reactions via a high-valent iron-carbenoid 
species (figure 1). Here we report that variants of the cytochrome P450 from Bacillus 
megaterium (CYP102A1, or P450BM3) are efficient catalysts for the asymmetric 
metallocarbene-mediated cyclopropanation of styrenes. 
 
 
Figure 1. Canonical mode of reactivity of cytochrome P450s (left): monooxygenation of 
olefins and C-H bonds to epoxides and alcohols catalyzed by the ferryl porphyrin radical 
intermediate (Compound I). Artificial mode of formal carbene transfer activity of 
cytochrome P450s utilizing diazoester reagents as carbene precursors (right).  
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Because iron porphyrins catalyze carbene-based cyclopropanations (9, 10), we 
first probed whether some common heme proteins display measurable levels of 
cyclopropanation activity in aqueous media (phosphate buffer, with 5% methanol co-
solvent). We chose the reaction between styrene and ethyl diazoacetate (EDA), (figure 2), 
a well-recognized model system for validating new cyclopropanation catalysts. Initial 
experiments showed that optimal formation of the desired cyclopropanation products 
occurred in the presence of a reducing agent (e.g., sodium dithionite, Na2S2O4) under 
anaerobic conditions (tables S1-S4). Horseradish peroxidase (HRP), cytochrome c (cyt 
c), myoglobin (Mb), and P450BM3 all displayed multiple turnovers toward the 
cyclopropane products, with HRP, cyt c, and Mb showing negligible enantioinduction, 
and formed the trans cyclopropane with over 90% diastereoselectivity, which is 
comparable to the diastereoselectivity induced by free hemin (table S1). P450BM3, despite 
forming the cyclopropane products in low yield, catalyzed the reaction with different 
diasteroselectivity (cis:trans 37:63) and slight enantioinduction (table 1), showing that 
carbene transfer and selectivity are dictated by the heme cofactor bound in the enzyme 
active site.  
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Figure 2. Absolute stereoselectivity of select P450BM3 cyclopropanation catalysts. 
Reaction conditions: 20 µM catalyst, 30 mM styrene, 10 mM EDA, 10 mM Na2S2O4, 
under argon in aqueous potassium phosphate buffer (pH 8.0) and 5% MeOH cosolvent 
for 2 hours at 298 K. Enzyme loading is 0.2 mol% with respect to EDA. The structures of 
each product stereoisomer are shown above the reaction gas chromatograms. 
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we have accumulated thousands of variants that exhibit monooxygenase activity on a 
wide range of substrates (12). We tested some of these variants for altered 
cyclopropanation diastero- and enantioselectivity by analysis of product distributions 
using gas chromatography (GC) with a chiral stationary phase. A panel of 92 P450BM3 
variants, chosen for diversity of activity and protein sequence, was screened in 
Escherichia coli lysate for the reaction of styrene and EDA under aerobic conditions in 
the presence of Na2S2O4 (tables S5 and S6). The 10 most promising hits were selected for 
purification and characterization under standardized anaerobic reaction conditions (tables 
1 and S7). 
Five of the 10 selected P450s showed improvements in activity as compared to 
the wild type [total turnover numbers (TTNs) > 100], a comprehensive range of 
diastereoselectivities with cis:trans ratios varying from  9:91 to 60:40, and up to 95% 
enantioselectivities (table S7). For example, variant H2-5-F10, which contains 16 amino 
acid substitutions, catalyzes 294 total turnovers, equivalent to ~58% yield under these 
conditions (0.2% enzyme loading with respect to EDA). This represents a 50-fold 
improvement over wild-type P450BM3. Furthermore, mutations affect both the diastereo- 
and enantioselectivity of cyclopropanation: H2-5-F10 favors the trans cyclopropanation 
product (cis:trans 16:84) with 63% enantiomeric excess (eetrans), whereas H2A10, with a 
TTN of 167, shows reversed diastereoselectivity (cis:trans 60:40) with high 
enantioselectivity (95% eecis).  
We used H2A10 to verify the role of the enzyme in catalysis and identify optimal 
conditions (table S8, figures S1 and S2). Heat inactivation produced diastereo- and 
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enantioselectivities similar to those obtained with free hemin, consistent with protein 
denaturation and release of the cofactor. Complete inhibition was achieved by 
preincubating the reaction mixture with carbon monoxide, which irreversibly binds the 
reduced P450 heme, confirming that catalysis occurs at the active site. Air inhibited the 
cyclopropanation reaction by about 50%, showing that dioxygen and EDA compete for 
reduced FeII. Cyclopropanation was also achieved with NADPH as the reductant, 
confirming that the activity can also be driven by the endogenous electron transport 
machinery of the diflavin-containing reductase domain. The presence of a reducing agent 
in substoichiometric amounts proved essential for cyclopropanation (table S9), implying 
that the active species is FeII rather than the resting state FeIII.  
            Highly active P450BM3 variants H2A10, H2-5-F10, and H2-4-D4 have three to 
five active-site alanine substitutions with respect to 9-10A-TS-F87V (12 mutations from 
P450BM3, supplementary material text), which itself shows negligible cyclopropanation 
activity. These variants exhibit a range of TTNs, diastereoselectivity, and 
enantioselectivity (table 1). To better understand how protein sequence controls P450-
mediated cyclopropanation, we constructed 12 variants to assess the contributions of 
individual alanines to catalysis and stability [table S10, (13)]. T268A is key for achieving 
high cyclopropanation activity, and this mutation alone converts inactive 9-10A-TS-
F87V into an active cyclopropanation catalyst. Variant 9-10A-TS-F87V-T268A (here 
called BM3-CIS) is a competent cyclopropanation catalyst (199 TTNs), displays strong 
preference for the cis product (cis:trans 71:29), forms both diastereomers with over 90% 
ee, and is as stable as wild-type P450BM3. Other active site alanine mutations tune the 
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product distribution. The addition of I263A to BM3-CIS reverses diastereoselectivity 
(cis:trans 19:81). We also investigated the effects of similar mutations introduced in the 
poorly active wild type P450BM3 (table S11). P450BM3-T268A, with a single mutation, is 
an active cyclopropanation catalyst (323 TTNs, table 1) with exquisite trans-selectivity 
(cis:trans 1:99) and high enantioselectivity for the major diastereomer (−96% eetrans, 
figure 1). Whereas BM3-CIS is a cis-selective cyclopropanation catalyst, identical active 
site mutations in wild-type P450BM3 result in a trans-selective enzyme (table S11), 
demonstrating that mutations outside of the active site also influence the stereochemical 
outcome. 
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Table 1. Stereoselective P450BM3 cyclopropanation catalysts. Reactions were run in 
aqueous phosphate buffer (pH 8.0) and 5% MeOH cosolvent at room temperature under 
argon with 30 mM styrene, 10 mM EDA, 0.2 mol% catalyst (with respect to EDA), and 
10 mM Na2S2O4. Yields, diastereomeric ratios, and enantiomeric excess were determined 
by GC analysis. Yields based on EDA. TTN = total turnover number. *(R,S) – (S,R). 
†(R,R) – (S,S). See supplementary text for protein sequences indicating mutations from 
wild type P450BM3.  
 
Catalyst % yield TTN cis:trans %eecis* %eetrans† 
Hemin 15 73 6:94 −1 0 
P450BM3 1 5 37:63 −27 −2 
P450BM3 -T268A 65 323 1:99 −15 −96 
9-10A-TS-F87V 1 7 35:65 −41 −8 
H2-5-F10 59 294 16:84 −41 −63 
H2A10 33 167 60:40 −95 −78 
H2-4-D4 41 206 53:47 −79 −33 
BM3-CIS 40 199 71:29 −94 −91 
BM3-CIS-I263A 38 190 19:81 −62 −91 
BM3-CIS-A328G 37 186 83:17 52 −45 
BM3-CIS-T438S 59 293 92:8 −97 −66 
 
Because the design of cis-selective small-molecule catalysts for diazocarbonyl-
mediated cyclopropanations has proven more challenging than that of their trans 
counterparts (14), we investigated whether active site engineering of P450BM3 could 
provide robust cis-selective water-compatible catalysts to complement existing 
organometallic systems (15). We chose five active site residues (L181, I263, A328, L437, 
and T438) for individual site-saturation mutagenesis (13). The A328G, T438A, T438S 
and T438P variants exhibited enhanced cis-selectivity (table S12). A328G also reversed 
the enantioselectivity for the cis-diastereomer (table 1). BM3-CIS-T438S displayed the 
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highest diastereo- and enantioselectivities (cis:trans 92:8 and −97% eecis) and maintained 
TTNs comparable to those of BM3-CIS (table 1).  
BM3-CIS exhibits Michaelis-Menten kinetics (figure S3 and table S13) with 
relatively high KM values for the olefin (~1.5 mM) and the diazoester (~5 mM), reflecting 
the lack of evolutionary pressure for this enzyme to bind these substrates. BM3-CIS 
exhibits a notable kcat for cyclopropanation of 100 min-1, comparable to the kcat of many 
native P450s for hydroxylation, but about 50 times less than P450BM3-catalyzed fatty acid 
hydroxylation (table S14). Free hemin does not exhibit saturation kinetics and displays 
slower initial rates than BM3-CIS (only 30 min-1 at 10 mM styrene and 15 mM EDA), 
indicating that the protein scaffold enhances kcat as compared to the free cofactor in 
solution. When used at 0.2 mole % (mol %) equivalent, BM3-CIS catalyzed 
cyclopropanations reached completion after 30 minutes. Adding more EDA enhanced 
turnovers for cyclopropanes and preserved BM3-CIS stereoselectivity (table S15), 
confirming catalyst integrity and implying that the reaction stops because of EDA 
depletion rather than inactivation.  
To assess the substrate scope of P450BM3-catalyzed cyclopropanation, we 
investigated the activities of six variants against a panel of olefins and diazo compounds 
(table 2 and tables S16 to S20). P450 cyclopropanation is robust to both electron-
donating (p-vinylanisole and p-vinyltoluene) and electron-withdrawing (p-
trifluoromethylstyrene) substitutions on styrene, and variant 7-11D showed consistent 
cis-selectivity for these substrates. The P450s were also active on 1,1-disubstituted 
olefins (i.e., α-methyl styrene), with chimeric P450 C2G9R1 forming cyclopropanes in 
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77% yield (with respect to EDA). The P450s were only moderately active with t-butyl 
diazoacetate as substrate (<30% yield), forming the trans product with >87% selectivity 
and offering no advantage over free hemin (table S20). For reactions involving EDA and 
aryl-substituted olefins, however, the P450s consistently outperformed the free cofactor 
in both activity and stereoselectivity.  
 
Table 2. Scope of P450 catalyzed cyclopropanation of styrenyl substrates. Ar = p-X-
C6H4. Reaction conditions: 20 µM catalyst, 30 mM olefin, 10 mM diazoester, 10 mM 
Na2S2O4, under argon in aqueous potassium phosphate buffer (pH 8.0) and 5% MeOH 
cosolvent for 2 hours at 298 K. Enzyme loading is 0.2 mol % with respect to diazoester. 
N/A = not available when enantiomers did not separate to baseline resolution. 
 
 
  
X
R1 O
N2
O R2
Reagents P450 catalyst
R1 = H, X = Me, R2 = Et                 BM3-CIS                228        78 : 22       -81           N/A
R1 = H, X = OMe, R2 = Et               H2-5-F10               364        11 : 89       38            N/A
R1 = H, X = CF3, R2 = Et                  7-11D                   120        76 : 24        31            59
R1 = Me, X = H, R2 = Et                    7-11D                  157         41 : 49       42            N/A
R1 = H, X = H, R2 = t-Bu                   H2A10                 120          3 : 97        N/A          N/A
0.2 mol% P450BM3 
5% MeOH
0.1 M KPi pH 8.0+
TTN Z : E %eeZ %eeE
Ar COOR2
R1
R1
Ar
COOR2
Z E
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Screening natural enzymes against synthetic reagents chosen based on chemical 
intuition offers a simple strategy for identifying enzymes with basal levels of nonnative 
activity. As we have shown, a single mutation can be enough to promote such activity 
and achieve synthetically useful stereoselectivities. The accumulation of beneficial 
mutations by directed evolution or other protein engineering strategies can generate a 
spectrum of highly active catalysts for desired substrate and product specificities. The 
established reaction promiscuity of natural enzymes (16, 17) and the surprising ease with 
which cyclopropanation activity could be installed into P450BM3 suggest that this 
approach will be useful for other synthetically important transformations for which 
biological counterparts do not yet exist.  
 
* * *  
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I. Materials and Methods 
 
 Unless otherwise noted, all chemicals and reagents for chemical reactions were 
obtained from commercial suppliers (Sigma-Aldrich, Acros) and used without further 
purification. The following heme proteins were all purchased from Sigma-Aldrich: 
myoglobin (from equine heart), peroxidase II (from horseradish), cytochrome c (from 
bovine heart), catalase (from Corynebacterium glutamicum), and chloroperoxidase (from 
Caldariomyces fumago). Silica gel chromatography purifications were carried out using 
AMD Silica Gel 60, 230-400 mesh. 1H and 13C NMR spectra were recorded on either a 
Varian Mercury 300 spectrometer (300 and 75 MHz, respectively), or a Varian Inova 500 
MHz (500 and 125 MHz, respectively), and are internally referenced to residual solvent 
peak. Data for 1H NMR are reported in the conventional form: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), 
coupling constant (Hz), integration. Data for 13C are reported in terms of chemical shift (δ 
ppm) and multiplicity. High-resolution mass spectra were obtained with a JEOL JMS-
600H High Resolution Mass Spectrometer at the California Institute of Technology Mass 
Spectral Facility. Reactions were monitored using thin layer chromatography (Merck 60 
silica gel plates) using an UV-lamp for visualization. Optical rotation was measured 
using a JASCO P-2000 Polarimeter.  
 Gas chromatography (GC) analyses were carried out using a Shimadzu GC-17A 
gas chromatograph, a FID detector, and J&W scientific cyclosil-B columns (30 m × 0.32 
mm, 0.25 µm film and 30 m × 0.25 mm, 0.25 µm film). High-performance liquid 
chromatography (HPLC) was carried out using an Agilent 1200 series, an UV detector, 
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and an Agilent XDB-C18 column (4.6 x 150 mm, 5 µm). Cyclopropane product standards 
for the reaction of ethyl diazoacetate (EDA) with styrene (ethyl 2-phenylcyclopropane-1-
carboxylate) and α-methylstyrene (ethyl 2-methyl-2-phenylcyclopropane-1-carboxylate) 
were prepared as reported (18). These standards and enzyme-prepared cyclopropanes 
demonstrated identical retention times in gas chromatograms when coinjected, 
confirming product identity. Absolute stereoconfiguration of cyclopropane enantiomers 
was determined by measuring optical rotation of purified cyclopropane products from 
preparative bioconversion reactions using enantioselective P450-BM3 variants and 
referenced to values taken from reference (19). Authentic P450-catalyzed cyclopropane 
samples were also prepared as described in section VIII and were characterized by NMR 
(1H and 13C) and mass spectrometry. 
 Plasmids pCWori[BM3] and pET22 were used as cloning vectors. Site-directed 
mutagenesis was accomplished by standard overlap mutagenesis using primers bearing 
desired mutations (IDT, San Diego, CA). Primer sequences are available upon request. 
Electrocompetent Escherichia coli cells were prepared following the protocol of 
Sambrook et al. (20). Restriction enzymes BamHI, EcoRI, XhoI, Phusion polymerase, 
and T4 ligase were purchased from New England Biolabs (NEB, Ipswich, MA). Alkaline 
phosphatase was obtained from Roche (Nutley, NJ). The 1,000x trace metal mix used in 
expression cultures contained 50 mM FeCl3, 20 mM CaCl2, 10 mM MnSO4, 10 mM 
ZnSO4, 2 mM CoSO4, 2 mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, and 2 mM H3BO3.   
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II.  General Procedures 
 
Enzyme library screening. Libraries maintained in our laboratory are stored at -78 °C as 
glycerol stocks (Luria-Bertani medium (LBamp), 150 µL, 25% v/v glycerol with 0.1 mg 
mL-1 ampicillin) in 96-well plates. These stocks were used to inoculate 96-shallow-well 
plates containing 300 µL LBamp medium using a 96-pin stamp. Single colonies from site-
saturation libraries were picked with toothpicks and used to inoculate 300 µL of LBamp. 
The cells were incubated at 37 °C, 250 rpm shaking, and 80% relative humidity 
overnight. After 16 h, 50 µL aliquots of these overnight cultures were transferred into 2 
mL, deep-well plates containing terrific broth (TBamp) (800 µL containing 0.1 mg mL-1 
ampicillin, 1 µL mL-1 trace metal mix and 20 mg L-1 aminolevulinic acid) using a 
Multimek 96-channel pipetting robot (Beckman Coulter, Fullerton, CA). The cultures 
were incubated at 37 °C for 3 h and 30 min, and 30 min after reducing the incubation 
temperature to 25 °C (250 rpm, 80% relative humidity), 50 µL isopropyl β-D-1-
thiogalactopyranoside (IPTG, 4.5 mM in TBamp) was added, and the cultures were 
allowed to continue for another 24 h at 25 °C (250 rpm, 80% relative humidity). Cells 
were then pelleted (3,000 × g, 15 min, 4 °C) and stored at -20 °C until further use, but at 
least for 2 h. For cell lysis, plates were allowed to thaw for 30 min at room temperature 
and then cell pellets were resuspended in 275 µL phosphate buffer (0.1 M, pH = 8.0, 0.65 
mg mL-1 lysozyme, 10 mM magnesium chloride and 40 U mL-1 DNAse I). The lysing 
cells were incubated at 37 °C for 1 h. Cell debris was separated by centrifugation at 5,000 
× g and 4 °C for 15 min. The resulting crude lysates were then transferred to 96-well 
microtiter plates for CO assays and to 2 mL deep-well plates for bioconversions. 
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CO binding assay. Na2S2O4 (160 µL, 0.1 M in phosphate buffer, 0.1 M, pH = 8.0) was 
added to P450BM3 variants in cell lysate (40 µL). The absorbance at 450 and 490 nm was 
recorded using a Tecan M1000 UV/Vis plate reader, and the microtiter plates were placed 
in a vacuum chamber. The chamber was sealed, evacuated to approximately - 15 in Hg, 
purged with CO gas, and incubated for 30 min. The plates were then removed and the 
absorbance at 450 and 490 nm was again recorded using a plate reader. The difference 
spectra could then be used to determine the P450 concentration in each well as previously 
described (21).  
 
P450 expression and purification. For the enzymatic transformations, P450BM3 variants 
were used in purified form. Enzyme batches were prepared as follows. One liter TBamp 
was inoculated with an overnight culture (100 mL, LBamp) of recombinant E. coli DH5α 
cells harboring a pCWori plasmid encoding the P450 variant under the control of the tac 
promoter. After 3.5 h of incubation at 37 °C and 250 rpm shaking (OD600 ca. 1.8), the 
incubation temperature was reduced to 25 °C (30 min), and the cultures were induced by 
adding IPTG to a final concentration of 0.5 mM. The cultures were allowed to continue 
for another 24 hours at this temperature. After harvesting the cells by centrifugation (4 
°C, 15 min, 3,000 × g), the cell pellet was stored at -20 °C until further use but at least for 
2 h. The cell pellet was resuspended in 25 mM Tris.HCl buffer (pH 7.5 at 25 °C) and 
cells were lysed by sonication (2x1 min, output control 5, 50% duty cycle; Sonicator, 
Heat Systems—Ultrasonic, Inc.). Cell debris was removed by centrifugation for 20 min at 
4 °C and 27,000 × g and the supernatant was subjected to anion exchange 
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chromatography on a Q Sepharose column (HiTrapTM Q HP, GE Healthcare, 
Piscataway, NJ) using an AKTAxpress purifier FPLC system (GE healthcare). The P450 
was eluted from the Q column by running a gradient from 0 to 0.5 M NaCl over 10 
column volumes (P450 elutes at 0.35 M NaCl). The P450 fractions were collected and 
concentrated using a 30 kDa molecular weight cutoff centrifugal filter and buffer-
exchanged with 0.1 M phosphate buffer (pH = 8.0). The purified protein was flash-frozen 
on dry ice and stored at -20 °C. P450 concentration was determined in triplicate using the 
CO binding assay described above (10 µL P450 and 190 µL 0.1 M phosphate buffer, pH 
8.0, per well).  
 
Thermostability measurements. Duplicate measurements were taken for all values 
reported in tables S10 and S11.  Purified P450 solutions (4 µM, 200 µL) were heated in a 
thermocycler (Eppendorf) over a range of temperatures (38–65 °C) for 10 min followed 
by rapid cooling to 4 °C for 1 min. The precipitate was removed by centrifugation. The 
concentration of folded P450 remaining in the supernatant was measured by CO-
difference spectroscopy (as described above). The temperature at which half of the 
protein was denatured (T50) was determined by fitting the data to the equation: f (T) = 100 
/ (1 + exp(a*(T – T50))).  
 
Typical procedure for small-scale cyclopropanation bioconversions under anaerobic 
conditions. Small-scale reactions (400 µL) were conducted in 2 mL crimp vials (Agilent 
Technologies, San Diego, CA). P450 solution (80 µL, 100 µM) was added to the vial 
	  
 
 
105	  
with a small stir bar before crimp sealing with a silicone septum. Phosphate buffer (260 
µL, 0.1 M, pH = 8.0) and 40 µL of a solution of the reductant (100 mM Na2S2O4, or 20 
mM NADPH) were combined in a larger crimp-sealed vial and degassed by bubbling 
argon through the solution for at least 5 min (figure S1). In the meantime, the headspace 
of the 2 mL reaction vial with the P450 solution was made anaerobic by flushing argon 
over the protein solution (with no bubbling). When multiple reactions were conducted in 
parallel, up to 8 reaction vials were degassed in series via cannulae. The buffer/reductant 
solution (300 µL) was syringed into the reaction vial, while under argon. The gas lines 
were disconnected from the reaction vial before placing the vials on a plate stirrer. A 40x 
styrene solution in MeOH (10 µL, typically 1.2 M) was added to the reaction vial via a 
glass syringe, and left to stir for about 30 s. A 40x EDA solution in MeOH was then 
added (10 µL, typically 400 mM) and the reaction was left stirring for the appropriate 
time. The final concentrations of the reagents were typically: 30 mM styrene, 10 mM 
EDA, 10 mM Na2S2O4, 20 µM P450.   
The reaction was quenched by adding 30 µL HCl (3M) via syringe to the sealed 
reaction vial. The vials were opened and 20 µL internal standard (20 mM 2-
phenylethanol in MeOH) was added followed by 1 mL ethyl acetate. This mixture was 
transferred to a 1.8 mL eppendorf tube which was vortexed and centrifuged (16,000xg, 1 
min). The top organic layer was dried over an anhydrous sodium sulfate plug and 
analyzed by chiral phase GC. 
 A slightly modified workup was implemented for kinetic experiments. The 
reactions were quenched after the set time by syringing 1 mL EtOAc to the closed vials 
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and immediately vortexing the mixture. The vials were then opened and 20 µL internal 
standard was added. The mixture was transferred to a 1.8 mL eppendorf tube, vortexed 
and centrifuged (16,000 × g, 1 min). The top organic layer was dried over an anhydrous 
sodium sulfate plug and analyzed by GC.  
 
Typical procedure for preparative-scale cyclopropanation bioconversions under 
anaerobic conditions. The P450 solution was added to a Schlenk flask with a stir bar. 
With the flask kept on ice, the headspace was evacuated and backfilled with argon (4×) 
with care not to foam the protein solution. Phosphate buffer and reductant were premixed 
and degassed together in a separate round-bottom flask by bubbling argon through the 
solution for 20 min. The buffer/reductant solution was transferred to the Schlenk flask via 
syringe. Styrene was added under argon and left to mix for 1 min. EDA was added 
dropwise under argon. The solution was left to stir under argon until reaction completion. 
The reaction was quenched under argon by adding hydrochloric acid (3 M) to adjust the 
pH to 4, before opening the Schlenk flask. The reaction mixture was stirred with sodium 
chloride and dichloromethane (CH2Cl2). The combined emulsion layers were then filtered 
through Celite to break the emulsion, and the Celite pad was rinsed with 3 × 20 mL 
CH2Cl2. The resulting biphasic mixture was transferred to a separating funnel and the 
organic phase was removed. The remaining aqueous phase was reextracted with 3 × 40 
mL CH2Cl2. The combined organic extracts were dried with sodium sulfate, filtered, and 
concentrated. The resulting residue was purified by SiO2 chromatography.  
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III. Preliminary Experiments with Heme Proteins 
 
The following six heme proteins were initially screened for cyclopropanation activity: 
catalase, chloroperoxidase (CPO), horseradish peroxidase (HRP), cytochrome C (cyt c), 
myoglobin (Mb) and P450BM3. Small-scale (400 µL) reactions were conducted as 
described in section II and were analyzed by GC (cyclosil-B 30 m x 0.25 mm x 0.25 µm): 
oven temperature = 130 °C.    
 
 
 
Table S1. Heme catalysts under anaerobic conditions with sodium dithionite (Na2S2O4)  
catalyst axial ligand cat. loading (% mol eq) TTN cis:trans*
 %ee cis† %ee trans‡ 
catalase O-Tyr 0.16 0 - - - 
CPO§ S-Cys 0.40 0 - - - 
HRP N-His 1.00 9 7:93 8 −7 
cyt c N-His, S-Met 1.00 19 6:94 0 12 
Mb N-His 1.00 43 6:94 −1 2 
P450BM3 S-Cys 0.20 5 37:63 −27 −2 
hemin - 0.20 73 6:94 −1 0 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S). § Bioconversion conducted at 0.1 M citrate buffer pH = 4.0.   
  
OEt
O
N
N
+ + catalyst
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
30 mM 10 mM
Anaerobic
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
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Table S2. Heme catalysts under anaerobic conditions without Na2S2O4   
catalyst axial ligand cat. loading (% mol eq) TTN cis:trans*
 %ee cis† %ee trans‡ 
catalase O-Tyr 0.16 0 - - - 
CPO§ S-Cys 0.40 0 - - - 
HRP N-His 1.00 0 - - - 
cyt c N-His, S-Met 1.00 12 8:92 8 −3 
Mb N-His 1.00 0.8 11:89 −2 8 
P450BM3 S-Cys 0.20 0 0 - - 
hemin - 0.20 4 11:89 −1 3 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S). § Bioconversion conducted at 0.1 M citrate buffer pH = 4.0.   
 
 
Table S3. Heme catalysts under aerobic conditions with Na2S2O4  
catalyst axial ligand cat. loading (% mol eq) TTN cis:trans*
 %ee cis† %ee trans‡ 
catalase O-Tyr 0.16 0 - - - 
CPO§ S-Cys 0.40 0 - - - 
HRP N-His 1.00 1 12:88 −3 −7 
cyt c N-His, S-Met 1.00 3 9:91 −6 16 
Mb N-His 1.00 6 7:93 −13 12 
P450BM3 S-Cys 0.20 1 13:87 −38 −8 
hemin - 0.20 6 8:92 −5 1 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S). § Bioconversion conducted at 0.1 M citrate buffer pH = 4.0.   
OEt
O
N
N
+ + catalyst
0.1 M KPi pH 8.0
5% MeOH
30 mM 10 mM
Anaerobic
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
OEt
O
N
N
+ + catalyst
30 mM 10 mM
Aerobic
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
	  
 
 
109	  
 
Table S4. Heme catalysts under aerobic conditions without Na2S2O4 
catalyst axial ligand cat. loading 
(% mol eq) 
TTN cis:trans* %ee cis† %ee trans‡ 
catalase O-Tyr 0.16 0 - - - 
CPO§ S-Cys 0.40 0 - - - 
HRP N-His 1.00 0 - - - 
cyt c N-His, S-Met 1.00 0 - - - 
Mb N-His 1.00 0 - - - 
P450BM3 S-Cys 0.20 0.4 46:54 −46 36 
hemin - 0.20 0 - - - 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S). § Bioconversion conducted at 0.1 M citrate buffer pH = 4.0.   
   
  
OEt
O
N
N
+ + catalyst
0.1 M KPi pH 8.0
5% MeOH
30 mM 10 mM
Aerobic
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
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IV. Screening P450BM3 Variants for Cyclopropanation Activity 
 
Lysate screening under aerobic conditions. The 92 variants in our compilation plate 
(table S5, following pages) represent a diverse selection of P450BM3 variants that have 
previously been engineered for monooxygenase activity on a variety of substrates, 
including but not limited to short alkane hydroxylation, demethylation of protected 
monosaccharides, and oxidation of lead drug compounds. These P450BM3 variants carry 
various mutations accumulated along sequential rounds of engineering efforts for activity 
towards the target substrates (table S5) or were generated by recombination with 
homologous enzymes (table S6). The compilation plate was expressed and lysed as 
described in section II (enzyme library screening). Lysate (150 µL) was transferred 
(Multimek 96-channel pipetting robot, Beckman Coulter, Fullerton, CA) to a 2 mL deep-
well plate, with 50 µL of 120 mM Na2S2O4 in 0.1 M KPi (pH = 8.0). 100 µL of a 30 mM 
styrene, 60 mM EDA mixed solution in 15% MeOH in 0.1 M KPi (pH = 8.0) was added 
to the plate to initiate the reaction. The plate was sealed and was left shaking (300 rpm) 
for four hours. The plastic seal was removed and 30 µL HCl (3 M) was added to quench 
the reaction followed by 20 µL of an internal standard solution (20 mM α-methylstyrene 
in methanol). The reactions were extracted by adding 500 µL EtOAc and carefully 
vortexing the plate. The plate was centrifuged (1,700 × g) to separate the biphasic 
mixture. The top organic layer was transferred (2 × 150 µL) to a separate deep-well plate. 
The extracts for each of the 92 reactions were dried through 92 separate anhydrous 
sodium sulfate plugs. The dried extracts were analyzed by GC (cyclosil-B 30 m × 
0.32 mm × 0.25 µm): oven temperature = 60 °C 3 min, 7.5 °C / min   to 160 °C, 
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20 °C / min to 250 °C, 250 °C 2 min, cis-cyclopropanes (20.3 min and 20.45 min), trans-
cyclopropanes (21.8 min). The top 10 protein variants of importance with respect to this 
report are highlighted in tables S5 and S6. 
 
Table S5. Raw data from P450BM3 compilation plate screen 
 
Diastereo- and enantioselectivity were determined by gas chromatography using a chiral 
β-CDX column as the stationary phase.  
 
P450BM3 variant 
mutations with respect to 
wild-type P450BM3 
absolute 
activity* de
† ee (cis) ‡ 
CYP102A3 N/A 0.004053 -74 -8 
CYP102A2 N/A 0.002963 -76 -36 
CYP102A1 
(P450BM3) 
None 0.002240 -81 7 
WT F87A F87A 0.001704 -28 57 
WT T88L T88L 0.004522 -78 23 
WT A328V A328V 0.000830 -100 N/A 
J (22) 
V78A, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, L353V 
0.001334 -100 N/A 
139-3 (23) 
V78A, H138Y, T175I, V178I, 
A184V, F205C, S226R, 
H236Q, E252G, R255S, 
A290V, L353V 
0.001386 -86 0 
9-10A (22) 
R47C, V78A, K94I, P142S, 
T175I, A184V, F205C, S226R, 
H236Q, E252G, R255S, 
A290V, L353V 
0.004292 -74 -20 
9-10A L75W 
(24) 9-10A L75W 0.005191 -83 -8 
9-10A L75I (24) 9-10A L75I 0.002267 -85 -3 
9-10A A78F (24) 9-10A L78F 0.002008 -82 -35 
9-10A A78S (24) 9-10A A78S 0.005098 -81 -6 
9-10A A82G (24) 9-10A A82G 0.002245 -76 -7 
9-10A A82F (24) 9-10A A82F #VALUE! N/A N/A 
9-10A A82C (24) 9-10A A82C 0.002487 -74 16 
9-10A A82I (24) 9-10A A82I 0.001031 -100 N/A 
9-10A A82S (24) 9-10A A82S 0.001483 -82 14 
9-10A A82L (22) 9-10A A82L 0.000591 -100 N/A 
9-10A F87A 9-10A F87A 0.001701 -61 -10 
9-10A F87V (24) 9-10A F87V 0.000000 N/A N/A 
9-10A F87I (24) 9-10A F87I 0.000983 -100 N/A 
9-10A F87L (24) 9-10A F87L 0.000710 -100 N/A 
9-10A T88C (24) 9-10A T88C 0.002516 -77 3 
9-10A T260S 9-10A T260S 0.004259 -82 -6 
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(24) 
9-10A T260N 
(24) 9-10A T260N 0.003882 -77 15 
9-10A T260L 
(24) 9-10A T260L 0.006173 -77 -2 
9-10A A328V 
(22) 9-10A A328V 0.006471 -68 -8 
9-10A A328M 
(24) 9-10A A328M 0.005180 -82 6 
9-10A A328F 
(24) 9-10A A328F 0.002009 -63 -32 
49-1A 
R47C, V78T, A82G, F87V, 
K94I, P142S, T175I, A184V, 
F205C, S226R, H236Q, 
E252G, R255S, A290V, 
A328L, L353V 
0.001874 -75 -32 
35-7F 
R47C, V78F, A82S, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328L, 
L353V 
0.004514 -73 -52 
53-5H (24) 9-10A A78F, A82S, A328F 0.002840 -80 2 
7-11D 9-10A A82F, A328V 0.036840 -24 -28 
49-9B 
R47C, V78A, A82G, F87V, 
K94I, P142S, T175I, A184V, 
F205C, S226R, H236Q, 
E252G, R255S, A290V, 
A328L, L353V 
0.000000 N/A N/A 
41-5B 
R47C, V78F, A82G, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328V, 
L353V 
0.008391 -77 -17 
13-7C (24) 9-10A A78T, A328L 0.005493 -73 -43 
12-10C 
R47C, V78A, A82G, F87V, 
K94I, P142S, T175I, A184V, 
F205C, S226R, H236Q, 
E252G, R255S, A290V, 
A328V, L353V 
0.004566 -73 -21 
77-9H (24) 9-10A A78T, A82G, A328L 0.003053 -73 -34 
11-8E 
R47C, V78A, F87V, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328L, 
L353V 
0.001453 -77 15 
1-12G (22) 9-10A A82L, A328V 0.003884 -70 -19 
29-3E 
R47C, V78A, A82F, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328F, 
L353V 
0.003425 -80 15 
29-10E R47C, V78F, A82G, K94I, 0.001935 -70 16 
	  
 
 
113	  
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328F, 
L353V 
68-8F (24) 9-10A A78F, A82G, A328L 0.004127 -72 -32 
35E11 (25) 
R47C, V78F, A82S, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328F, 
L353V, E464G, I710T 
0.003600 -71 -14 
19A12 (25) 35E11 L52I, L188P, I366V 0.006909 -70 -27 
ETS8 (25) 35E11 L52I, I366V 0.003966 -79 -19 
(11-3) (25) 35E11 L52I, A74S, L188P, I366V 0.005633 -76 -39 
(7-7) (25) 35E11 L52I, A74E, S82G, A184V, L188P, I366V 0.010499 -77 -9 
H2A10 9-10A TS F87V, L75A, L181A, T268A 0.066422 -8 -94 
SL2-6F8 
R47C, L52I, V78F, A82S, 
K94I, P142S,T175I, A184V, 
F205C, S226R, H236Q, 
E252G, R255S, A290V, 
A328L, K349N, L353V, 
I366V, E464G, I710T 
0.000778 -100 N/A 
A12SL-17-4 
R47C, L52I, A74E, V78F, 
A82S, K94I, P142S,T175I, 
A184V, L188P, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328F, 
L353V, I366V, E464G, I710T 
0.010935 -80 6 
H2-2-A1 (26) 9-10A TS F87V, L75A, L181A, L437A 0.003042 -75 -11 
A12RM-2-8 
R47C, L52I, A74E, V78F, 
A82S, K94I, P142S,T175I, 
A184S, L188P, F205C, S226R, 
H236Q, E252G, R255S, 
A290V, A328F, L353V, 
I366V, E464G, I710T 
0.007705 -77 -13 
H2-5-F10 9-10A TS F87V, L75A, I263A, T268A, L437A 0.141237 -46 -56 
13C9R1 
L52I, I58V, L75R, F87A, 
H100R, S106R, F107L, 
A135S, A184V, N239H, 
S274T, L324I, V340M, I366V, 
K434E, E442K, V446I 
0.001980 -100 N/A 
22A3 13C9R1 F162I E434K K442E I446V 0.004053 -70 4 
2C6 (27) 9-10A A78L, F87A, V184T, G315S, A330V 0.004257 -78 -15 
9C7 (27) 
9-10A C47R, A78L, F87G, 
I94K, A180V, V184T, G315S, 
A330V, Y345C 
0.007258 -79 -5 
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B1 (27) 
9-10A C47R, A78L, F87A, 
I94K, V184T, I263M, G315S, 
A330V 
0.002246 -61 -14 
B1SYN (27) 
9-10A C47S, N70Y, A78L, 
F87A, I174N, I94K, V184T, 
I263M, G315S, A330V 
0.002705 -76 -23 
H2-4-D4 
9-10A TS F87V, L75A, 
M177A, L181A, T268A, 
L437A 
0.052439 57 -84 
E12 A87V (27) 
9-10A C47R, A78L, F87V, 
I94K, A111V, V141I, A180V, 
V184T, G315S, A330V 
0.001990 -65 -52 
GlcA4 T180A 9-10A C47R, F81W, A82S, F87A, I94K 0.004925 -78 12 
H2-8-C7 (26) 9-10A TS F87V, L75A, L181A 0.000808 -100 N/A 
CH-F8 
9-10A L51A, C47A, F87V, 
I94K, L181A, C205F, S254R, 
I366V, L437A, E442K 
0.001126 -100 N/A 
H2-4-H5 (26) 9-10A TS F87V, L75A, M177A, L181A 0.001229 -100 N/A 
SA9 9-10A C47R, F81W, A82I, F87A, I94K, A180T, A197V 0.004170 -81 11 
ManA10 9-10A C47R, F81S, A82V, F87A, I94K, A180T, A197V 0.006340 -82 14 
Man1 9-10A C47R, F81L, A82T, F87A, I94K 0.003053 -73 21 
MB2 9-10A C47R, F81W, A82I, F87A, I94K 0.003282 -77 10 
HA62 9-10A C47R, F81A, A82L, F87A, I94K 0.003375 -81 -5 
9-10A TS 
V78A, P142S, T175I, A184V, 
S226R, H236Q, E252G, 
A290V, L353V, I366V, 
E442K 
0.001920 -75 -54 
9-10A TS F87A 9-10A TS F87A 0.001546 -60 5 
25F7 9-10A C47R, A74F, A78S, F87A, I282K, C205F, S255R 0.001829 -81 43 
24C4 9-10A C47R, A74I, A78L, F87A, I94K, C205F, S255R 0.000783 -100 N/A 
5A1 
9-10A M30T, C47R, A74F, 
A78S, I94K, C205F, S255R, 
Q310L, I366V, E442K 
0.002471 -80 15 
8B3 
9-10A M30T, C47R, A74F, 
A78S, I94K, C205F, C255R, 
L310Q, Q323L, I366V, 
N381K, R398H, E441K 
0.001315 -100 N/A 
 
* Reported as the sum of the area of the cyclopropane peaks over the area of the internal 
standard. † Diastereomeric excess = ([cis]-[trans])/([cis]+[trans]). ‡ (R,S) – (S,R). 
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Table S6. Raw GC screening data for the chimeric P450s in the compilation plate 
 
P450 chimeric P450s (heme domain block sequence) 
absolute 
activity* de
† ee (cis) ‡ 
CYP102A1 
(P450BM3) F87A 
(28) 
11111111 0.001704 -28 56 
CYP102A2 
F88A (28) 22222222 N/A N/A N/A 
CYP102A3 
F88A (28) 33333333 N/A N/A N/A 
5R1 (29) 32312231 0.008625 58 19 
9R1 (29) 12112333 0.0042707 58 24 
12R1 (29) 12112333 0.0701514 32 -49 
C1D11R1 (29) 21113312 0.007138 51 9 
C2B12R1 (29) 32313233 0.005914 38 -5 
C2C12R1 (29) 21313111 0.006226 28 9 
C2E6R1 (29) 11113311 0.008731 25 6 
C2G9R1 (29) 22213132 0.007975 15 31 
C3D10R1 (29) 22132231 0.004898 -16 -2 
C3E4R1 (29) 21313311 0.007893 14 17 
F3H12R1 (29) 21333233 0.005586 -56 -17 
F6D8R1 (29) 22313233 0.008088 -76 -6 
C3B5R1 (29) 23132233 0.014722 -81 4 
X7R1 (29) 22312333 0.017305 -4 -34 
 
* Reported as the sum of the area of the cyclopropane peaks over the area of the internal 
standard. † Diastereomeric excess = ([cis]-[trans])/([cis]+[trans]). ‡ (R,S) – (S,R). 
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Determining the cyclopropanation activity of the top 10 hits (highlighted in yellow 
on tables S5-6) under anaerobic conditions. Small-scale reactions (400 µL total 
volume) were conducted as described in section II and were analyzed by GC (cyclosil-B 
30 m x 0.32 mm x 0.25 µm): oven temperature = 100 °C 5 min, 1 °C / min to 135 °C, 135 
°C 10 min, 10 °C / min to 200 °C, 200 °C 5 min, cis-cyclopropanes (39.40 min and 40.20 
min), trans-cyclopropanes (44.69 min and 45.00 min). 
 
 
 
Table S7. Stereoselective P450BM3-based cyclopropanation catalysts 
 
P450 % yield* TTN cis:trans† %ee cis‡ %ee trans§ 
WT 1 5 37:63 −10 −9 
WTF87A 1.2 6 37:63 26 −6 
H2A10 33.4 167 60:40 −95 −78 
H2-4-D4 41.2 206 53:47 −79 −33 
H2-5-F10 58.8 294 16:84 −41 −63 
C2C12R1 1.6 8 36:64 45 1 
C3E4R1 1.6 8 43:57 51 −7 
X7R1 2.4 12 33:67 23 −4 
12 R1 6.2 31 17:83 9 −2 
C2E6 R1 4.6 23 27:73 25 −6 
C2G9 R1 48 240 9:91 10 −2 
7-11D 32 160 35:65 −22 −18 
 
* based on EDA. † Diastereomeric ratios and enantiomeric excess were determined by GC 
analysis. ‡ (R,S) – (S,R). § (R,R) – (S,S).  
 
OEt
O
N
N
+ + P450
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
30 mM 10 mM
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
20 µM
0.2% mol eq
(wrt EDA)
Anaerobic
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V. Experimental Characterization of P450BM3 Cyclopropanation 
Catalysts 
 
V.I. Controls to confirm the enzymatic cyclopropanation activity of variant H2A10. 
Small-scale reactions (400 µL total volume) were set up and worked up as described in 
section II. For the carbon monoxide (CO) inhibition experiment, the reaction vial and the 
buffer/reductant vial were purged with CO after having been purged with argon. For the 
boiled P450 experiment, a 100 µM solution of variant H2A10 was heated at 60 °C for 10 
min. For the hemin experiment, hemin (80 µL) was added from a 1 mM solution in 50% 
DMSO-H2O, such that its final concentration in the reaction was 200 µM. Complete 
System = 10 mM styrene, 20 mM EDA, 20 mM Na2S2O4, 20 µM P450 (H2A10) under 
anaerobic conditions. The dried ethyl acetate extracts were analyzed by chiral phase GC, 
using 2-phenylethanol as an internal standard (injector temperature = 300 °C, oven 
temperature = 100 °C for 5 min, 1 °C / min ramp up to 135 °C, 135 °C for 10 min, 10 °C 
/ min ramp up to 200 °C, 200 °C for 5 min). Elution time: cis-cyclopropanes (39.40 min 
and 40.20 min), trans-cyclopropanes (44.69 min and 45.00 min).   
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Table S8. Controls for P450 based cyclopropanation using variant H2A10 
conditions TTN % inhibition cis:trans* % ee cis† % ee trans‡ 
complete system (CS) 101 - 70:30 −95 −78 
CS-Na2S2O4+NADPH 45 −55 61:39 −87 −31 
CS-Na2S2O4+NADH 38 −62 53:47 −76 −19 
CS-Na2S2O4 0 −100 - - - 
CS-P450 0 −100 - - - 
CS+CO 0 −100 - - - 
boiled P450 146 +45 16:84 2 −2 
H2A10heme 85 −16 67:33 −92 −67 
CS-P450+hemin 16 −84 15:85 −1 −2 
CS (aerobic) 43 −57 67:33 −94 −76 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S).  
 
V.II. Optimizing cyclopropanation reaction conditions for variant H2A10. Small-
scale reactions (400 µL final volume) were set up and worked up as described in section 
II. The dried ethyl acetate extracts were analyzed by chiral phase GC, using 2-
phenylethanol as an internal standard (injector temperature = 300 °C, oven temperature = 
100 °C for 5 min, 5 °C / min ramp up to 200 °C, 20 °C / min ramp up to 250 °C, 250 °C 
for 5 min). Elution time: cis-cyclopropanes (19.20 min and 19.33 min), trans-
cyclopropanes (20.44 min). The reaction conditions that gave optimal yields of 
OEt
O
N
N
+ + P450
H2A10holo
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
10 mM 20 mM
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
20 µM
0.2% mol eq
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cyclopropanes (with respect to EDA) were: 30 mM styrene, 10 mM EDA and 20 µM 
P450 and were used in subsequent experiments.   
 
V.II.I. Styrene concentration 
 
 
 
 
Figure S1. Effect of styrene concentration on cyclopropane yield.  
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V.II.II. P450 concentration 
 
 
 
 
 
Figure S2. Effect of P450 (H2A10) concentration on cyclopropane yield  
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V.II.III. Dithionite concentration 
 
 
 
 
Table S9. Effect of concentration of Na2S2O4 on cyclopropane yield 
 
[Na2S2O4] / mM [cyclopropanes] / mM TTN 
0 0 0 
1 2.59 129 
5 2.72 136 
10 3.34 167 
20 3.13 156 
50 2.79 140 
100 2.71 136 
 
OEt
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Ph
COOEt
20 mM 10 mM Variable
20 µM
0.2% mol eq 
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V.III. Mutational analysis of active site alanine substitutions in 9-10A TS F87V 
 
 
 
 
Table S10. Mutational analysis of alanine substitutions on 9-10A TS F87V 
 Mutations relative to 9-10A TS F87V      
P450 (Holo) L75A M177A L181A I263A T268A L437A TTN cis:trans* %ee cis† %ee trans‡ T50 (°C) 
9-10A TS F87V No No No No No No 7 35:65 −41 −8 59.5 
9-10A TS F87V 
L75A Yes No No No No No 5 42:58 −59 −11 52.3 
9-10ATS F87V 
L181A No No Yes No No No 5 41:59 −27 −7 53.3 
9-10A TS F87V 
I263A No No No Yes No No 8 29:71 −31 −39 55.4 
9-10A TS F87V 
T268A (BM3-CIS) No No No No Yes No 199 71:29 −94 −91 55.2 
BM3-CIS I263A No No No Yes Yes No 190 19:81 −62 −91 54.0 
BM3-CIS L181A No No Yes No Yes No 159 56:44 −92 −94 50.8 
H2A10 Yes No Yes No Yes No 167 60:40 −95 −78 48.9 
BM3-CIS L181A 
I263A No No Yes Yes Yes No 203 14:86 −46 −95 50.9 
BM3-CIS L181A 
L437A No No Yes No Yes Yes 180 27:73 −74 −98 48.4 
BM3-CIS L181A 
I263A L437A No No Yes Yes Yes Yes 218 9:91 −55 −96 48.2 
4H5 Yes Yes Yes No No No 7 32:68 −9 0 49.4 
BM3-CIS I263A 
L437A No No No Yes Yes Yes 267 16:84 −59 −89 50.4 
H2-5-F10 Yes No No Yes Yes Yes 294 16:84 −41 −63 47.5 
H2-4-D4 Yes Yes Yes No Yes Yes 206 53:47 −79 −33 46.4 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S).  
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V. IV. Sequential introduction of BM3-CIS active site mutations in wild-type 
P450BM3 
 
 
 
Table S11. Introducing BM3-CIS related active site mutations in wild-type P450BM3 
 
Mutations relative to  
wild-type P450BM3 
 
    
P450 (Holo) V78 F87 T268 I263 TTN  cis:trans* %ee cis† %ee trans‡ 
 
T50 (°C) 
WT - - - - 5 37:63 −10 −9 56.0 
WT-F87A - A - - 6 38:62 26 −6 53.0 
WT-F87V - V - - 9 30:70 −33 −26 52.9 
WT-T268A - - A - 323 1:99 −15 −96 53.6 
WT-F87V/T268A - V A - 274 32:68 −77 −99 52.0 
WT-
V78A/F87V/T268A A V A - 190 32:68 −70 −20 50.8 
WT-
F87V/I263A/T268A - V A A 246 7:93 8 −94 50.0 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S).  
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cis trans
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VI. Active Site Saturation Mutagenesis of BM3-CISheme 
 
Library construction. To simplify library construction and screening, only the BM3-CIS 
heme domain, which comprises residues 1-462 was used. This truncated enzymes lacks 
the P450 native reductase and exhibits similar activity and stereochemical control to the 
full length enzyme using Na2S2O4 as a reductant, but not NADPH (data not shown). P450 
site-directed mutagenesis and site-saturation libraries were assembled from PCR 
fragments generated from oligonucleotides containing the desired codon mutation or a 
degenerate NNK (or for reverse primers, the reverse complement MNN; where N = 
A,T,G,C, K = G,T and M = A,C) codon, which codes for all 20 amino acids and the TAG 
stop codon. PCR fragments were assembled using either standard overlap extension PCR 
or through restriction cloning using the Type IIS restriction enzyme, BsaI, depending on 
convenience. 
 
Lysate screening under aerobic conditions. The compilation plate was expressed and 
lysed as described in section II (enzyme library screening). 150 µL lysate was 
transferred (Multimek 96-channel pipetting robot, Beckman Coulter, Fullerton, CA) to a 
2 mL deep-well plate, with 50 µL of 120 mM Na2S2O4 in 0.1 M KPi (pH = 8.0). 100 µL 
of a 90 mM styrene, 30 mM EDA mixed solution in 15% MeOH in 0.1 M KPi (pH = 8.0) 
was added to the plate to initiate the reaction. The plate was sealed and was left shaking 
(300 rpm) for four hours. The plastic seal was removed and 30 µL HCl (3 M) was added 
to quench the reaction followed by 20 µL of an internal standard solution (20 mM 2-
phenylethanol in methanol). Acetonitrile (400 µL) was added before carefully vortexing 
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the plate. The plate was centrifuged (1,700 × g), the supernatant was filtered (1 µm glass, 
96 well filter plate, Pall) and transferred (150 µL) to a 96-well microtiter plate (Agilent). 
Reactions were analyzed by reverse-phase HPLC (210 nm): 50% acetonitrile-water, 1.0 
mL min-1, cis-cyclopropanes (7.6 min), trans-cyclopropanes (9.7 min). Hits were selected 
based on enhancement of cis-selectivity over parent BM3-CIS. 
 
Determining the cyclopropanation activity of hits from the site-saturation libraries 
under anaerobic conditions. Small-scale reactions (400 µL total volume) were 
conducted as described in section II and were analyzed by GC (cyclosil-B 30 m x 0.25 
mm x 0.25 µm): oven temperature = 130 °C, 175 kPa, cis-cyclopropanes (39.40 min and 
40.20 min), trans-cyclopropanes (44.69 min and 45.00 min). 
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Table S12. Cyclopropanation activity of selected BM3-CISheme active site variants 
 
P450heme yield (%)* TTN cis:trans† %ee cis‡ %ee trans§ 
BM3-CIS 57 286 71:29 −92 −88 
BM3-CIS-L181G 47 234 59:41 −89 −90 
BM3-CIS-A328G 37 186 83:17 52 −45 
BM3-CIS-L437F 53 265 53:47 −82 −85 
BM3-CIS-L437Q 30 148 53:47 −73 −87 
BM3-CIS-L437G 58 290 54:46 −88 −91 
BM3-CIS-L437A 39 194 38:62 −84 −11 
BM3-CIS-T438A 54 273 91:9 −92 −75 
BM3-CIS-T438G 15 78 73:27 −87 −59 
BM3-CIS-T438S 59 293 92:8 −97 −66 
BM3-CIS-T438Q 41 206 38:62 67 70 
BM3-CIS-T438P 32 161 90:10 −91 −50 
 
* based on EDA. † Diastereomeric ratios and enantiomeric excess were determined by GC 
analysis. ‡ (R,S) – (S,R). § (R,R) – (S,S).  
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VII. Kinetic Characterization of BM3-CIS 
 
Determination of initial rates. Both styrene and EDA concentrations were varied in the 
presence of the P450s expressed as the heme-domain (0.5 or 1.0 µM BM3-CISheme). 
Reactions were set up in phosphate buffer (pH = 8.0) with Na2S2O4 as the reductant at 
298 K, and were worked up as described in section II. Three time points were taken and 
used to determine the rate of product formation by GC (cyclosil-B 30 m x 0.32 mm x 
0.25 µm): oven temperature = 100 °C 5 min, 5 °C / min to 200 °C, 20 °C / min to 250 °C, 
250 °C for 5 min. Elution time: cis-cyclopropanes (19.20 min and 19.33 min), trans-
cyclopropanes (20.44 min). Kinetic parameters were determined by fitting the data to the 
standard Michaelis-Menten model.    
 
 
 
Figure S3. Initial velocities plot for BM3-CISheme. A) EDA concentration was varied at a 
saturating concentration of styrene (30 mM). B) Styrene concentration was varied at a 
fixed concentration of EDA (20 mM). Initial rates were computed as the slope of a zero-
intercept linear fit of three different time points from independent reactions. Error bars 
correspond to 1-σ (68.3%) confidence intervals for the slope. 
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Table S13. Michaelis-Menten parameters for P450 cyclopropanation catalysts 
 
catalyst kcat (min-1) 
KM-EDA 
(mM) 
KM-styrene 
(mM) 
kcat / KM-
EDA (s-1 M-1) 
kcat / KM-
styrene 
(s-1 M-1) 
kcat / (KM-EDA x 
KM-styrene) 
(s-1 M-1 M-1) 
BM3-
CISheme 
100 ± 24 5.2 ± 3.5 1.4 ± 0.5 320 1,100 2.1 x 105 
 
 
 
Table S14. Kinetic parameters for wild-type cytochrome P450s acting on their native 
substrates and for an engineered variant of P450BM3 (propane monooxygenase, PMO)  
acting on the nonnative substrate propane 
 
P450 substrate kcat (min-1) KM (mM) kcat / KM (s
-1 
M-1) 
CYP153A6   
(30) octane 75 0.32 3,900 
P450BM3  
(31) lauric acid 5140 0.29 3.0 x 10
5 
PMO (32) propane 450 0.17 4.4 x 104 
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Table S15. Effect of EDA addition at t = 30 min on BM3-CIS-catalyzed 
cyclopropanations  
 
conditions TTN cis:trans* %ee cis † %ee trans‡ 
10 mM EDA added at t = 0 273 ± 2.5 72 : 28 −92 −90 
10 mM EDA added at t = 0  
+ 10 mM EDA at t = 30 min 425 ± 17 73 : 27 −93 −89 
 
TTN values are reported as the mean of triplicates ± standard deviation. * Diastereomeric 
ratios and enantiomeric excess were determined by GC analysis. † (R,S) – (S,R). ‡ (R,R) – 
(S,S) 
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VIII. Substrate Scope of P450 Cyclopropanation Catalysts 
 
Small-scale reactions. Selected P450 catalysts were surveyed at a small-scale (400 µL 
total volume) for each combination of reagents (olefins and diazo esters). The small-scale 
anaerobic bioconversions were conducted as described in section II and were analyzed by 
GC.  
 
 
 
Table S16. Substrate scope of P450 cyclopropanation catalysts: p-methylstyrene + EDA  
  
P450 % yield TTN cis:trans %ee cis %ee trans* 
7-11D 21 104 54:46 0.3 N/A 
H2-5-F10 44 222 11:89 14.9 N/A 
C2G9 R1 18 92 10:90 8.9 N/A 
H2A10 10 50 43:57 −84.3 N/A 
BM3-CIS 46 228 78:22 −81.4 N/A 
Hemin 7 37 6:94 −1.6 N/A 
 
GC (cyclosil-B column 30 m x 0.32 mm, 0.25 µm film): oven temperature = 100 °C for 5 
min, 5 °C / min to 200 °C, 20 °C / min to 250 °C, 250 °C for 5 min. Elution times: cis-
cyclopropanes (21.03 and 21.18 min), trans-cyclopropanes (22.71 min). * trans-
enantiomers did not resolve.  
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Table S17. Substrate scope of P450 cyclopropanation catalysts: p-vinylanisole + EDA 
   
P450 % yield TTN cis:trans %ee cis %ee trans* 
7-11D 59 297 70:30 −27 N/A 
H2-5-F10 73 364 11:89 38 N/A 
C2G9 R1 39 196 10:90 −1 N/A 
H2A10 16 80 40:60 −75 N/A 
BM3-CIS 43 214 48:52 −44 N/A 
hemin 19 96 7:93 0 N/A 
 
GC oven temperature = 110 °C for 8 min, 2 °C / min to 180 °C then 180 °C for 30 min, 
175 kPa. Cyclosil-B column (30 m x 0.25 mm, 0.25 µm film). Elution times: cis-
cyclopropanes (38.74 and  39.52 min), trans-cyclopropanes (43.07 min). * Baseline 
resolution could not be achieved for the trans-enantiomers. 
 
 
  
OEt
O
N
N
+ + P450
COOEt
30 mM 10 mM
20 µM
(0.2 mol%)
AnaerobicMeO
MeO
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
	  
 
 
132	  
 
 
Table S18. Substrate scope of P450 cyclopropanation catalysts: p-
(trifluoromethyl)styrene  
 
P450 % yield* TTN* cis:trans %ee cis %ee trans 
7-11D 24 120 76:24 31 59 
H2-5-F10 40 198 26:74 72 −65 
C2G9 R1 18 89 10:90 4 0 
H2A10 9 47 26:74 −24 22 
BM3-CIS 42 211 39:61 54 −93 
hemin 2 9 11:89 1 1 
 
* Assumed the same detector response factor as for ethyl 2-(4-
methylphenyl)cyclopropane-1-carboxylate. GC (cyclosil-B column 30 m x 0.25 mm, 0.25 
µm film): oven temperature = 110 °C for 8 min, 2 °C / min to 180 °C then 180 °C for 30 
min, 175 kPa. Elution times: cis-cyclopropanes (27.26 and  28.11 min), trans-
cyclopropanes (30.78 and 30.99 min).  
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Table S19. Substrate scope of P450 cyclopropanation catalysts: α-methyl styrene 
   
P450 % yield TTN Z:E %ee (Z) %ee (E) * 
7-11D 31 157 41:49 42 N/A 
H2-5-F10 66 329 21:79 −14  N/A 
C2G9 R1 77 387 16:84 −4 N/A 
H2A10 34 168 19:81 −31 N/A 
BM3-CIS 26 127 16:84 −6 N/A 
WT F87V T268A 62 312 7:93 3 N/A 
hemin 15 77 24:76 0 N/A 
 
GC oven temperature = 100 °C for 5 min, 1 °C / min up to 135 °C, 135 °C for 10 min, 10 
°C / min up to 200 °C, 200 °C for 5 min. Cyclosil-B column (30 m x 0.32 mm, 0.25 µm 
film). Elution times: Z-cyclopropanes (34.96 and 35.33 min), E-cyclopropanes (39.34 and 
39.61 min). * trans-enantiomers did not separate to baseline resolution. 
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Table S20.  Substrate scope of P450 cyclopropanation catalysts: t-butyl diazoacetate  
  
P450 % yield* TTN* cis:trans 
WT F87V 
T268A 1.4 7 4:96 
7-11D 11 54 13:87 
H2-5-F10 18 90 3:97 
H2A10 24 120 3:97 
BM3-CIS 0.3 2 3:97 
hemin 20 100 4:96 
 
* Assumed the same detector response factor as for ethyl 2-(4-
methylphenyl)cyclopropane-1-carboxylate. GC (cyclosil-B column 30 m x 0.32 mm, 0.25 
µm film): oven temperature = 100 °C for 5 min, 5 °C / min to 200 °C, 20 °C / min to 250 
°C, 250 °C for 5 min. Elution times: cis-cyclopropanes (21.66 min), trans-cyclopropanes 
(23.31 min). Cis- and trans-enantiomers did not resolve. 
 
 
  
O
O
N
N
+ + P450
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
30 mM 10 mM
20 µM
Anaerobic
(0.2 mol%)
O
O
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Preparative-scale bioconversions. These reactions were conducted anaerobically as 
described in section II.  
 
Cyclopropanation of styrene with EDA  
 
 
 
Prepared using 1.5 mmol styrene (3 equiv), 0.5 mmol EDA (1 equiv) and 1 µmol BM3-
CISheme (0.002 equiv). The product was purified by SiO2 chromatography (9:1 hexanes-
diethyl ether) to give 25 mg of the cis-cyclopropane (1) and 8 mg of a mixture of 
cyclopropanes with trans (2) in 5 : 1 excess over cis (33-35). Diagnostic data for the cis-
cyclopropane 1: 1H NMR (CDCl3, 500 MHz): δ 7.28 (m, 4H), 7.21 (m, 1H), 3.89 (q, J = 
7.1 Hz, 2H), 2.60 (m, 1H), 2.10 (m, 1H), 1.73 (m, 1H), 1.35 (m, 1H), 0.99 (t, J = 7.1 Hz, 
3H); 13C NMR (CDCl3, 125 MHz): δ 170.99, 136.56, 129.31, 127.88, 126.63, 60.18, 
25.47, 21.80, 14.02, 11.12; [α]25D = −7.056° (c 0.83, CHCl3). Diagnostic data for the 
trans-cyclopropane 2: 1H NMR (CDCl3, 500 MHz): δ 7.20 (m, 3H), 7.03 (m, 2H), 4.10 
(q, J = 7.1 Hz, 2H), 2.45 (m, 1H), 1.83 (m, 1H), 1.53 (m, 1H), 1.23 (m, 1H), 1.21 (t, J = 
7.1 Hz, 3H); 13C NMR  (CDCl3, 125 MHz): δ 173.43, 140.13, 128.46, 126.55, 126.16, 
60.72, 26.18, 24.20, 17.09, 14.27; [α]25D = +199.2° (c 0.50, CHCl3). MS (EI+) m/z: 190 
(M+), 162 (PhCH(CH2)CHCO2+), 145 (PhCH(CH2)CHCO+). The absolute configuration 
of compounds 1 and 2 was determined by comparison of the sign of their optical rotations 
N2 CO2Et+
0.2mol% C3C
0.1 M KPi pH 8, 5% MeOH
10 mM Na2S2O4
35%
Ph CO2Et
(S) (R)
Ph CO2Et
(S) (S)+
1 2(76:24)
92%ee 88%ee
BM3-CISheme
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with that reported (19). The enantiomeric excess was determined to be 92% for the cis-
cyclopropane and 88% for the trans-cyclopropane by GC. 
 
 
Cyclopropanation of p-methylstyrene with EDA 
 
 
Prepared using 1.5 mmol styrene (3 equiv), 0.5 mmol EDA (1 equiv) and 1 µmol BM3-
CISheme (0.002 equiv). The product was purified by SiO2 chromatography (9:1 hexanes-
diethyl ether) to give 10 mg of the cis-cyclopropane (3) and 16 mg of a mixture of 
cyclopropanes with trans(4) : cis / 2 : 1 (35). Diagnostic data for the cis-cyclopropane 3: 
1H NMR (CDCl3, 500 MHz): δ 7.17 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 8.0 Hz, 2H), 3.91 (q, 
J = 7.1 Hz, 2H), 2.56 (m, 1H), 2.32 (s, 3H) 2.06 (m, 1H), 1.69 (m, 1H), 1.32 (m, 1H), 
1.02 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 125 MHz): δ 171.12, 136.12, 133.42, 129.14, 
128.60, 60.17, 25.23, 21.68, 21.10, 14.08, 11.21. Diagnostic data for the trans-
cyclopropane 4: 1H NMR (CDCl3, 500 MHz): δ 7.09 (d, J = 8.0 Hz, 2H), 7.01 (d, J = 8.0 
Hz, 2H), 4.19 (q, J = 7.1 Hz, 2H), 2.50 (m, 1H), 2.33 (s, 3H), 1.88 (m, 1H), 1.59 (m, 1H), 
1.33 (m, 1H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR  (CDCl3, 125 MHz): δ 173.58, 137.04, 
136.08, 129.12, 126.10, 60.66, 25.94, 24.06, 21.11, 16.96, 14.28. MS (EI+) m/z: 204 
(M+), 175 ([M-Et]+) 131 ([M-COOEt]+). The enantiomeric excess was determined to be 
82% for the cis-cyclopropane by GC. Baseline resolution of the trans-enantiomers could 
not be achieved.  
N2 CO2Et+
0.2mol% C3C
0.1 M KPi pH 8, 5% MeOH
10 mM Na2S2O4
25%
CO2Et CO2Et
+
3 4
(80:20)
82%ee
BM3-CISheme
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Cyclopropanation of p-methoxystyrene with EDA 
 
 
Prepared using 1.5 mmol styrene (3 equiv), 0.5 mmol EDA (1 equiv) and 1 µmol BM3-
CISheme (0.002 equiv). The product was purified by SiO2 chromatography (9:1 hexanes-
diethyl ether) to give 16 mg of the trans-cyclopropane (6) and 3 mg of a mixture of 
cyclopropanes with cis : trans / 5 : 1 (35). Diagnostic data for the trans-cyclopropane 6: 
6.96 (m, 3H), 6.75 (m, 2H), 4.09 (q, J = 7.1 Hz, 2H), 3.72 (s, 3H), 2.41 (m, 1H), 1.75 (m, 
1H), 1.48 (m, 1H), 1.21 (t, J = 7.1 Hz, 3H), 1.18 (m, 1H). MS (EI+) m/z: 220 (M+), 191 
([M-Et]+), 175 ([M-EtO]+), 147 ([M-COOEt]+). The enantiomeric excess was determined 
to be 38% for the cis-cyclopropane by GC. The trans-enantiomers did not resolve to 
baseline resolution.  
 
Cyclopropanation of styrene with t-butyl diazo acetate 
 
 
Prepared using 0.75 mmol styrene (3 equiv), 0.24 mmol t-BuDA (1 equiv) and 0.5 µmol 
BM3-CISheme (0.002 equiv). The product was purified by SiO2 chromatography (9:1 
hexanes-diethyl ether) to give 9 mg of the trans-cyclopropane (8) (33, 35). Diagnostic 
data for the trans-cyclopropane 4: 1H NMR (CDCl3, 500 MHz): δ 7.20 (m, 2H), 7.12 (m, 
1H), 7.02 (m, 2H), 2.36 (m, 1H), 1.76 (m, 1H), 1.45 (m, 1H), 1.40 (s, 9H), 1.16 (m, 1H); 
N2 CO2Et+
0.2mol% H2-5-F10
0.1 M KPi pH 8, 5% MeOH
10 mM Na2S2O4
40%
CO2Et CO2Et
+
5 6
(10:90)
MeO
MeO MeO
38%ee
N2 CO2t-Bu+
0.2mol% H2-5-F10
0.1 M KPi pH 8, 5% MeOH
10 mM Na2S2O4
17%
Ph CO2t-Bu Ph CO2t-Bu
+
7 8(3:97)
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13C NMR (CDCl3, 125 MHz): δ 172.58, 140.52, 128.42, 126.32, 126.07, 80.57, 28.17, 
25.75, 25.31, 17.08. MS (EI+) m/z: 218 (M+), 145 ([M-OtBu]+).    
 
IX. Summary of Mutations in P450BM3 Variants 
Mutations in variant P450 cyclopropanation catalysts are reported with respect to wild-
type P450BM3. 
 
7-11D (24): R47C, V78A, K94I, P142S, T175I, A184V, F205C, S226R, H236Q, E252G, 
R255S, A290V, L353V, A82F, A328V  
9-10A TS (26): V78A, P142S, T175I, A184V, S226R, H236Q, E252G, A290V, L353V, 
I366V, E442K 
H2A10: 9-10A TS + F87V, L75A, L181A, T268A 
H2-5-F10: 9-10A TS + F87V, L75A, I263A, T268A, L437A 
H2-4-D4: 9-10A TS + F87V, L75A, M177A, L181A, T268A, L437A 
BM3-CIS: 9-10A TS + F87V, T268A 
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C h a p t e r  3  
HIGHLY EFFICIENT CARBENE TRANSFER TO OLEFINS CATALYZED IN VIVO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material from this chapter appears in: P. S. Coelho, Z. J. Wang, M. E. Ener, S. Baril, A. 
A. Kannan, F. H. Arnold,* E. M. Brustad* “Highly Efficient Carbene Transfer to Olefins 
Catalyzed in vivo” submitted. EMB and SB crystallized and solved the X-ray structures 
for the proteins described in this chapter. MEE was responsible for the redox titrations. 
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Abstract  
The ability to genetically encode catalysts for nonnatural chemical reactions will open 
new routes to sustainable production of chemicals, discovery of biologically active 
agents, and selective labeling of biological targets. We describe the design of a unique 
serine-heme ligated cytochrome “P411” that catalyzes formal carbene transfers from 
diazoesters to olefins in intact E. coli cells with very high efficiency. Proximal cysteine to 
serine substitution in a bacterial cytochrome P450 gives a signature ferrous-CO Soret 
peak at 411 nm, raises the resting state FeIII/FeII redox potential, abolishes 
monooxygenation activity and dramatically improves NAD(P)H-driven 
cyclopropanation. The serine-heme enzyme performs up to 60,000 turnovers in vivo, is 
highly stereoselective, and is more active than the purified protein at the same 
concentration in vitro. Reactions in intact E. coli cells require no organic cosolvents, and 
the cells can be stored as a dry powder without loss of activity. “ABC” catalysts based on 
cytochrome-P411 should be broadly useful for catalysis of nonnatural carbene transfer 
reactions. 
 
One sentence summary. Engineering a cytochrome P450 with axial serine ligation 
creates a “P411” enzyme that catalyzes tens of thousands of turnovers for nonnatural 
olefin cyclopropanation in bacterial cells.    
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Genetically programmed whole-cell biocatalysts are readily produced in 
simple growth media, do not require further purification or isolation, and can be 
engineered with metabolic pathways for the elaboration of complex molecules (1-3). The 
range of accessible transformations, however, is currently limited by the chemical 
repertoire of natural enzymes. Designing enzymes for nonnatural reactions in vivo has 
been challenging due to the requirements for assembly of the functional catalyst, the 
compatibility of synthetic reagents in the cellular milieu, and cell permeability to allow 
substrate influx and product release. The catalysis of synthetic transformations inside 
cells will enable alternative metabolic routes to natural and artificial products, biobased 
production of chemicals currently made using synthetic reactions, and will enhance 
control over the reactivity of abiotic functional groups in “bioorthogonal” chemistry (4).  
We recently showed that a few amino acid mutations in a bacterial cytochrome 
P450 monooxygenase can unlock significant cyclopropanation activity in vitro. Variants 
of P450 BM3 from Bacillus megaterium (BM3) catalyze hundreds of turnovers of formal 
carbene transfers from diazoesters (e.g., ethyl diazoacetate, EDA) to olefins (e.g., 
styrene) in the presence of a reductant, forming cyclopropane products with high levels of 
diastereo- and enantioselectivity (5). Olefin cyclopropanation is widely used in the 
synthesis of fine chemicals (6), and state of the art asymmetric organometallic catalysts 
are able to catalyze thousands to tens of thousands of turnovers (7-9). Because BM3 
variants are readily expressed in functional form in vivo and can catalyze nonnatural 
carbene transfers without requiring artificial cofactors or posttranslational modifications, 
we hypothesized that this system may be suitable for catalysis in vivo. To initiate the 
catalytic cycle inside a cell, it is necessary to drive the reduction to the catalytically active 
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ferrous-P450 with an endogenous reducing agent such as NAD(P)H. Based on 
consideration of heme ligation control of the P450 FeIII/FeII redox potential, we designed 
a genetically encoded “ABC” catalyst that catalyzes efficient and selective olefin 
cyclopropanation in intact cells.           
 Cytochrome P450-catalyzed cyclopropanations require substoichiometric (with 
respect to diazoester and olefin) reductant and proceed optimally under anaerobic 
conditions (5). This suggests that diazoester activation and carbene transfer involve a 
reduced P450-bound FeII-heme cofactor as opposed to the resting state FeIII-heme (figure 
1A). Active P450-derived cyclopropanation catalysts show marked preference for strong 
reducing agents such as sodium dithionite (E°’ = −660 mV, all potentials versus SHE) 
over native NAD(P)H (E°’ = −320 mV) (5). This suggests a limited substrate-induced 
low-spin (E°’ FeIII/II = −430 mV) to high-spin (E°’ FeIII/II = −290 mV) transition of the 
P450 heme-iron (10), which, while essential for monooxygenation, may not be 
achievable in this engineered system due to the poor affinity for the nonnatural substrates 
(KM ~5 mM) (5). We hypothesized that raising the redox potential of the resting state 
enzyme to facilitate NAD(P)H reduction would be important for enhancing FeII catalysis 
in vivo. Because the redox potential of heme proteins can be tuned by axial ligand 
substitutions (11, 12), we reasoned that mutating the axial cysteine in BM3 to the weaker 
donor serine should raise the FeIII/II potential (13). Furthermore, axial cysteinate ligation 
is essential for dioxygen activation and stabilization of the active ferryl-porphyrin cation 
radical oxidant (compound I) during monooxygenation (14), and axial cysteine to serine 
substitutions have been reported to abolish monooxygenation activity in mammalian 
P450s (15). Because free hemin is also a (poor) cyclopropanation catalyst (5), we 
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anticipated that the axial cysteine to serine mutation (C400S in BM3) would support 
carbene transfer activity while abolishing monooxygenation activity.  
We chose to introduce the C400S mutation into a cis-selective cyclopropanation 
catalyst from our previous work, BM3-CIS [13 mutations from BM3, (5, 13)]. BM3-CIS 
catalyzes hundreds of turnovers in the presence of dithionite in vitro and forms the ethyl 
2-phenylcyclopropane-1-carboxylate product with 71% cis-selectivity and −94% 
enantioselectivity (eecis) (5). Heme-serine ligation in BM3-CIS-C400S (hereafter called 
ABC-CIS) was confirmed by determining the crystal structures of the BM3-CIS and 
ABC-CIS heme domains at 2.5 and 3.3 Å, respectively (figure S1 and table S1); the 
structures are superimposable (RMSD = 0.52 Å, figure S1). Despite the limited resolution 
of the ABC-CIS structure, simulated annealing omit maps generated in the absence of 
modeled heme and C400S show density consistent with heme coordination by a proximal 
amino acid side chain (figure 1B and figure S2). The UV-vis spectra for the green-brown 
ABC-CIS (figures S3-S5) provide further evidence for heme-serine ligation and are 
consistent with those reported for a Ser-ligated mammalian P450 (15, 16) (table S2), 
marked by a ferrous carbon monoxide-bound complex at 411 nm. Redox titrations using 
the truncated heme domains of wild-type BM3, the C400S variant (which we call ABC), 
BM3-CIS and ABC-CIS (figure 1C and figures S6 to S9) showed that the C400S 
mutation raises the reduction potential of the resting state enzyme by +120 mV (E°’ 
FeIII/IISer = −295 mV and  −265 mV for ABC and ABC-CIS, respectively). This shift is 
similar in magnitude to that which occurs in BM3 upon substrate binding (10), and 
should therefore allow ABC-CIS to be reduced by NAD(P)H even in the absence of 
substrate.  
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Figure 1. (A) Cytochrome P450s inefficiently catalyze cyclopropanation using 
NAD(P)H as a reductant because the FeIII/FeII redox potential for the low-spin resting 
state (E°’Fe-cys = −370 mV) is lower than that of NAD(P)+/NAD(P)H (E°’1 = −320 mV). 
We hypothesized that serine ligation should increase the resting state redox potential and 
allow reduction from NAD(P)H to the active FeII species in vivo. (B) Close-up of the 
ABC-CIS active site (pdb: 4H24) superimposed with an Fo - Fc simulated annealing omit 
map contoured at 3 σ showing electron density (green mesh) corresponding to the bound 
heme and C400S mutation. Interconnected density between C400S and the heme iron is 
consistent with proximal heme ligation by the C400S side chain hydroxyl. The heme, 
C400S and additional active site amino acid side chains are shown as sticks. (C) 
Potentiometric redox titrations for BM3 (green circles) and ABC (blue triangles) with 
overlaid one-electron Nernst curves.   Insets show spectral changes between ferric 
(dashed line) and ferrous (solid line) enzymes. The changes in absorbance near 450-470 
nm (BM3) and 420-440 nm (ABC) were used to determine the FeII/FeIII ratio after 
reduction with dithionite.  The reduction is reversible (with reoxidation by potassium 
ferricyanide), and little or no hysteresis was observed. The midpoint potential of the 
serine-ligated mutant (-295 mV) is shifted 125 mV positive compared to WT (-420 mV). 
  
ABC-CIS is an active dithionite-driven cyclopropanation catalyst in vitro, with 
Michaelis-Menten parameters (kcat = 82 min-1, KM-styrene = 4.6 mM, KM-EDA = 5.7 mM, 
figure S11) comparable to those of BM3-CIS (table S3). ABC-CIS displays considerably 
improved diastereo- (cis:trans 93:7) and enantioselectivity (−99% eecis) compared to its 
cysteine homologue (figure S12), an unexpected result given the similar active site 
geometries of the two catalysts (figure S1). For a variety of styrenyl substrates, ABC-CIS 
showed superior cis-selectivity relative to BM3-CIS (table S4). ABC-CIS shows 
increased activity compared to BM3-CIS when NADPH is used as the reductant under 
anaerobic conditions (figure 2 and table S5). BM3-CIS only forms small amounts of 
cyclopropanes when NADPH is used, and forms styrene oxide, via monooxygenation, as 
the major product under aerobic conditions. In contrast, ABC-CIS produces negligible 
amounts of styrene oxide and is still able to form cyclopropanes under aerobic conditions, 
albeit with lower yields (43 TTN) due to oxygen inhibition (figure 2). Dioxygen 
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inhibition could be due to a two-electron oxidase activity as reported for CYP2B4-
C436S (15). NADH drives ABC-CIS-mediated cyclopropanation as efficiently as 
NADPH (table S6), suggesting that ABC-CIS is well suited for in vivo catalysis under 
anaerobic conditions where NADPH biosynthesis in E. coli does not take place. 
 
 
 
 
 
Figure 2. Cyclopropanation vs. epoxidation of styrene catalyzed by BM3-CIS and ABC-
CIS under anaerobic and aerobic conditions. Reaction conditions were as follows: 30 mM 
styrene, 10 mM EDA, 0.5 mM NADPH, 25 mM glucose, 2 U ml-1 glucose 
dehydrogenase and 20 µM P450 catalyst in aqueous potassium phosphate buffer and 5% 
MeOH cosolvent for six hours at 298 K. Measurements were taken in triplicate and the 
error bars represent the standard deviation of the measurements. 
 
We next investigated the efficiency of cyclopropanation using resting Escherichia 
coli (BL21) cells grown in M9Y media [M9, 1.5% yeast extract, (13)] expressing BM3-
CIS and ABC-CIS. Addition of glucose under anaerobic conditions significantly 
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increased product yield (figure S13), presumably due to enhanced intracellular 
production of NADH. ABC-CIS catalyzes thousands of turnovers in vivo, is about four 
times more active than BM3-CIS in whole-cells, and provides the cyclopropane products 
with enhanced cis- enantioselectivity (table 1, entries 1 and 2). The C400S mutation 
compromises protein expression such that ABC-CIS accounts for 2% of dry cell mass 
compared to 6% for BM3-CIS. The reduced expression is not due to decreased protein 
stability, as C400S contributes to increased thermostability in the purified ABC-CIS 
heme domain (figure S10). The holo enzyme, which contains both heme and diflavin 
reductase domains, is over two times more active on a molar basis than the heme domain 
alone (ABC-CISheme) (entry 3), confirming that reduction to the ferrous state in vivo is 
important, but also showing that the reducing intracellular environment achieves heme 
reduction even in the absence of the reductase domain. The C400S mutation (ABC) 
improves the in vivo cyclopropanation activity of BM3 by over two orders of magnitude 
(entries 4 and 5). Purified ABC is also an efficient NADH-driven cyclopropanation 
catalyst in vitro, whereas BM3 is barely active (table S7). 
Both ABC-CIS and BM3-CIS whole cells are significantly inhibited by dioxygen 
(figure S14). Whole-cells containing the ABC-CIS gene but with no induction and whole 
cells devoid of the ABC-CIS gene are able to form small amounts of cyclopropanes, but 
do so with stereoselectivity similar to that of free hemin (figure S15). This is not 
surprising since free hemin and other heme proteins present in cells are also able to 
catalyze styrene cyclopropanation at low levels (5). Whole-cell ABC-CIS catalysts are as 
stereoselective as purified ABC-CIS in vitro at equivalent catalyst loading (vide infra), 
demonstrating that the overexpressed P411 enzyme favorably outcompetes background 
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catalysis. In vivo cyclopropanation is strongly inhibited by carbon monoxide (table 1, 
entry 6), which irreversibly binds ferrous heme, confirming that catalysis occurs in the 
enzyme active site. Yields could be increased to 80% by increasing the cell density up to 
OD600 = 50 (figure S16). Reaction yield was only slightly improved by using excess 
styrene (figure S17). Lysate of cells expressing ABC-CIS and with NADH added retain 
only about 30% of the activity of the intact whole-cells and are not active in the absence 
of exogenous reductant (table S8). Addition of dithionite inhibited ABC-CIS whole-cell 
reactions and was less efficient than NADH in driving the reaction in cell lysate (figure 
S15 and table S8) 
 
Table 1. Cyclopropanation activities for intact E. coli cells expressing BM3, ABC, BM3-
CIS, ABC-CIS and ABC-CISheme. Reaction conditions were as follows: 2 eq styrene, 1 eq 
EDA, 0.2 eq glucose, E. coli whole-cells in aqueous nitrogen-free M9 minimal medium 
and 5% MeOH cosolvent under anaerobic conditions for twelve hours at 298 K. Yields, 
diastereomeric ratios, and enantiomeric excess were determined by GC analysis. Yields 
based on EDA. TTN = total turnover number. *(2R,1S) – (2S,1R). †(2R,1R) – (2S,1S). 
‡Neat reagents were used without addition of MeOH; reactions were left for 24 h. 
§Isolated yield (1.63 g cyclopropanes). The data represent the averages of triplicate 
experiments. Standard errors are within 20% of the reported average. 
 
Entry Catalyst [EDA] (mM) 
Cell 
Density 
(gcdw/L) 
[P450] 
(μM) 
Yield 
(%) TTN cis:trans 
eecis 
(%)* 
eetrans 
(%)† 
1 BM3-CIS 8.5 7.7 3.7 42 950 22:78 −60 −22 
2 ABC-CIS 8.5 7.7 1.3 55 3,700 76:24 −96 −25 
3 ABC-CISheme 8.5 7.7 3.6 67 1,600 71:29 −95 −17 
4 BM3 8.5 13.4 4.8 0.9 15 25:75 −24 −21 
5 ABC 8.5 8.1 1.5 50 2,900 13:87 −12 −8 
6 ABC-CIS + CO 8.5 8.4 1.8 0.6 30 20:80 −35 −20 
7 ABC-CIS‡ 170 8.4 1.8 72  67,800 90:10 −99 −43 
8 ABC-CIS‡ 200 20 3.2 78§ 48,800 88:12 −99 −35 
Ph
COOEt
N2
+
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
cis trans
E. coli
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In order to provide a direct comparison of enzyme activity in vivo versus in vitro, 
we monitored both reactions at the same enzyme concentration over 8 hours (figure 3). 
On a molar basis, the in vivo catalyst showed almost 6 times higher TTN than the purified 
enzyme in vitro after 8 hours and retained the same stereoselectivity (75:25 cis:trans, -
95% eecis). Both catalysts remained active over 6 hours, suggesting that the observed 
differences in yield and TTN are due to improved activity rather than enhanced catalyst 
stability in vivo. Gradual addition of EDA did not improve the reaction yield.  
 
 
Figure 3. Time course for in vivo and in vitro ABC-CIS at a P411 loading of 1.6 µM 
[ε411-490 = 103 mM-1 cm-1 for the ferrous-CO complex (15)]. Reaction conditions were as 
follows: 40 mM styrene, 20 mM EDA, 2 mM glucose, 10.2 gcdw L-1 whole cell ABC-CIS 
(in vivo), 1.6 µM purified ABC-CIS, 1 mM NADH (in vitro) in aqueous nitrogen-free M9 
minimal medium and 5% MeOH cosolvent under anaerobic conditions at 298 K. Yields 
at each time point are reported as averages of two independent reactions (13).  
 
At high substrate loading (170 mM EDA, 400 mM styrene, added as neat 
reagents), more than 60,000 catalytic turnovers were observed in the in vivo reaction with 
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ABC-CIS (table 1, entry 6). ABC-CIS whole-cell reactions are readily scalable to 
make gram quantities of cyclopropanes with high stereoselectivity, product titer 
(27 g L−1) and yield (78%, entry 8). No organic cosolvents are necessary, and the 
cyclopropane products can be readily obtained by extraction with organic solvent at the 
end of the reaction (13). Furthermore, the cells can be lyophilized with a cryoprotectant 
such as sucrose and stored as a powder for weeks at 4 °C without degradation of catalytic 
activity or regio- and enantioselectivity (table S9). The lyophilized cells can be readily 
packaged and distributed. These features render the whole-cell process extremely 
attractive for facile benchtop synthesis. 
 The ABC catalyst based on a Ser-ligated cytochrome-P411 is spectroscopically, 
electrochemically, and catalytically distinct from cytochrome P450s. Whole-cell ABC 
catalysts are easy to use and deliver high conversion, optical purity and yield for substrate 
input in the tens of grams per liter. The ability to catalyze this nonnatural C−C bond 
forming reaction in vivo will expand the scope of transformations accessible to microbial 
organic synthesis and should provide artificial metabolic pathways to complement 
nature’s existing strategies for making cyclopropanes (17).   
 
* * * 
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I. Materials and Methods 
 
 Unless otherwise noted, all chemicals and reagents for chemical reactions were 
obtained from commercial suppliers (Sigma-Aldrich, Acros) and used without further 
purification. Silica gel chromatography purifications were carried out using AMD Silica 
Gel 60, 230-400 mesh. 1H and 13C NMR spectra were recorded on either a Varian 
Mercury 300 spectrometer (300 and 75 MHz, respectively), or a Varian Inova 500 MHz 
(500 and 125 MHz, respectively), and are internally referenced to residual solvent peak. 
Data for 1H NMR are reported in the conventional form: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), 
coupling constant (Hz), integration. Data for 13C are reported in terms of chemical shift (δ 
ppm) and multiplicity. High-resolution mass spectra were obtained with a JEOL JMS-
600H High Resolution Mass Spectrometer at the California Institute of Technology Mass 
Spectral Facility. Reactions were monitored using thin layer chromatography (Merck 60 
silica gel plates) using a UV lamp for visualization.  
 Gas chromatography (GC) analyses were carried out using a Shimadzu GC-17A 
gas chromatograph, a FID detector, and an Agilent J&W cyclosil-B column (30 m x 0.25 
mm, 0.25 µm film) and 2-phenylethanol as an internal standard. Injector temperature = 
300 °C, oven temperature = 130 °C for 30 min, pressure = 175 kPa. Elution time: cis-
cyclopropanes (19.7 and 21.0 min), trans-cyclopropanes (25.8 and 26.4 min). 
Cyclopropane product standards for the reaction of ethyl diazoacetate (EDA) with styrene 
(ethyl 2-phenylcyclopropane-1-carboxylate) and α-methylstyrene (ethyl 2-methyl-2-
phenylcyclopropane-1-carboxylate) were prepared as reported (18). These standards and 
enzyme-prepared cyclopropanes demonstrated identical retention times in gas 
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chromatograms when coinjected, confirming product identity. Absolute 
stereoconfiguration of cyclopropane enantiomers was determined by measuring optical 
rotation of purified cyclopropane products from preparative bioconversion reactions 
using enantioselective P450-BM3 variants and referenced to values taken from reference 
(19). Authentic P450-catalyzed cyclopropane samples were also prepared as described in 
section II and were characterized by NMR (1H and 13C) and mass spectrometry. 
 Plasmids pCWori[BM3] and pET22 were used as cloning vectors. Site-directed 
mutagenesis was accomplished by standard overlap mutagenesis using primers bearing 
desired mutations (IDT, San Diego, CA). Primer sequences are available upon request. 
Electrocompetent Escherichia coli cells were prepared following the protocol of 
Sambrook et al. (20). Restriction enzymes BamHI, EcoRI, XhoI, Phusion polymerase, 
and T4 ligase were purchased from New England Biolabs (NEB, Ipswich, MA). Alkaline 
phosphatase was obtained from Roche (Nutley, NJ). The 1,000x trace metal mix used in 
expression cultures contained 50 mM FeCl3, 20 mM CaCl2, 10 mM MnSO4, 10 mM 
ZnSO4, 2 mM CoSO4, 2 mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, and 2 mM H3BO3.   
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II.  General Procedures 
 
CO binding assay. P450 concentration was determined from ferrous CO binding 
difference spectra using extinction coefficients of ε450-490 = 91 mM-1 cm-1 for cysteine-
ligated BM3 (21) and ε411-490 = 103 mM-1 cm-1 for serine ligated ABC (15). 
 
P450 expression and purification. For the in vitro transformations, P450BM3 variants 
were used in purified form. Enzyme batches were prepared as follows. One liter TBamp 
was inoculated with an overnight culture (100 mL, LBamp) of recombinant E. coli BL21 
cells harboring a pCWori plasmid encoding the P450 variant under the control of the tac 
promoter. After 3.5 h of incubation at 37 °C and 250 rpm shaking (OD600 ca. 1.8), the 
incubation temperature was reduced to 25 °C (30 min), and the cultures were induced by 
adding IPTG to a final concentration of 0.5 mM. The cultures were allowed to continue 
for another 24 hours at this temperature. After harvesting the cells by centrifugation (4 °C, 
15 min, 3,000 × g), the cell pellet was stored at -20 °C until further use but at least for 2 h. 
The cell pellet was resuspended in 25 mM Tris.HCl buffer (pH 7.5 at 25 °C) and cells 
were lysed by sonication (2 × 1 min, output control 5, 50% duty cycle; Sonicator, Heat 
Systems—Ultrasonic, Inc.). Cell debris was removed by centrifugation for 20 min at 4 °C 
and 27,000xg and the supernatant was subjected to anion exchange chromatography on a 
Q Sepharose column (HiTrapTM Q HP, GE Healthcare, Piscataway, NJ) using an 
AKTAxpress purifier FPLC system (GE healthcare). The P450 (or P411) was eluted from 
the Q column by running a gradient from 0 to 0.5 M NaCl over 10 column volumes 
(P450 elutes at 0.35 M NaCl). The P450 (or P411) fractions were collected and 
concentrated using a 30 kDa molecular weight cutoff centrifugal filter and buffer-
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exchanged with 0.1 M phosphate buffer (pH = 8.0). The purified protein was flash-
frozen on dry ice and stored at -20 °C. P450 and P411 concentrations were determined in 
triplicate using the CO binding assay described above (10 µL P450 and 190 µL 0.1 M 
phosphate buffer, pH 8.0, per well).  
 For crystallization experiments, a two step purification was performed using the 
AKTAxpress purifier FPLC system. Frozen cell pellets containing expressed, 6XHis 
tagged heme domains were resuspended in Ni-NTA buffer A (25 mM Tris.HCl, 200 mM 
NaCl, 25 mM imidazole, pH 8.0, 0.5 mL/gcw) and lysed by sonication (2 × 1 min, output 
control 5, 50% duty cycle). The lysate was centrifuged at 27,000xg for 20 min at 4 °C to 
remove cell debris. The collected supernatant was first subjected to a Ni-NTA 
chromatography step using a Ni sepharose column (HisTrap-HP, GE healthcare, 
Piscataway, NJ). The P450 (or P411) was eluted from the Ni sepharose column using 25 
mM Tris.HCl, 200 mM NaCl, 300 mM imidazole, pH 8.0. Ni-purified protein was buffer 
exchanged into 25 mM Tris.HCl pH 7.5 using a 30 kDa molecular weight cutoff 
centrifugal filter and subsequently loaded onto a Q sepharose column (HiTrapTM Q HP, 
GE healthcare, Piscataway, NJ) and purified to homogeneity by anion exchange. The 
P450 (or P411) was eluted from the Q column by running a gradient from 0 to 0.5 M 
NaCl over 10 column volumes. P450 (or P411) fractions were collected and buffer 
exchanged into 25 mM Tris.HCl pH 7.5, 25 mM NaCl. The purified protein was 
concentrated with a 30 kDa molecular weight cutoff centrifugal filter to approximately 10 
mg/mL. 50 µL aliquots were flash frozen on dry ice and stored at −80 °C until needed. 
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Protein crystallography. BM3-CIS and ABC-CIS were crystallized by vapor 
diffusion. A 1:1 mixture of protein stock (10 mg/mL in 25 mM Tris.HCl pH 7.5, 25 mM 
NaCl) and mother liquor was combined in 24-well sitting drop plates (Hampton 
Research). Optimal crystallization conditions for BM3-CIS were found in 0.1 M sodium 
cacadolyte, pH 5.7, 0.14 MgCl2 and 17 % PEG 3350. CM3-CIS crystals typically grew 
over a span of 7–14 days. ABC-CIS crystals optimally formed in 0.1 M Bis-Tris, pH 5.3, 
0.2 M sodium formate and 18% PEG 3350. Initial ABC-CIS drops are marked with a 
dense layer of protein precipitate; however, after 36–48 hours, noticeable protein crystals 
were observed underneath the precipitate layer.  
 
X-ray data collection and protein structure determination. X-ray diffraction data 
were collected at the General Medical Sciences and Cancer Institutes Structural Biology 
Facility (GM/CA) at the Advanced Photon Source (APS, Argonne National Laboratory) 
using beamline ID23-D and a MAR300 CCD detector. Data were collected at 100K and a 
wavelength of 1.033 Å. Data collections statistics are listed in table S1. Diffraction 
datasets were integrated with XDS (22) and scaled using SCALA (23). Initial phases 
were determined by molecular replacement against the closed form of wild type P450-
BM3h structure taken from PDB 1JPZ (24), chain B using MOLREP software (25), a 
component of the CCP4 crystallography software suite (26). Refinement was 
accomplished by iterative cycles of manual model building within COOT (27) and 
automated refinement using REFMAC (28) within CCP4. Final cycles of REFMAC 
refinement included TLS parameters. Non-crystallographic symmetry constraints were 
not used during refinement. Model quality was assessed using the “complete validation” 
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tool inside of the PHENIX software suite (29). Ramachandran outliers generally lie in 
poorly structured loops connecting P450BM3 F and G helices. These residues are often 
missing or marked by poor density in these and other P450BM3 structures within the 
protein database. All protein structure figures and alignments were generated using 
PyMol software (The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, 
LLC.). 
 
Thermostability measurements. Duplicate measurements were taken for all values 
reported in figure S10.  Purified P450 (or P411) solutions (4 µM, 200 µL) were heated in 
a thermocycler (Eppendorf) over a range of temperatures (40–70 °C) for 10 min followed 
by rapid cooling to 4 °C for 1 min. The precipitate was removed by centrifugation. The 
concentration of folded P450 (or P411) remaining in the supernatant was measured by 
CO-difference spectroscopy (as described above). The temperature at which half of the 
protein was denatured (T50) was determined by fitting the data to the equation: 
.(30)  
 
Typical procedure for in vitro small-scale cyclopropanation bioconversions under 
anaerobic conditions. Small-scale reactions (400 µL) were conducted in 2 mL crimp 
vials (Agilent Technologies, San Diego, CA). P450 solution (80 µL, 100 µM) was added 
to the vial with a small stir bar before crimp sealing with a silicone septum. Phosphate 
buffer (260 µL, 0.1 M, pH = 8.0) and 40 µL of a solution of the reductant (100 mM 
Na2S2O4, or 20 mM NADPH) were combined in a larger crimp-sealed vial and degassed 
f (T ) = 100
1+ e
−a 1T −
1
T50
"
#
$
%
&
'
 160 
by bubbling argon through the solution for at least 5 min (figure S1). In the meantime, 
the headspace of the 2 mL reaction vial with the P450 (or P411) solution was made 
anaerobic by flushing argon over the protein solution (with no bubbling). When multiple 
reactions were conducted in parallel, up to 8 reaction vials were degassed in series via 
cannulae. The buffer/reductant solution (300 µL) was syringed into the reaction vial, 
while under argon. The gas lines were disconnected from the reaction vial before placing 
the vials on a plate stirrer. A 40x styrene solution in MeOH (10 µL, typically 1.2 M) was 
added to the reaction vial via a glass syringe, and left to stir for about 30 s. A 40x EDA 
solution in MeOH was then added (10 µL, typically 400 mM) and the reaction was left 
stirring for the appropriate time. The final concentrations of the reagents were typically: 
30 mM styrene, 10 mM EDA, 10 mM Na2S2O4, 20 µM P450.   
The reaction was quenched by adding 30 µL HCl (3M) via syringe to the sealed 
reaction vial. The vials were opened and 20 µL internal standard (20 mM 2-
phenylethanol in MeOH) was added followed by 1 mL ethyl acetate. This mixture was 
transferred to a 1.8 mL eppendorf tube which was vortexed and centrifuged (16,000xg, 1 
min). The top organic layer was dried over an anhydrous sodium sulfate plug and 
analyzed by chiral phase GC. 
 A slightly modified workup was implemented for kinetic experiments. The 
reactions were quenched after the set time by syringing 1 mL EtOAc to the closed vials 
and immediately vortexing the mixture. The vials were then opened and 20 µL internal 
standard was added. The mixture was transferred to a 1.8 mL eppendorf tube, vortexed 
and centrifuged (16,000xg, 1 min). The top organic layer was dried over an anhydrous 
sodium sulfate plug and analyzed by GC.  
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Media and cell cultures for in vivo cyclopropanation. E. coli (BL21) cells were grown 
from glycerol stock overnight (37 °C, 250 rpm) in 5 mL M9Y medium (1 L: 31 g 
Na2HPO4, 15 g KH2PO4, 2.5 g NaCl, 5.0 g NH4Cl, 0.24 g MgSO4, 0.01 g CaCl2, 1.5% 
yeast extract, 1 mL micronutrients, 0.1 mg mL-1 ampicillin). The preculture was used to 
inoculate 45 mL of M9Y medium in a 125 mL Erlenmeyer flask and this culture was 
incubated at 37 °C, 250 rpm for 2 hours and 30 minutes. At OD600 = 1.2, the cultures 
were cooled to 25 °C and the shaking was reduced to 160 rpm before inducing with IPTG 
(0.25 mM) and δ-aminolevulinic acid (0.25 mM). Cultures were harvested after 20 hours 
and resuspended (OD600 = 30) in nitrogen-free M9 medium (1 L: 31 g Na2HPO4, 15 g 
KH2PO4, 2.5 g NaCl, 0.24 g MgSO4, 0.01 g CaCl2, 1 mL micronutrients). The 
micronutrient solution contains 0.15 mM (NH4)6Mo7O24, 20.0 mM H3BO3, 1.5 mM 
CoCl2, 0.5 mM CuSO4, 4.0 mM MnCl2, and 0.5 mM ZnSO4. Aliquots of the cell 
suspension were used for determination of the cell dry weight (cdw, 2 mL) and P450 (or 
P411) expression level (4 mL). 
 
Small-scale whole-cell bioconversions. E. coli cells (OD600 = 30, 425 µL) were made 
anaerobic by bubbling argon through the cell suspension in a crimped 2 mL vial. A 
degassed solution of glucose (50 µL, 20 mM) was added to the cells before adding EDA 
(12.5 µL of a 400 mM solution in MeOH) and olefin (12.5 µL of a 1.2 M solution in 
MeOH). The reactions were stirred at room temperature for the appropriate and were 
worked up by adding 20 µL of the internal standard (20 mM 2-phenylethanol) and 
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extracting with 1 mL ethyl acetate. The organic layer was dried over Na2SO4 before 
analyzing the product mixture by chiral phase GC.  
 
Preparative-scale whole-cell bioconversions. E. coli (BL21) cells were grown from 
glycerol stock overnight (37 °C, 250 rpm) in 50 ml M9Y medium. The preculture was 
used to inoculate 2-475 mL of M9Y medium in 2-1 L Erlenmeyer flask (using 25 mL 
each) and this culture was incubated at 37 °C, 250 rpm for 2 h and 30 min. At OD600 = 
1.8, the cultures were cooled to 25 °C and the shaking was reduced to 150 rpm before 
inducing with IPTG (0.25 mM) and δ-aminolevulinic acid (0.25 mM). Cultures were 
harvested after 24 h and resuspended (OD600 = 75) in nitrogen-free M9 medium. Aliquots 
of the cell suspension were used for determination of the cell dry weight (cdw, 2 mL) and 
P450 (or P411) expression level (2 mL). E. coli cells (OD600 = 70, 53.6 mL) were made 
anaerobic by bubbling argon through the cell suspension in a 500 mL sealed round 
bottom flask. A degassed solution of glucose (1.4 mL, 500 mM) was added to the cells 
before adding EDA (1.36 mL, 85% EDA in DCM as packaged by Sigma Aldrich) and 
styrene (2.5 mL, neat). The reaction was stirred at room temperature under positive argon 
pressure for 24 h.  The crude mixture was poured into 3-50 mL conical tubes, and the 
reaction was quenched by the addition of HCl (1 mL, 3 M) to each tube.  The aqueous 
mixtures were extracted with 1:1 EtOAc: hexanes (20 mL each) and centrifuged (5,000 
rpm, 5 min).  The organics were collected and this extraction sequence was performed 
two more times.  The organics were combined, dried over Na2SO4 then concentrated.  
Excess styrene was removed via azeotrope with H2O/benzene and 1.85 g of crude product 
was isolated.  Cis/trans selectivity of the reaction was determined via gas 
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chromatography of this crude mixture.  Column chromatography of the crude product 
with 8% Et2O/hexanes afforded the desired products as a mixture of cis and trans isomers 
(1.63 g combined, 78% yield).  Based on comparison of crude and purified yields, the 
crude product was approximately 88% pure.  NMR of the isolated products were identical 
to those reported in the literature (5). 
 
Time course of in vivo and in vitro reactions.  Following the procedure for small scale 
bioconversions, a series of in vivo and in vitro reactions were set up and EDA was added 
to each sample at time 0 hours.  Time points were taken at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 
8 hours.  Each reported yield reflects an average of two independent reactions that were 
allowed to stir for the indicated amount of time.  The error bars shown reflect the two 
unaveraged data points.  Yields of each reaction were determined by GC. 
 
Potentiometric titrations. Enzyme samples were buffer-exchanged into 100 mM KPO4, 
100 mM KCl, pH 7.4, and deoxygenated via 4x20 gentle pump-backfill cycles with argon, 
with care taken to avoid bubbling. Potentiometric redox titrations were performed in an 
anaerobic glove box, using a quartz spectroelectrochemical cell with path length of 1mm, 
platinum mesh working electrode, platinum wire counter electrode, and a Ag/AgCl 
electrode (Bioanalytical Systems, Inc.) Was used as the reference (Ag/AgCl vs NHE: 
+197 mV). Protein solutions consisted of approximately 600 µl of 50-100 µM protein 
with the following mediators added to ensure electrochemical communication between 
the protein and electrode: methyl viologen (5 µM), benzyl viologen (10µM) and 2-
hydroxy-1,4-napthaquinone (20 µM). Enzyme samples were titrated using sodium 
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dithionite (reduction) and potassium ferricyanide (re-oxidation).  The open circuit 
potential of the cell was monitored (WaveNow potentiostat, Pine Research 
Instrumentation) over a 10-minute equilibration period, and spectra were recorded using a 
Ocean Optics spectrometer (USB2000+). 
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III. Summary of P450-Derived Cyclopropanation Catalysts 
Mutations in cyclopropanation catalysts are reported with respect to wild-type P450BM3. 
The heme domain comprises the first 462 amino acids in the P450BM3 sequence. 
 
ABC: BM3 + C400S 
 
BM3-CIS: V78A, F87V, P142S, T175I, A184V, S226R, H236Q, E252G, T268A A290V, 
L353V, I366V, E442K 
 
ABC-CIS: BM3-CIS + C400S  
 
IV. Rationale for the C400S Mutation 
 
The very negative FeIII/II potential of cytochromes P450 relative to other heme proteins 
has been ascribed to the strong donating character of the axial cysteinate ligand. This 
effect has been modeled in cytochrome c: substitution of the native axial methionine for 
cysteine decreases the FeIII/II  potential by an impressive 652 mV, from 262 vs SHE for 
the Met/His ligated variant to -390 mV vs SHE for the Cys/His variant (31). Even within 
cytochrome P450, the reduction potential can be further reduced by increasing the 
electron donating character of the cysteinate ligand.  Removal of a single amide proton 
proposed to stabilize the cysteinate negative charge shifts the FeIII/II potential negative by 
35-45 mV with respect to wild-type (32).   
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In order to facillitate cyclopropanation activity in vivo, it was necessary to shift the 
reduction potential sufficiently positive to allow reduction by NADPH. In cytochrome c, 
it was observed that axial ligation by a weakly donating water molecule raises the 
reduction potential of the His/H2O ligated variant (FeIII/II: -45 mV vs SHE) by 345 mV 
compared to the Cys/His variant (31). To that end, we hypothesized in P450, substitution 
of the cysteinate axial ligand with the weakly donating serine alcohol would be expected 
to shift the C400S reduction potential positive compared to wild-type. The pKa of serine 
(~15) is approximately 7 pH units above that of cysteine (~8), and so while cysteine 
remains deprotonated as the cysteinate ligand in both ferric and ferrous states of the 
enzyme, we anticipated that serine would remain protonated in at least the ferrous form. 
The serine-ligated mammalian P450 mutant has been suggested to be serinate in the ferric 
form, and serine in the ferrous form based on analysis of absorption spectra and magnetic 
circular dichroism (16), and we anticipated that similar ligation in Ser-P450-BM3 would 
result in a more positive FeIII/II potential. 
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V. Physical Characterization of ABC-CIS 
 
V.I.   X-Ray Crystallography Statistics 
 
Figure S1. Active site and protein alignments of BM3-CIS with ABC-CIS and wild type 
P450BM3.  
 
To investigate the nature of enhanced stereoselectivity in ABC-CIS, crystal 
structures of both proteins were determined to assess any structural changes that may 
have occurred due to the axial Cys  Ser mutation. The top panels shows alignments of 
BM3-CIS (green) and ABC-CIS (peach) with left, middle, and right panels showing 
active site residues, the active site I-helix, and global protein fold, respectively. No 
significant structural changes were observed (RMSD 0.52 Å). Middle panels: Large 
variations are observed upon comparing BM3-CIS with the open (ligand-free) form of 
wild type BM3 (purple, taken from PDB# 2IJ2, RMSD 1.2 Å). Pronounced 
 168 
rearrangements are observed in active site side chain residues (left) as well as 
rotations within the I-helix. Global movements are also observed in the N-terminal beta 
domain as well as F- and G-helices (right, marked by double-headed arrows). These 
movements are consistent with well-known transitions that occur upon substrate binding 
and are important for native monooxygenation catalysis. Bottom panels: Alignment of 
BM3-CIS with a ligand-bound BM3 structure (cyan, taken from PDB# 1JPZ, RMSD 0.52 
Å) demonstrates that BM3-CIS and ABC-CIS mimic the closed protein conformation 
even in the absence of substrate.   
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Table S1. Data collection and refinement statistics for P450BM3 crystals 
 
 BM3-CIS ABC-CIS 
pdb accession # 4H23 4H24 
   
Data collection*   
Space group I 1 2 1 P 2 21 21 
wavelength 1.033 1.033 
Cell dimensions     
a, b, c (Å) 187.79, 62.74, 210.28 63.16, 124.46, 127.69 
    α, β, γ  (°) 90.00, 115.75, 90.00 90.00, 90.00, 90.00  
Resolution (Å) 48.6 - 2.5 (2.5 - 2.6) 
** 
44.9 – 3.3 (3.3 – 3.5) 
** 
Rmerge 5.3(39.5) 17.6(51.4) 
I / σI 13.4(3.0) 11.8(5.7) 
Completeness 
(%) 
98.7(99.2) 99.9(99.9) 
Redundancy 2.6(2.6) 5.3(5.4) 
   
Refinement   
Resolution (Å) 48.6 - 2.5 44.9 – 3.3 
No. reflections 72085 14884 
Rwork / Rfree 0.19 / 0.25 0.18/0.26 
 
No. atoms 
  
Protein 14401 6890 
Ligand/ion 128 86 
Water 196 24 
 
B-factors 
  
Protein 33.9 25.4 
Ligand/ion 25.4 19.9 
Water 26.7 18.9 
 
R.m.s. deviations 
  
Bond lengths (Å) 0.017 0.016 
Bond angles (°) 
 
Ramachandran 
outliers*** 
1.70 
 
0.3% 
1.65 
 
0.7% 
*All data sets were collected from single crystals.  
**Highest-resolution shell is shown in parentheses. 
*** Ramachandran outliers lie in regions of protein that are known to be flexible and 
show similar disorder among P450BM3 structures in the literature. 
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Fig. S2. Heme electron density of ABC-CIS: Maximum likelihood weighted electron 
density maps of serine-ligated heme in ABC-CIS. (A) Stereo image of heme bound to 
ABC-CIS viewed from the top of the heme in the active site. (B) Stereo image of heme 
bound to ABC-CIS rotated ~90° from panel A shows clear indication of heme-iron 
ligation by the side chain hydroxyl of Cys400Ser. All atoms are shown as sticks. All 
electron density maps were contoured at σ = 1.0. For perspective, in panel B, the main 
chain atoms of residues 399 and 401 are also shown as sticks. 
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V.II.   UV-vis Spectroscopy 
 
 
 
Figure S3. Absolute spectra for ferric (blue), dithionite reduced ferrous (red) and carbon 
monoxide bound ferrous (green) ABC-CISheme. Soret bands (nm): FeIII, 404; FeII, 410, 
425; FeII-CO, 411. FeII-CO displays α and β bands at 532 and 565 nm. Insert shows the 
carbon monoxide ferrous (pink) and the dithionite reduced ferrous (yellow) enzymes at 
4.5 µM protein concentration.  
 
The shoulder at 410 nm for the ferrous spectrum is due to incomplete reduction to 
FeII under the aerobic conditions in which these spectra were taken. Reduction of 
cytochrome P411 under strict anaerobic conditions, as is the case for the redox titrations 
(figures S7 and S9) gives a single peak at 421 nm.  
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Figure S4. Absolute spectra for ferric (blue), dithionite reduced ferrous (red) and carbon 
monoxide bound ferrous (green) ABC-CISholo. Soret bands (nm): FeIII, 404; FeII, 410, 
422; FeII-CO, 411. FeII-CO displays α and β bands at 533 and 566 nm. Ferric spectrum 
displays a broad peak at 465 nm. 
 
 
 
Figure S5. Difference spectra for ferrous carbonyl with respect to ferrous for (A) ABC-
CISheme and (B) ABC-CISholo. 
 
 
Table S2: Comparison of λmax for ABC-CISheme and CYP2B4-C436S (15) 
	   ABC-­CISheme	  
(nm)	  
CYP2B4-­C436S	  	  (nm)	  Ferric	  resting	  state	   404	   405	  Ferrous	   425	   422	  Ferrous-­‐CO	   411	   413	  
-­‐0.05	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V.III.   Redox Titrations 
 
 
 
 
Figure S6. Potentiometric Titration for BM3heme; E°’ = −420 mV. 
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Figure S7. Potentiometric titration of ABCheme; E°’ = −293 mV. 
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Figure S8. Potentiometric Titration of BM3-CISheme; E°’ = −360 mV. 
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Figure S9. Potentiometric Titration of ABC-CISheme; E°’ = −265 mV. 
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V.IV.   Effect of C400S on Thermostability 
 
 
 
 
 
Figure S10. Thermostabilities of heme domains of BM3-CIS (blue) and ABC-CIS (red). 
The C400S mutation stabilizes the heme domain by +1.7 °C. The T50 is the temperature at 
which half of the enzyme population has unfolded. Error bars correspond to 1-σ (68.3%) 
confidence intervals for the T50.  
 
VI. In vitro Cyclopropanation Activities of ABC-CIS and ABC 
 
VI.I. Michaelis-Menten Kinetics 
 
Determination of initial rates. Both styrene and EDA concentrations were varied in the 
presence of the enzymes expressed as the heme-domain (0.5 or 1.0 µM BM3-CISheme). 
Reactions were set up in phosphate buffer (pH = 8.0) with Na2S2O4 as the reductant at 
298 K, and were worked up as described in section II. Three time points were taken and 
used to determine the rate of product formation by GC (cyclosil-B 30 m x 0.32 mm x 
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0.25 µm): oven temperature = 100 °C 5 min, 5 °C / min to 200 °C, 20 °C / min to 250 
°C, 250 °C for 5 min. Elution time: cis-cyclopropanes (19.20 min and 19.33 min), trans-
cyclopropanes (20.44 min). Apparent kinetic parameters were determined by fitting the 
data to the standard Michaelis-Menten model.    
 
 
 
Figure S11. Initial velocities plot for ABC-CISheme. (A) EDA concentration was varied at 
a saturating concentration of styrene (30 mM). (B) Styrene concentration was varied at a 
fixed concentration of EDA (20 mM). Initial rates were computed as the slope of a zero-
intercept linear fit of three different time points from independent reactions. Error bars 
correspond to 1-σ (68.3%) confidence intervals for the slope. 
 
 
Table S3. Michaelis-Menten parameters for P450 cyclopropanation catalysts. Error bars 
correspond to 99% confidence intervals for the fitted parameters. 
Catalyst kcat (min-1) KM-EDA 
(mM) 
 
KM-styrene 
(mM) 
kcat / KM-
EDA (s-1 M-1) 
 
kcat / KM-
styrene  
(s-1 M-1) 
kcat / (KM-EDA x 
KM-styrene)  
(s-1 M-1 M-1) 
BM3-
CISheme (5) 
100 ± 24 5.2 ± 3.5 1.4 ± 0.5 320 1,100 2.1 x 105 
ABC-
CISheme 
82 ± 15 5.7 ± 2.9 4.6 ± 2.4 240 300 5.5 x 104 
  
A" B"
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VI.II. Enhanced Cis Selectivity and Substrate Scope 
 
Activity under Anaerobic versus Aerobic Conditions with Sodium Dithionite as the 
Reductant  
 
 
 
Catalyst Conditions Yield (%)* TTN O2 
inhibition 
(%) 
cis:trans† %ee 
cis‡ 
%ee 
trans§ 
BM3-
CISheme 
Anaerobic 32 212 ± 20 - 77:23 −94 −91 
BM3-
CISheme 
Aerobic 12 83 ± 5 −61 65:35 −87 −86 
ABC-
CISheme 
Anaerobic 51 342 ± 21 - 93:7 −99 −51 
ABC-
CISheme 
Aerobic 2 10 ± 1 −97 45:55 −79 −31 
* Based on EDA.  † Diastereomeric ratios and enantiomeric excess were determined by 
GC analysis. ‡ (2R,1S) – (2S,1R). § (2R,1R) – (2S,1S). 
 
Figure S12. Cyclopropanation activities of BM3-CIS and ABC-CIS driven by sodium 
dithionite under anaerobic and aerobic conditions. Measurements were taken in triplicate, 
and the error bars represent the standard deviation of the measurements.      
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Small-scale reactions. Selected P450 catalysts were surveyed at a small-scale reaction 
(400 µL total volume) for each combination of reagents (olefins and diazo esters). The 
small-scale anaerobic bioconversions were conducted as described in section II and were 
analyzed by GC. GC methods for these products are reported in reference (5). 
 
 
 
Table S4. Enhanced Z selectivity for ABC-CIS over BM3-CIS  
 
Reagents	   P450	   %	  yield*	   TTN	   Z:E†	   %ee	  Z‡	   %ee	  E‡	  R1	  =	  H,	  X	  =	  Me,	  R2	  =	  Et	   BM3-­‐CIS	   46	   228	   78:22	   -­‐81.4	   N/A	  ABC-­‐CIS	   32	   157	   93:7	   -­‐87.1	   N/A	  R1	  =	  H,	  X	  =	  OMe,	  R2	  =	  Et	   BM3-­‐CIS	   43	   214	   48:52	   -­‐44	   N/A	  ABC-­‐CIS	   47	   235	   81:19	   -­‐61	   N/A	  R1	  =	  H,	  X	  =	  CF3,	  R2	  =	  Et	   BM3-­‐CIS	   42	   211	   39:61	   54	   -­‐93	  ABC-­‐CIS	   24	   121	   76:24	   55	   -­‐75	  R1	  =	  Me,	  X	  =	  H,	  R2	  =	  Et	   BM3-­‐CIS	   26	   127	   16:84	   -­‐6	   N/A	  ABC-­‐CIS	   17	   86	   30:70	   34	   N/A	  R1	  =	  H,	  X	  =	  H,	  R2	  =	  
t-­‐Bu	   BM3-­‐CIS	   0.3	   2	   3:97	   N/A	   N/A	  ABC-­‐CIS	   15	   76	   8:92	   N/A	   N/A	  
* Based on EDA.  † Diastereomeric ratios and enantiomeric excess were determined by 
GC analysis. ‡Enantiomeric excess is only reported when the enantiomers resolved to 
baseline resolution. 
 
  
  
X
R1 O
N2
O R2
0.2 mol% P450BM3 
10 mM Na2S2O4
5% MeOH
0.1 M KPi pH 8.0
+
Ar COOR2
R1
R1
Ar
COOR2
Z E
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VI.III. Monooxygenation versus Cyclopropanation Activities for BM3-CIS and 
ABC-CIS 
 
Activity under anaerobic versus aerobic conditions with NADPH as the reductant. 
Small-scale reactions (400 µL total volume) were conducted as described in section II 
with the following modifications: glucose dehydrogenase (GDH, 4 µL, 225 U mL-1) was 
added to the reaction vial together with the P450 solution. Glucose (40 µL, 250 mM) and 
NADPH (40 µL, 5 mM) were degassed together with the buffer solution. Measurements 
were taken in triplicate and the error bars represent the standard deviation from the mean 
value. 
 
 
 
 
Table S5. In vitro activities for purified ABC-CIS vs BM3-CIS driven by NADPH 
 
Cat. Conditions Cyclopropa-
nes (TTNcyc) 
Styrene 
oxide 
(TTNepo) 
TTNcyc / 
TTNepo 
O2 
inhibi-
tion (%) 
cis: 
trans* 
%ee 
cis† 
%ee 
trans‡ 
BM3-
CIS 
Anaerobic 60 ± 18 12 ± 10 5 - 60:40 −89 −53 
BM3-
CIS 
Aerobic 82 ± 13 406 ± 21 0.20 +36 56:44 −88 −58 
ABC-
CIS 
Anaerobic 304 ± 15 0  - - 72:28 −92 −19 
ABC-
CIS 
Aerobic 43 ± 5 14 ± 2 3.1 -86 49:51 −74 −14 
Diastereomeric ratios and enantiomeric excess were determined by GC analysis. 
 † (2R,1S) – (2S,1R). ‡ (2R,1R) – (2S,1S). 
  
P450
Glucose / NADPH / GDH
Ph COOEt Ph COOEt
+
cis trans
+
20 µM
(0.2% mol eq)
wrt EDA
O
Ph
styrene oxide
+Ph
COOEt
N2
+
30 mM 10 mM
0.1 M KPi pH 8.0
5% MeOH
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VI.IV. Choice of Reductant: NADPH vs NADH 
 
 
 
 
Table S6. In vitro ABC-CISholo cyclopropanation driven by Na2S2O4, NADPH and 
NADH 
 
[NADPH] 
/ mM 
[NADH] 
/ mM 
[Na2S2O4] 
/ mM 
Yield 
(%)* 
TTN cis:trans† %ee cis‡ %ee trans§ 
0 0 0 1 3 54:46 - - 
0 0 10 35 218 94:6 −99 −43 
1 0 0 47 294 93:7 −98 −40 
5 0 0 58 364 90:10 −97 −28 
10 0 0 49 305 91:9 −98 −26 
0 1 0 70 437 93:7 −98 −38 
0 5 0 68 428 93:7 −98 −34 
0 10 0 47 295 93:7 −98 −34 
* Based on EDA.  † Diastereomeric ratios and enantiomeric excess were determined by 
GC analysis. ‡ (2R,1S) – (2S,1R). § (2R,1R) – (2S,1S). 
  
Ph N2
COOEt
+ + ABC-CISholo
0.1 M KPi pH 8.0
5% MeOH
30 mM 10 mM
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
16 µM
0.16% mol eq
(wrt EDA)
+ reductant
variable
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VI.V. In vitro Cyclopropanation Activities of BM3 and ABC 
 
Small-scale (500 µL) reactions were conducted as described in section II with purified 
BM3 and ABC catalysts.  
 
 
 
 
Table S7. In vitro cyclopropanation activities of BM3 and ABC driven by NADH 
 
Catalyst Yield (%)* TTN cis:trans† %ee cis‡ %ee trans§ 
BM3 0.2 2 ± 0.5  17:83 −29 −21 
ABC 36 364 ± 50 12:88 −5 −1 
* Based on EDA.  † Diastereomeric ratios and enantiomeric excess were determined by 
GC analysis. ‡ (2R,1S) – (2S,1R). § (2R,1R) – (2S,1S) 
  
Ph N2
COOEt
+ + Catalyst
0.1 M KPi pH 8.0
5% MeOH
30 mM 10 mM
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
10 µM
0.1% mol eq
(wrt EDA)
+
1.6 mM
NADH
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VII. Whole-Cell Cyclopropanation Catalysts 
 
All experiments using whole-cells were done in triplicate; the error bars represent the 
standard deviation of the measurements. “Total turnovers” is defined here as the amount 
of cyclopropane product (mmol) formed per mass of catalyst (gcdw). 
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VII.I. Effect of Glucose Addition 
 
 
Whole-
Cell 
Catalyst 
[Glucose]  
(mM) 
Yield 
(%)* 
Total 
Turnover 
(mmol 
gcdw-1) 
Effect of 
glucose 
addition 
(%) 
Cell 
density 
(gcdw L-1) 
cis: 
trans† 
%ee 
cis‡ 
%ee 
trans§ 
BM3-
CIS 
0 7 0.120 ± 
0.03 
- 5.53 34:66 −73 −22 
BM3-
CIS 
2 13 0.240 ± 
0.02 
+98 5.53 48:52 −86 −30 
ABC-
CIS 
0 35 0.550 ± 
0.06 
- 6.38 70:30 −95 −11 
ABC-
CIS 
2 48 0.760 ± 
0.01 
+37 6.38 76:24 −96 −14 
* Based on EDA.  † Diastereomeric ratios and enantiomeric excess were determined by 
GC analysis. ‡ (2R,1S) – (2S,1R). § (2R,1R) – (2S,1S).  
Figure S13. Effect of adding exogenous glucose (2 mM) on olefin cyclopropanation 
catalyzed by E. coli whole cells. 
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VII.II. Anaerobic vs Aerobic Reaction Conditions 
 
 
 
 
 
 
Figure S14. Effect of dioxygen exposure on whole-cell catalyzed cyclopropanation. 
ABC-CIS is strongly inhibited by dioxygen in vivo. All reactions had a cell density 
equivalent to OD600 = 25. Reactions were conducted in the absence of exogenous glucose.  
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VII.III. Empty Plasmid, No Induction Controls and Dithionite Addition to 
Whole-Cells 
 
 
 
 
Catalyst Yield (%)* cis:trans† %ee cis‡ %ee trans§ 
ABC-CIS 49 60:40 −93 −9 
ABC-CIS no 
induction 
16 17:83 −50 −9 
Empty 
pcWori 
15 11:89 −10 −12 
ABC-CIS + 
dithionite 
13 46:54 −87 −5 
* Based on EDA.  † Diastereomeric ratios and enantiomeric excess were determined by 
GC analysis. ‡ (2R,1S) – (2S,1R). § (2R,1R) – (2S,1S). 
 
Figure S15. E. coli cells carrying the ABC-CIS gene but grown without the addition of 
IPTG (ABC-CIS no induction); E. coli cells carrying the pcWori plasmid but not the 
ABC-CIS gene (empty pcWori); ABC-CIS reaction with the addition of exogenous 
dithionite instead of glucose (ABC-CIS + dithionite). Reactions were left for two hours at 
298 K.  
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VII.IV. Effect of Styrene Concentration 
 
  
 
Figure S16. Effect of using 1, 2, 3, 4, and 5 equivalents of styrene on reaction yield. 
Excess styrene gives only small improvements in yield.  
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VII.V. Effect of Cell Density 
 
 
 
 
Figure S17. Increasing cell density increases cyclopropane yields up ~80%. Total 
turnovers do not increase for cell densities higher than OD600 = 20.  
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VII.VI. Lysate Compared to Intact Whole-Cells 
 
 
Table S8. Lysate activity compared to in vivo activity 
Catalyst Conditions [P411] 
(µM) 
Yield 
(%)* 
TTN cis: 
trans† 
%ee 
cis‡ 
ABC-CIS In vivo 1.0 44 5120 80:20 −96 
ABC-CIS Lysate, no 
reductant 
1.0 0.6 55 67:33 −92 
ABC-CIS Lysate + 
NADH 
1.0 18 1780 80:20 −97 
ABC-CIS Lysate + 
dithionite 
1.0 0.8 79 64:36 −86 
* Based on EDA.  † Diastereomeric ratios and enantiomeric excess were determined by 
GC analysis. ‡ (2R,1S) – (2S,1R). 
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VII.VII. Lyophilization of Whole-Cell Catalysts 
 
Cells were lyophilized in 10% sucrose (m/V) and were stored at 4 °C for two weeks. An 
appropriate mass of the resulting powder was transferred to a 2 mL glass vial, which was 
crimp sealed and purged with argon. Degassed solutions of nitrogen-free M9 medium and 
glucose (20 mM) were added via syringe. Cells were resuspended to OD600 = 25 and 2 
mM final concentration of glucose.  
 
 
 
Table S9. Cyclopropanation activity of lyophilized ABC-CIS whole-cell catalysts.  
Catalyst [Cell 
density]  
(gcdw L-1) 
[P411] 
(µM) 
Yield 
(%)* 
Total 
Turnover 
(mmol 
gcdw-1) 
TTN cis: 
trans† 
%ee 
cis‡ 
%ee 
trans§ 
ABC-CIS 6.0 0.8 43 0.710 ± 
0.08 
5300 ± 
600 
67:33 −93 −25 
* Based on EDA.  † Diastereomeric ratios and enantiomeric excess were determined by 
GC analysis. ‡ (2R,1S) – (2S,1R). § (2R,1R) – (2S,1S). 
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C h a p t e r  4  
INTRAMOLECULAR C-H AMINATION CATALYZED BY ENGINEERED 
CYTOCHROME P450 ENZYMES  
 
 
 
 
 
 
 
 
 
 
 
 
 
Material from this chapter appears in J. A. McIntosh,* P. S. Coelho,* J. C. Lewis, C. 
Farwell, Z. J. Wang,  T. R. Brown, and F. H. Arnold. “Enantioselective intramolecular 
C−H amination catalyzed by engineered cytochrome P450 enzymes in vitro and in vivo”, 
submitted. *Authors contributed equally to this work. JAM conducted the 2D NMR 
experiments described in this chapter.  
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Abstract  
Direct nitrene transfer to unactivated C-H bonds is a powerful method to introduce 
nitrogen atoms into organic scaffolds. Transition metal-catalyzed C-H amination 
proceeds through a nitrenoid intermediate with no mechanistic parallel in natural 
enzymes, but is isoelectronic with oxene transfers catalyzed by cytochromes P450. 
Engineered cytochrome P450BM3 enzymes bind arylsulfonyl azides with micromolar 
affinity and show promiscuous levels of intramolecular benzylic C-H amination activity 
with these synthetic reagents. Formation of dimerized products and reduction of the 
sulfonyl azide to the sulfonamide are the major competing reactions. Sterically hindered 
multisubstituted arylsulfonyl azides favor C-H amination. These preliminary findings 
demonstrate the plasticity of cytochrome P450s to catalyze abiological bond 
disconnections.   
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Natural products and fine chemicals are often highly functionalized with 
amines and amides. The efficient installation of amines is thus of primary importance to 
organic synthesis. Methods for C-N bond formation often require functional group 
interconversion and the use of protecting groups, rendering such approaches redox and 
atom inefficient. The ability to insert nitrogen directly—via formal nitrene transfers—
into unactivated C-H bonds allows for more convenient synthesis of otherwise difficult to 
make molecules (1, 2). Significant progress in this direction has been made by the 
development of organometallic catalysts that can transfer nitrene equivalents to C-H 
bonds with high levels of regio- and stereoselectivities (3, 4). These approaches, however, 
require organic solvents, expensive transition metals, elaborate ligand designs and often 
high catalyst loadings (>1% mol eq). 
 Nature makes amines using entirely different strategies (figure S1). For example, 
dehydrogenases and transaminases can convert a carbonyl to an amine (i.e., reductive 
amination), and aminomutases can catalyze the redox neutral radical rearrangement of α 
to β amino acids (5). Oxidative aminations, whereby a C-H bond is directly converted to 
an amine, are not known in nature. A chemomimetic approach to achieve enzymatic 
nitrene transfer can provide a more direct biosynthetic route to amines whilst 
complementing the existing synthetic methods.  Since iron-porphyrin amination catalysts 
have been described (6), we reasoned that heme enzymes might also catalyze this 
reaction if provided with appropriate nitrene precursors. Furthermore, mammalian 
cytochrome P450s have been shown to catalyze trace levels of C-H amination from 
iminoiodane nitrene precursors (7), a transformation which is isoelectronic to the well 
established P450 catalyzed transfers of “oxenes” from iodosylbenzene.  
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We chose to use sulfonylazides instead of iminoiodanes as nitrene precursors 
due to their ease of synthesis, greater solubility in P450-compatible cosolvents, atom 
efficiency (since activation to the nitrene is accompanied by loss of only dinitrogen) and 
the demonstrated viability of these reagents for C-H amination (8). We focused our 
investigation on intramolecular C-H amination from arylsulfonyl azides so as to increase 
the likelihood of productive reaction (given the high local concentration of relatively 
weak benzylic C-H bonds in 2-substituted arylsulfonylazides). We chose to screen 
engineered variants of the bacterial cytochrome P450BM3 (CYP102A1 or BM3) owing to 
its remarkable plasticity as well as the ready availability of many diverse and active 
variants in our laboratory (5). 
We first screened a selection of 92 BM3 variants for binding to 2-
isopropylbenzenesulfonyl azide (1), by monitoring changes in the ferric Soret peak in the 
UV-vis spectra, as a strategy to narrow our search for P450s with C-H amination activity. 
Many BM3 variants showed “type I” binding for azide 1 (figure S2), with spectral 
features characteristic for nondonor ligands (figure S3 to S6). We assessed several 
binders for reaction with azide 1 (2 mM) under anaerobic conditions in the presence of 
NADPH (0, 0.05, and 1 equivalent, with respect to azide), and 1 mole % (mol %) P450 in 
phosphate buffer with 2.5% DMSO cosolvent (figure 1). The desired benzosultam, 
however, was not formed in any of these reactions (figures 2-4). When NADPH is 
supplied in substoichiomteric amounts, some P450s are able to catalyze efficient 
formation of sulfonamide 2. For example, variant 12-10C [16 amino acid mutations from 
BM3 (5)] makes 2 with ~60 TTN (TTN, total turnover number) when NADPH is 
supplied in 0.05 equivalents, and with ~20 TTN in the complete absence of exogenous 
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NADPH. NADPH-independent formation of sulfonamide 2 could be consistent with 
the hydrolysis of an “aza analogue” of compound I as proposed by White and McCarthy 
for the p-tosyl iminoiodane (PhINTs) dependent hydroxylation of cyclohexane (9) (figure 
S7). This mechanism would also explain the formation of the oxidative products [olefin 3 
and alcohol 10 (5)] under anaerobic conditions that are formed in small amounts by 12-
10C and other P450s (figures 3 to 5). Efficient reduction of the sulfonyl azide to the 
sulfonamide was readily achieved by various P450s when NADPH is supplied in one 
equivalent (figure S12). For example, wild-type BM3 (BM3) catalyzes formation of 2-
isopropylbenzenesulfonamide (2) to 90% yield, corresponding to 90 TTNs (figure 4). 
Only variants H2A10 (15 mutations from BM3, SM) and H2-4-H5 (2 mutations from H2-
A10, SM) did not form sulfonamide 2 as the major product with 1 eq. NADPH.  
 
 
Figure 1. P450 bioconversions with 2-isopropylbenzenesulfonyl azide (1) under 
anaerobic conditions. NES = negative electrospray, PES = positive electrospray. 
Authentic standards for 7 and 9 were coinjected to assess formation of these compounds. 
Reaction conditions: 2 mM azide, 20 µM P450, oxygen depletion system (5) in 2.5% 
DMSO at 298 K for 12 hours. Reactions were analyzed by LC-MS. 
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Figure 2. P450 reactions with azide 1 in the absence of NADPH. Alcohol 10 and 
arylsulfonamide 2 are defined in figure 1.  
 
 
 
Figure 3. P450 reactions with azide 1 in presence of 0.1 mM NADPH (0.05 eq). Alcohol 
10 and arylsulfonamide 2 are defined in figure 1.  
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Figure 4. P450 reactions with azide 1 in presence of 2 mM NADPH (1 eq). Alcohol 10, 
arylsulfonamide 2 and dimer 4 are defined in figure 1.  
 
The effect of varying the concentration of NADPH on azide conversion and 
product distribution was further investigated for BM3, BM3-F87A, H2A10 and H2A10-
A75L (figure S8). For BM3 and BM3-F87A, yields for sulfonamide 2 increased with 
increasing concentration of NADPH reaching close to 90% when stoichiometric amounts 
of NADPH are used. For H2A10 and H2A10-A75L, sulfonamide 2 was not the dominant 
product at any of the concentrations of NADPH investigated. H2A10-A75L formed 
alcohol 10 as the major product (20 TTN) when low concentrations of NADPH were 
used, but formed dimer 4a (35 TTN) in the presence of a high concentration of NADPH. 
H2A10-A75L production of alcohol 10 is inhibited by dioxygen (table S1), confirming 
that 10 is not made via monooxygenation due to trace oxygen in the anaerobic reaction. 
Heat denaturation of H2A10-A75L significantly reduced production of alcohol 10 (table 
S1), confirming the involvement of the P450 in catalysis.  
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Figure 5. P450-catalyzed amination of benzylic C–H bonds from arylsulfonyl azides. 
Reaction conditions: 2 mM azide, 20 µM P450, 2 mM NADPH under argon in phosphate 
buffer (pH 8.0) for 4 hours at 298 K. Products isolated from small-scale (30 mg azide) 
bioconversions were analyzed by NMR and mass spectrometry. 
 
We scaled up the reaction of azide 1 with H2A10, purified the products by 
reverse-phase HPLC, and characterized the by-products shown in figure 2 by NMR and 
mass spectrometry (5). Dehydrogenations to form alkenes, as observed for olefin 3, were 
also reported by Breslow and Gellman for iron-porphyrins reacting with iminoiodanes (6). 
Formation of the dimerization products 4a and 4b require the nitrenoid intermediate (or 
an equivalent species at the same oxidation state) to react with a second molecule of 
sulfonamide 2 (as speculated in figure S7). That is the active site is likely able to 
simultaneously accommodate at least one molecule of 1 and one of 2. The H2A10 active 
site has high affinity for binding azide 1 (Kd = 40 µM), and only weak affinity for 
sulfonamide 2 (Kd = 900 µM) (figures S9 and S10).  
Due to the unexpected dimerizations (4a and 4b), we reasoned that intramolecular 
C–H amination might be favored in more bulky multisubstituted arylsulfonyl azides. 
P450s chosen based on their ability to bind 1 could in fact catalyze benzosultam 
formation from 2,5-diisopropylbenzenesulfonyl azide (5) and 2,4,6-
triisopropylbenzenesulfonyl azide (8) (figures 6 to 10). None of the P450s could form 
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benzosultam 6 as the major product, though B1SYN and chimera X7-R1 catalyzed 
over 30 TTNs of C-H amination. BM3, 2C6, B1SYN, Glc4T180A, ManA10, MB2 and 9-
10A TS F87A all formed benzosultam 9 as the major product, with B1SYN catalyzing 45 
TTN (45% yield). B1SYN (23 mutations from P450BM3) binds azides 5 and 8 with 
micromolar affinity [Kd (5) = 1.5 µM, Kd (8) = 19 µM, figure S11]. B1SYN was used for 
preparative-scale amination reactions (figure 2), making benzosultams 6 and 9 with 
moderate isolated yields (27% for 6 and 42% for 9).  
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Figure 6. P450 bioconversions with 2,5-diisopropylbenzenesulfonyl azide (5) under 
anaerobic conditions. NES = negative electrospray, PES = positive electrospray. Reaction 
conditions: 2 mM azide, 20 µM P450, oxygen depletion system (5) in 2.5% DMSO at 
298 K for 12 hours. Reactions were analyzed by LC-MS. 
 
 
Figure 7. P450 reactions with azide 5 in presence of 2 mM NADPH (1 eq). Benzosultam 
6, arylsulfonamide 7, and dimer 12 are defined in figure 6. 
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Figure 8. P450 bioconversions with 2,4,6-triisopropylbenzenesulfonyl azide (8) under 
anaerobic conditions. NES = negative electrospray. Reaction conditions: 2 mM azide, 20 
µM P450, oxygen depletion system (5) in 2.5% DMSO at 298 K for 12 hours. Reactions 
were analyzed by LC-MS. 
 
 
Figure 9. P450 reactions with azide 8 in presence of 2 mM NADPH (1 eq). Benzosultam 
9, arylsulfonamide 13, alcohol 14, alkene 15 and dimer 16 are defined in figure 8. 
 
 
Figure 10. P450 reactions with azide 8 in presence of 2 mM NADPH (1 eq). 
Benzosultam 9, arylsulfonamide 13, alcohol 14, alkene 15 and dimer 16 are defined in 
figure S15. 
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Free hemin was only an effective amination catalyst for the triisopropyl-
substituted azide 8 and not the diisopropyl-substituted azide 5 (using dithionite as the 
reductant, tables S2-S3). Hemin was able to make both sulfonamides 7 and 13. The fact 
that hemin can activate both azides but unlike P450s it can only form the benzosultam for 
the more hindered 8 (which also has two equivalent tertiary C-H bonds), suggests that the 
enzyme serves primarily to impose a conformation on the substrate that is favorable for 
nitrene C–H insertion.  
These findings attest to the catalytic promiscuity of engineered P450BM3 variants 
to catalyze nonnatural nitrene transfer reactions from synthetic azide reagents. Further 
engineering of the P450 active site will be required to improve C-H amination activity.    
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I. Materials and Methods  
 Unless otherwise noted, all chemicals and reagents for chemical reactions were 
obtained from commercial suppliers (Sigma-Aldrich, Acros) and used without further 
purification. Silica gel chromatography purifications were carried out using AMD Silica 
Gel 60, 230-400 mesh. 1H and 13C NMR spectra were recorded on either a Varian 
Mercury 300 spectrometer (300 and 75 MHz, respectively), or a Varian Inova 500 MHz 
(500 and 125 MHz, respectively), and are internally referenced to residual solvent peak. 
Data for 1H NMR are reported in the conventional form: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), 
coupling constant (Hz), integration. Data for 13C are reported in terms of chemical shift (δ 
ppm) and multiplicity. High-resolution mass spectra were obtained with a JEOL JMS-
600H High Resolution Mass Spectrometer at the California Institute of Technology Mass 
Spectral Facility. Reactions were monitored using thin layer chromatography (Merck 60 
silica gel plates) using an UV-lamp for visualization.  
 High-performance liquid chromatography (HPLC) was carried out using an 
Agilent 1200 series, an UV detector, and an Agilent XDB-C18 column (4.6 x 150 mm, 5 
μm). Azides 5 and 8, and benzosultam standards 6 and 9 were prepared as reported (8). 
Benzosultam 11 was purchased from Sigma. These standards were used in co-injection 
experiments to determine the authenticity of P450-catalyzed benzosultams. Authentic 
P450 catalyzed benzosultam samples were also prepared as described in section VI and 
were characterized by NMR (1H and 13C) and mass spectrometry.    
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II. General Procedures  
Typical procedure for small-scale amination bioconversions under anaerobic 
conditions. Small-scale reactions (400 µL) were conducted in 2 mL crimp vials (Agilent 
Technologies, San Diego, CA) as for cyclopropanation reactions but an oxygen depletion 
system, composed of glucose oxidase and catalase, was also added to ensure strict 
anaerobic conditions. P450 solution (80 µL, 100 µM), glucose oxidase (20 µL, 2,000 U 
mL-1) and catalase (20 µL, 28,000 U mL-1) were added to the vial with a small stir bar 
before crimp sealing with a silicone septum. Phosphate buffer (190 µL, 0.1 M, pH = 8.0), 
glucose (40 µL, 250 mM) and NADPH (40 µL, 20 mM) were combined in a larger crimp 
sealed vial and degassed by bubbling argon through the solution for at least 5 min. In the 
meantime, the headspace of the 2 mL reaction vial with the P450 solution was made 
anaerobic by flushing argon over the protein solution (with no bubbling). The 
buffer/reductant/glucose solution (270 µL) was syringed into the reaction vial, while 
under argon.  The gas lines were disconnected from the reaction vial before placing the 
vials on a plate stirrer. A 40x arylsulfonyl azide solution in DMSO (10 µL, typically 80 
mM) was added to the reaction vial via a glass syringe, and the reaction was left stirring 
for the appropriate time. The final concentrations of the reagents were typically 2 mM 
arylsulfonyl azide, 2 mM NADPH, 25 mM glucose, 20 µM P450. Reactions were 
quenched by adding 30 µL 3 M HCl under argon. The vials were opened and 50 µL of 
internal standard (10 mM ortho-toluenesulfonamide) was added. The mixture was 
extracted twice with 500 µL ethyl acetate. The combined organic phase was dried under a 
light argon stream. The residue was dissolved in 100 µL of 50% water-acetonitrile for 
HPLC analysis.  
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Typical procedure for preparative-scale amination bioconversions under anaerobic 
conditions. Enzymes (P450, glucose oxidase and catalase) were added to a Schlenk flask 
with a stir bar. With the flask kept on ice, the headspace was evacuated and back-filled 
with argon (4×) with care not to foam the protein solution. Phosphate buffer, NADPH 
and glucose were premixed and degassed together in a separate round-bottom flask by 
bubbling argon through the solution for 20 min. The buffer/reductant solution was 
transferred to the Schlenk flask via syringe. The arylsulfonyl azide (80 mM in DMSO) 
was added under argon, and the solution was left to stir under argon until reaction 
completion. The reaction was quenched under argon by adding hydrochloric acid (3 M) 
to adjust the pH to 4, before opening the Schlenk flask. The reaction mixture was stirred 
with sodium chloride and dichloromethane (CH2Cl2). The combined emulsion layers 
were then filtered through Celite to break the emulsion and the Celite pad was rinsed with 
3x20 mL CH2Cl2. The resulting biphasic mixture was transferred to a separating funnel 
and the organic phase was removed. The remaining aqueous phase was reextracted with 
3x40 mL CH2Cl2. The combined organic extracts were dried with sodium sulfate, filtered, 
and concentrated. The resulting residue was purified by reverse-phase HPLC .  
 
 Small-scale amination reactions under anaerobic conditions for azide 1. Reaction 
conditions were as described in section II and were analyzed by reverse-phase LC-MS 
(Agilent 1100 series LC-MSD), acetonitrile-water, using a C18 column (Peeke Scientific, 
Kromasil 100 5 µm, 50 x 4.6 mm ID). Acetonitrile gradient for 2-
isopropylbenzenesulfonyl azide reactions: 10%-22% (8 min), 22%-60% (10 min), 60% (2 
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min), at 1.5 mL min-1. Retention times: alcohol 10 (6.3 min), sulfonamide 2 (10.6 
min), dimer 4 (12.3 min), azide 1 (17.6 min). Acetonitrile gradient for 2,5-
diisopropylbenzenesulfonyl azide and 2,4,6-triisopropylbenzenesulfonyl azide reactions: 
30%-50% (10 min), 50%-90% (8 min), 90% (2 min), at 1.5 mL min-1. Retention times: 
benzosultam 6 (5.4 min), sulfonamide 7 (7.2 min), dimer 12 (8.6 min), azide 5 (14.4 
min); alcohol 14 (8.3 min), benzosultam 9 (9.8 min), olefin 15 (10.8 min), sulfonamide 
13 (11.8 min), dimer 16 (15.4 min), azide 8 (16.5 min).   
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III. Summary of Mutations (with Respect to Wild-Type P450BM3) for 
P450 Amination Catalysts 
 
12-10C: R47C, V78A, A82G, F87V, K94I, P142S, T175I, A184V, F205C, S226R, 
H236Q, E252G, R255S, A290V, A328V, L353V 
9-10A TS: V78A, P142S, T175I, A184V, S226R, H236Q, E252G, A290V, L353V, 
I366V, E442K 
H2A10: 9-10A TS F87V, L75A, L181A, T268A 
H2A10-A75L: 9-10A TS F87V, L181A, T268A 
H2-4-H5: H2-A10 M177A A268T  
H2-5-F10: 9-10A TS F87V, L75A, I263A, T268A, L437A 
H2-4-D4: 9-10A TS F87V, L75A, M177A, L181A, T268A, L437A 
B1SYN: R47C, V78A, K94I, P142S, T175I, A184V, F205C, S226R, H236Q, E252G, 
R255S, A290V, L353V, C47S, N70Y, A78L, F87A, I174N, I94K, V184T, I263M, 
G315S, A330V 
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IV. Natural Approaches for Amine Biosynthesis  
 
 
Fig S1. Natural approaches for amine biosynthesis. (A) Dehydrogenases convert carbonyl 
groups to amines using NAD(P)H and ammonia (e.g., glutamate dehydrogenase). (B) 
Transaminases convert carbonyls to amines using another amine (or amino acid) as the 
amine donor (e.g., acetylornithine transaminase, involved in putrescine biosynthesis). (C) 
Amino mutases catalyze the radical rearrangement of α to β amino acids.  
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V. P450 Amination Catalysts  
 
Arylsulfonyl azide binding screen. Cell lysate of the compilation plate described in 
chapter 2 was scanned from 500 to 350 nm in a plate reader (Tecan M1000 UV/Vis) in 
the absence and presence of 100 µM 2-isopropylbenzenesulfonyl azide. Selected 
absorbance difference spectra that displayed type I binding to the azide (figure S2) are 
shown below (figures S3-6).  
 
Figure S2. P450BM3 variants display type I binding to arylsulfonyl azides.  
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Figure S3. Absorbance difference spectra for P450BM3 variants binding 2-
isopropylbenzenesulfonyl azide. Sequence identities are shown on table S5 in chapter 2.  
 
 
Figure S4. Absorbance difference spectra for P450BM3 variants binding 2-
isopropylbenzenesulfonyl azide. Sequence identities are shown on table S5 in chapter 2.  
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Figure S5. Absorbance difference spectra for P450BM3 variants binding 2-
isopropylbenzenesulfonyl azide. Sequence identities are shown on table S5 in chapter 2.  
 
 
 
Figure S6. Absorbance difference spectra for P450BM3 variants binding 2-
isopropylbenzenesulfonyl azide. Sequence identities are shown on table S6 in chapter 2.  
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Figure S7. Putative mechanism for azide activation and decomposition catalyzed by 
cytochrome P450. Nitrenoid hydrolysis and subsequent to a ferryl species which 
catalyzes subsequent oxidation is based on the mechanism proposed by White and 
McCarthy (9).  
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Figure S8. Effect of varying the concentration of NADPH on the reaction of azide 1 
with: (A) BM3; (B) BM3-F87A; (C) H2A10; (D) H2A10-A75L. For plots A and B, 
[NADPH] = 0.1, 0.5, 1.0, 1.5, 2.0 mM. For plots C and D, [NADPH] = 0.1, 0.3, 0.5, 1.0, 
2.0 mM NADPH.  
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Table S1. Controls for the reaction of H2A10-A75L with azide 1 with 0.05 eq. NADPH. 
Complete System (CS) = 2 mM azide, 20 µM P450, 100 µM NADPH in anaerobic 
conditions with an oxygen depletion system. 
 
Conditions 10 (TTN) 2 (TTN) 
CS 29 16 
CS-NADPH 5 4 
CS+O2 7 3.8 
CS+O2-ODS 0 1.6 
boiled P450 3.8 13.9 
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+
10 22 mM 20 µM1% mol eq
Glucose 
GOX
Catalase
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Figure S9. Absorbance difference spectrum for azide 1 (concentration shown in the 
legend) binding to H2A10. All spectra are referenced against a 1 µM H2A10 solution 
with 1% DMSO.  
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Figure S10. Biding curves for azide 1 (A) and sulfonamide 2 (B) to H2A10. The y-axes 
show the difference in absorbance at 391 and 425 nm with respect to 1 µM H2A10 
solution with 1% DMSO and no ligand. Kd (1) = 40 µM. Kd (2) = 900 µM. 
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Figure S11. B1SYN type I binding curves for azides 5 (A) and 8 (B). Kd (5) =  1.5 µM, 
Kd (8) = 19 µM.    
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Table S2. Hemin reactions with azide 2a under anaerobic conditions 
Cat. loading 
(mol%) 
Reductant TTN benzosultam 6 TTN arylsulfonamide 7 (% 
yield) 
1 None 0 0 
1 2 mM Na2S2O4 0 5 (5) 
1 10 mM Na2S2O4 0 58 (58) 
1 2 mM NADPH 0 1 (1) 
10 2 mM Na2S2O4 0 1 (10) 
10 10 mM Na2S2O4 0 6 (60) 
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Table S3. Hemin reactions with azide 2b under anaerobic conditions 
Cat. loading 
(mol%) 
Reductant TTN benzosultam 9 
(% yield) 
TTN arylsulfonamide 13 
(% yield) 
1 None 0 0 
1 2 mM Na2S2O4 4 (4) 1 (1) 
1 10 mM Na2S2O4 61 (61) 23 (23) 
1 2 mM NADPH 0 1 (1) 
10 2 mM Na2S2O4 0 0 
10 10 mM Na2S2O4 4 (40) 3 (30) 
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VI. Preparative-Scale Bioconversions  
These reactions were conducted anaerobically as described in section II.  
 
 
H2A10 scale-up with 2-isopropylbenzenesulfonyl azide (1). Preparation used 48 mg of 
azide 1 and 2 µmol H2A10holo (0.01 equiv). The products were purified by reverse phase 
HPLC to give 6 mg of arylsulfonamide 2 (15%), 2 mg of olefin 3 (5%), 11 mg of dimer 
4a (25%) and 4 mg of dimer 4b (5%).  
2-isopropylbenzenesulfonamide (2).  1H NMR (500 MHz, DMSO): d 7.82 (d, J = 8.14, 
1H), 7.54 (m, 2H), 7.45 (br s, 2H), 7.31 (ddd, J = 2.16, 6.03, 8.16, 1H), 3.84 (sep, J = 
6.71, 1H), 1.20 (d, J = 6.71, 6H). 13C NMR (125 MHz, DMSO): d 147.04, 141.35, 132.11, 
127.63, 126.76, 125.64, 28.54, 23.87.  Expected m/z for C9H13NO2NaS+ 222.0559.  
Observed m/z 222.0552.   
2-(prop-1-en-2-yl)benzenesulfonamide (3). 1H NMR (500 MHz, DMSO): d 7.89 (dd, J = 
8.08, 1.23, 1H), 7.53 (m, 1H), 7.44 (m, 1H), 7.26 (dd, J = 7.60, 1.34, 1H), 7.22 (s, 2H), 
5.20 (ap p, J = 1.60, 1H),  4.86 (m, 1H), 2.05 (br s, 3H).  13C NMR (HMBC/HSQC 500 
MHz, DMSO): d 141.83, 141.39, 131.27, 129.76, 126.89, 126.70, 115.79, 24.86.  
Expected m/z for C9H12NO2S+ 198.0583.  Observed m/z 198.19.  
2,2'-(2,3-dimethylbutane-2,3-diyl)dibenzenesulfonamide (4a).  1H NMR (500 MHz, 
DMSO): d 8.16 (dd, J = 8.22, 1.45, 1H), 7.53 (s, 2H), 7.33 (ddd, J = 8.18, 6.74, 1.26, 1H), 
7.25 (m, 1H), 7.18 (d, J = 8.06, 1H), 1.59 (s, 6H).  13C NMR (HMBC/HSQC 500 MHz, 
SO2N3
SO2NH2
++
1 2
H2A10holo (1 mol%)
2.5% DMSO
1 eq NADPH
SO2NH2
SO2NH2
4b
SO2NH2
3
+
SO2NH2
4a SO2NH2
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DMSO): d 145.11, 144.81, 134.17, 128.95, 128.26, 125.77, 48.79, 29.78.  Expected 
m/z for C18H25N2O4S2+ =397.1250.  Observed m/z 397.0147. 
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Summary of NMR data for dimer 4b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S23: Summary of NMR data for dimer 4b
position !C, type !H (J in Hz) HMBC COSY
1 140.45, C - - -
2 143.51, C - - -
3 27.97, CH 3.77, sep (6.77) 1, 2, 4, 5 4
4 23.72, CH3 1.17, d (6.72) 2, 3 3
5 126.72, CH 7.38, d (8.22) 1, 3, 8 6
6 129.67, CH 7.18, d (8.23) 2, 7, 9 5, 7
7 124.17, CH 7.63, m 1, 2, 6, 9 7
8 148.33, C - - -
9 44.56, C - - -
10 31.82, CH3 1.80, s 8, 11, 12 -
11 145.77, C - - -
12 129.96, CH 7.57, m 9, 14, 16 -
13 131.47, CH 7.56, m - -
14 126.59, CH 7.46, m 12, 16 15
15 129.74, CH 8.08, d (7.97) 11, 13 14
16 143.15, C - - -
NH 6.83, br s - -
NH 7.30, br s - -
Expected m/z for C18H25N2O4S2+ 397.1250.  Observed m/z 397.1245.
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B1SYN scale-up with 2,5-diisopropylbenzenesulfonyl azide (5). Preparation used 24 
mg of azide 5 and 0.9 µmol B1SYNholo (0.01 equiv). The products were purified by 
reverse phase HPLC to give 6 mg of benzosultam 6 (27%) and 7 mg of arylsulfonamide 7 
(32%).  
Enzymatically produced diisopropyl benzosultam (6). 1H NMR (600 MHz, CDCl3): d 
7.59 (s, 1H), 7.48 (d, J = 8.03, 1H), 7.29 (d, J = 8.11, 1H), 4.50 (s, 1H), 3.01 (sep, J = 
6.95, 1H), 1.64 (s, 6H), 1.28 (d, J  = 6 .98, 6H).  13C NMR (150 MHz, CDCl3): d 150.83, 
143.69, 135.34, 132.39, 122.74, 118.70, 60.78, 34.17, 29.92, 23.92.  Expected m/z for 
C12H18NO2S+ 240.1053.  Observed m/z 240.1059. NMR spectra of enzymatically 
produced diisopropylbenzosultam were identical with those of a synthetic standard 
produced according to Ruppel et al (8).  Moreover, the identity of the benzosultam could 
be further supported by the observation of HMBC correlations from the amide proton to 
the geminal dimethyl groups. 
 
2,5-diisopropylbenzenesulfonamide (7). 1H NMR (500 MHz, CDCl3): d 7.86 (d, J = 1.7 
Hz, 1H), 7.41 (m, 2H), 4.81 (2H, br s),  3.76 (sep, J = 6.80 Hz, 1H), 2.94 (sep, J = 
6.97 Hz, 1H), 1.30 (J = 6.80 Hz, 6H), 1.26 (d, J = 6.96 Hz, 6H). 13C NMR (125 MHz, 
SO2N3 SO2NH2
NH
S
O O
5 6
2.5% DMSO
1 eq NADPH
7
+
B1SYNholo (1 mol%)
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CDCl3): d 146.93, 145.34, 138.67, 131.43, 128.03, 126.16, 33.85, 29.53, 24.21, 23.92. 
Expected m/z for C12H20NO2S+ 242.1209.  Observed m/z 242.1210.  
 
B1SYN scale-up with 2,5-diisopropylbenzenesulfonyl azide (8). Preparation used 13 
mg of azide 8 and 0.4 µmol B1SYNholo (0.01 equiv). The product was purified by reverse 
phase HPLC to give 5 mg of benzosultam 9 (42%). Enzymatically produced triisopropyl 
benzosultam (9). 1H NMR (500 MHz, CDCl3): d 7.22 (d, J = 1.37, 1H), 6.98 (d, J = 1.38, 
1H), 4.47 (s, 1H), 3.61 (sep, J = 6.80, 1H), 2.98 (sep, J = 7.01, 1H), 1.63 (s, 6H), 1.35 (d, 
6.81, 6H), 1.27 (d, 6.92, 6H).  13C NMR (125 MHz, CDCl3): d 155.7, 146.8, 145.5, 131.0, 
124.5, 117.9, 59.9, 34.8, 30.0, 29.6, 24.05, 23.72.  Expected m/z for C15H24NO2S+  
282.1522.  Observed m/z 282.1528. 
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S
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8
9
B1SYNholo (1 mol%)
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VII. Synthesis of Arylsulfonyl Azides 
Synthesis of 2-isopropylbenzenesulfonyl azide (1) 
 
 
 
2-isopropylbenzenesulfonyl chloride. Freshly polished magnesium turnings (0.488 g, 
20.1 mmol) were suspended in dry THF (16 mL) and stirred vigorously. An aliquot of a 
solution of 2-bromocumene (2.00 g, 10 mmol) in 8 mL dry THF was added and the 
reaction was initiated by heating to a brief boil. The remainder of the starting material 
was slowly added to maintain reaction. After three hours, the reaction was cooled with an 
ice bath, and the solution was transferred under nitrogen via Teflon tubing to a solution of 
SO2Cl2 (4.0 mL, 50 mmol) in dry hexanes (25 mL) also at 0 oC and left overnight. The 
reaction was slowly poured over ice cold water (50 mL) and extracted with DCM 4 times. 
The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The crude 
product was purified by chromatography (SiO2, 10% ether/hexanes) to afford the sulfonyl 
chloride (1.302 g, 60%). 1H NMR (CDCl3, 300 MHz): δ = 8.00 (m, 1H), 7.73 – 7.55 (m, 
2H), 7.40 – 7.31 (m, 1H), 4.22 – 4.08 (m, 1H), 1.36 (d, J = 6.8 Hz, 6H).  
 
2-isopropylbenzenesulfonyl azide (1). The chloride (0.800 g, 3.7 mmol) was dissolved 
in acetone (9.5 ml) and cooled with an ice bath. A cold solution of sodium azide (0.358 g, 
5.5 mmol) in water (9.5 ml) was added dropwise and left to react overnight. The reaction 
Br Mg
THF
MgBr excess SO2Cl2
Hexanes
O oC - RT
SO2Cl 1.5 eq NaN3
1:1 Acetone / H2O
SO2N3
1
SO2NH2
2
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mixture was extracted with DCM, dried, filtered and solvent was evaporated in 
vacuo. Flash chromatography (SiO2, 10% ether/hexanes) gave the sulfonyl azide 1 (0.666 
g, 80%). 1H NMR (CDCl3, 300 MHz): δ = 8.04 (dd, J = 8.1, 1.3 Hz, 1H), 7.70 – 7.56 (m, 
2H), 7.38 (m, 1H), 3.82 – 3.67 (m, 1H), 1.36 – 1.27 (d, J = 6.8 Hz, 6H). HRMS (EI+): 
Calcd. for C9H11SO2N3 (M+) m/z 225.0572; found 225.0581.  
 
2-isopropylbenzenesulfonyl amide (2). The chloride (0.241 g, 1.11 mmol) was 
dissolved in chloroform (9 ml) and cooled with an ice bath. Ammonium hydroxide (30%, 
0.35 mL, 5.6 mmol) was added dropwise and left to react overnight. The reaction mixture 
was extracted with DCM, dried, filtered and solvent was evaporated in vacuo. Flash 
chromatography (SiO2, 10% ether/hexanes) gave the sulfonyl amide 7 (0.68 g, 62%). 1H 
NMR (CDCl3, 300 MHz): δ = 8.02 (d, J = 9.3 Hz, 1H), 7.60 – 7.47 (m, 2H), 7.35 – 7.27 
(m, 1H), 4.78 (s, 2H), 3.87 – 3.74 (m, 1H), 1.32 (d, J = 6.8 Hz, 6H). HRMS (EI+): Calcd. 
for C9H13SO2N (M+) m/z 199.0667; found 199.0627.  
 
2,5-diisopropylbenzenesulfonyl amide (7). Same procedure as used above for 2. 
Sulfonamide 7 was obtained in 75% yield (0.345 g). 1H NMR (CDCl3, 300 MHz): δ = 
7.92 – 7.80 (m, 1H), 7.46 – 7.36 (m, 2H), 4.75 (s, 2H), 3.85 – 3.68 (m, 1H), 3.02 – 2.85 
(m, 1H), 1.31 (d, J = 6.8 Hz, 6H), 1.26 (d, J = 6.9 Hz, 6H). 
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C h a p t e r  5  
ON PREADAPTATION AND THE EVOLUTION OF ENZYMES WITH 
SYNTHETIC CATALYTIC FUNCTION 
 
 
 
 
 “A structure is said to be preadapted for a new function if its present form which enables 
it to discharge its original function also enables it to assume the new function whenever 
need for this function arises.” — W. J. Bock (1959) 
 
 
 
 
 
 
 
 
 
 
I was particularly influenced by the work of Seffernick et al. on the evolution of atrazine 
chlorohydrolase and by S. J. Gould’s beautifully simple illustration of preadaptation in 
his book “Ever Since Darwin”.   
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Abstract. The introduction of synthetic compounds into the environment since the 
industrial revolution has led, in some cases, to the rapid evolution of microbial catabolic 
enzymes with novel catalytic functions. A hallmark example is the evolution of atrazine 
chlorohydrolase, a unique metal-dependent hydrolase that cleaves C-Cl bonds in triazine 
containing herbicides. Synthetic reagents can also be used in the laboratory for screening 
existing enzymes to discover synthetic catalytic functions. Our own work shows that only 
a few mutations can unlock substantial C=C cyclopropanation and C-H amination in 
naturally occurring cytochrome P450 enzymes. We invoke preadaptation to explain how 
some structures are poised for novel catalytic functions. We propose that a mechanism-
based approach, which requires only minimal knowledge of the mechanism of the target 
reaction and of structural features of the natural enzyme, can be used to engineer other 
abiological synthetically useful transformations into naturally occurring enzymes. 
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Using Evolutionary Design to Install Synthetic Activities in Existing Enzymes 
 It seems at first counterintuitive to use evolutionary approaches in attempting to 
create biocatalysts with wholly nonnatural functions. Since Darwinian evolution works 
by the incremental accumulation of beneficial mutations, how can this process be 
successful when the novel function has absolutely no natural precedence? Two 
requirements must be fulfilled for evolutionary methods to work: (i) the proposed novel 
reaction has to share mechanistic features with the existing wild-type function; and (ii) 
there must exist an evolutionary pathway for improving the novel activity (i.e., 
improvements can be reached by accumulating sequential amino acid mutations).   
Over the last twenty years, evidence has mounted that naturally occurring 
enzymes often exhibit measurable levels of “promiscuous” catalytic activity for 
nonnatural reactions. Examples of catalytic promiscuity have been found in 
environmental microbiology and in vitro biocatalysis. Rather than being a special 
property of a few enzymes, catalytic promiscuity is now widely established, and many 
recent advances in biocatalysis are based on this phenomenon.1 Searches for promiscuous 
enzymes are based on mechanistic hypotheses as to why the novel reaction may be 
catalyzed by a given enzyme.  
Whilst many enzymes will exhibit basal levels of promiscuous activity on a given 
nonnatural target reaction, some enzymes may be more preadapted for undergoing 
optimization for the novel function. That is, synthetically useful levels of activity and 
selectivity can be reached by just a few amino acid mutations from the wild-type enzyme. 
We evaluate the effects that influence preadaptation and illustrate how to choose natural 
enzymes as candidates for catalyzing synthetic bond disconnections  
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The Introduction of Synthetic Compounds in the Environment Drives the 
Evolution of Enzymes with Novel Catabolic Activities  
Melamine has been used since the early 20th century as a plastic component 
(Formica) and as a colorant. Melamine is a nonnatural compound and its persistency in 
the environment was described as non-biodegradable in the 1930s, slightly more 
biodegradable in the 1960s, and readily biodegradable in the 2000s.2 This increasing 
biodegradability is due to the evolution of melamine deaminase (TriA), an enzyme 
originally isolated from Pseudomonas sp. strain NRRL B-12227.3 TriA likely evolved 
from a pyrimidine deaminase,2 an enzyme that belongs to the aminohydrolase 
superfamily. Aminohydrolases share a common (αβ)8 barrel structure and the 
coordination sites for one or two divalent metals that serve to activate water for 
nucleophilic attack on the substrate.4 Pyrimidine deaminases typically catalyze the 
hydrolysis reaction shown in figure 1A. Deamination of melamine involves hydrolysis of 
an amine from the s-triazine ring (figure 1B), which is more activated than the pyrimidine 
ring toward nucleophilic aromatic substitution. Dense and diverse microbial populations 
and relatively low levels of nutrients in the soil make for strong selective pressure, 
favoring bacteria that can rapidly adapt to using alternative nutrient sources. Since 
melamine can be used as a source of nitrogen,3 positive selection can be expected for 
microbes that can catalyze the initial hydrolysis of melamine en route to cyanuric acid 
and ammonium. TriA catalyzes melamine deamination with a catalytic rate constant (kcat) 
of 4.1 s−1 and a Michaelis-Menten constant (KM) of 305 µM (kcat/KM = 1.3 x 104 s−1 M−1).5 
Atrazine was introduced in the late 1950s as a potent herbicide, and it is estimated 
that over 1 million tons have been applied globally. Until 1993 atrazine did not readily 
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degrade in the soil; however, rapid degradation has been reported from 1993 
onwards.2 Since 1993, various bacteria were ascertained to initiate atrazine catabolism 
via a chlorohydrolase (figure 1C). The genes encoding atrazine chlorohydrolase (AtzA, 
EC 3.8.1.8) from bacteria independently isolated from four continents have been shown 
to be essentially identical, suggesting recent evolution of AtzA (i.e., after the introduction 
of atrazine) and fast dissemination of this phenotype across the globe.6 AtzA from 
Pseudomonas sp ADP shares 98% amino acid sequence identity to TriA, the two 
enzymes differing by just nine out of 475 amino acids.7 The small number of amino acid 
substitutions, the lack of silent DNA mutations between the two genes, and the 
observation that AtzA and TriA can be found in the same bacterial species are all 
consistent with rapid evolution of AtzA from TriA due to an intense evolutionary 
pressure operating over a short time period.2, 7 Both melamine and atrazine contain the s-
triazine ring, but nucleophilic aromatic substitution for atrazine is expected to be more 
facile because chloride better stabilizes the anionic intermediate as well as being a better 
leaving group. TriA shows modest promiscuous atrazine chlorohydrolase activity (about 
two orders of magnitude lower than its deamination activity with comparable triazine 
substrates). Interestingly, AtzA shows no vestigial aminohydrolase activity on melamine 
(nor on an equivalent amine analogue of atrazine), and catalyzes atrazine dechlorination 
just as efficiently (kcat = 2.2 s-1, KM = 153 µM, kcat/KM = 1.5 x 104 s-1 M-1), thus showing a 
complete switch in reaction specificity.5  
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Figure 1: (A) The prototypical reaction for a pyrimidine aminohydrolase. (B) Melamine 
aminohydrolase (TriA) cleaves an s-triazine-NH2 bond. (C) Atrazine chlorohydrolase 
(AtzA) cleaves an s-triazine-Cl bond. (D) Evolution of TriA is based on substrate 
promiscuity since the novel and native reactions involve the same bond disconnection, 
whereas evolution of AtzA is a case of catalytic promiscuity as the novel reaction 
requires a bond disconnection that is different from the native reaction.  
 
The progression from pyrimidine to melamine to atrazine is an example of a 
substrate walk (figure 1D), whereby activity on a substrate of intermediate structural 
similarity (melamine) is first developed in order to create a catalyst that will show some 
promiscuous activity on the final target substrate (atrazine). Substrate walk approaches 
have been used with great success in directed evolution experiments in the laboratory.8 
The pyrimidine to atrazine walk is particularly interesting because it achieved not only a 
change of substrate (pyrimidine to triazine; i.e., substrate promiscuity) but also a change 
of reaction (cleavage of a C−N bond to cleavage of a C−Cl bond; i.e., catalytic 
promiscuity). Therefore a nonnatural reaction eventually emerged, whilst maintaining 
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similar mechanistic features to the native aminohydrolase activity. AtzA is a unique 
metal-dependent halohydrolase.2 Other hydrolytic dehalogenases are known in nature; 
but these use a carboxylate nucleophile instead of water activated by a divalent metal, 
and do not belong to the amidohydrolase superfamily. The catalytic promiscuity of AtzA 
has been further developed by directed evolution, which has expanded the substrate range 
of AtzA to include C−S and C−O bond cleavage.9 It can, therefore, be seen that very 
small changes in structure are sufficient to enable the emergence of novel catalytic 
function in homologous proteins with very high sequence similarity.  
There are several other cases where the introduction of a synthetic compound into 
the environment drives the evolution of a novel bacterial catabolic activity. For example, 
the dry cleaning solvent tetrachloroethene, once thought to be nonmetabolizable, can be 
decomposed by reductive dehalogenation (figure 2A), thus serving as the final electron 
acceptor in microbial anaerobic respiration occurring in contaminated sediments.10 
Tetrachloroethene reductive dehalogenase (EC 1.97.1.8) contains two 4Fe-4S clusters 
and a cobalamin.11 It is not clear if this dehalogenase evolved from an ancient reductive-
type enzyme scaffold, and what its natural substrate may have been.12 Anaerobic 
degradation of methyl aromatics involves benzylsuccinate synthase (EC 4.1.99.1), a 
glycyl radical carbon-carbon lyase, that formally catalyzes the hydroalkylation of 
fumarate with toluene, cresol, xylenes or methylnaphthalene (figure 2B).13 The 
organophosphate insecticide parathion is degraded by phosphotriesterase, which cleaves 
the phosphorous-oxygen bond shown in figure 2C.14 This enzyme belongs to the 
aminohydrolase superfamily together with TriA and AtzA; its natural substrate has not 
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been identified.14 It is also possible that phosphotriesterase evolved under selective 
pressure since the introduction of phosphotriester insecticides some decades ago.        
 
Figure 2: (A) Tetrachloroethene reductive dehalogenase catalyzes the reductive 
dechlorination of tetrachloroethene. AH2 is an unknown electron donor.	   (B) 
Benzylsuccinate synthase catalyzes the first step in the anaerobic degradation of toluene, 
which involves the formal hydroalkylation of fumarate. (C) Phosphotriesterase, a 
member of the aminohydrolase superfamily, catalyzes the hydrolysis of the 
phosphotriester insecticide parathion.  
 
Novel Enzymatic Activity can be Discovered by Screening Natural Enzymes Against 
Synthetic Reagents in the Laboratory   
Reaction promiscuity in enzymes is often the starting point for development of 
unnatural bond-making or bond-breaking catalysts. In this context, reaction promiscuity 
refers to the ability of enzymes to utilize functional groups not found in nature or else 
different from those present in its natural substrate. The products from transformations 
with synthetic or unnatural reagents can be quite different from the enzyme’s natural 
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product; however, both reactions often proceed via a common intermediate or share 
mechanistic similarities such as a deprotonation/nucleophilic addition sequence.  Many 
examples of reaction promiscuity exist in nature,1 such as the ability of some lipases to 
hydrolyze ester and amide bonds, but only bond connections that have no natural 
counterpart or involve unnatural functional groups will be discussed here.   
Hydroxynitrile lyases (HNLs) constitute a family of versatile enzymes that 
catalyze the reversible cleavage of α-hydroxy nitriles and are utilized for the production 
of enantiopure cyanohydrins from aldehydes or ketones and HCN.15 Based on the 
mechanism of this biotransformation,16 Purkarthofer et al. recognized that HCN could be 
replaced by other nucleophiles of similar size and acidity to HCN (pKa ~9).17 The 
nitroaldol (or the Henry) reaction is a synthetically useful carboligation process involving 
the addition of nitroalkanes to carbonyl compounds to furnish vicinal nitroalcohols. 
Addition of nitromethane to benzaldehyde in the presence of the hydroxynitrile lyase 
from Hevea brasiliensis gave 2-nitro-1-phenylethanol in 63% yield with an enantiomeric 
excess of 92% (figure 3A).17 This constituted the first example of a biocatalytic 
asymmetric nitroaldol reaction. Nitroalkanes are not common in nature. The enzyme also 
showed promiscuous activity for the addition of nitroethane to benzaldehyde, a reaction 
that generates two stereocenters simultaneously. The product mixture contained almost 
90% of the main product (1S,2R)-2-nitro-1-phenylpropanol with a diastereoselectivity of 
9:1 anti/syn ratio and an enantiomeric excess of 95% for the anti isomer.17  
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Figure 3: Native and promiscuous activities for (A) hydroxynitrile lyases; (B) halohydrin 
dehydrogenases; and (C) O-acetylserine sulfhydrylase.    
 
In nature, halohydrin dehalogenases (HHDHs) catalyze both the decomposition of 
chloro- and bromohydrins into epoxides.18  Due to the ability of Agrobacterium 
radiobacter HHDH strain AD1 to act on a variety of substrates and catalyze both epoxide 
formation and the microscopic reverse epoxide ring opening with nucleophile, Spelberg 
et al. posited that native enzyme may be used for styrene epoxide ring opening with 
azides.19  In contrast to halohydrins, the azido-alcohol product that would be formed from 
epoxide ring opening with azide is thermodynamically favored (Keq >33).  Reaction of 
the racemic styrene epoxide with Agrobacterium radiobacter AD1 yielded both the (S)-
styrene oxide and the (R)-azido alcohol in 95% combined yield and 96%-99% 
enantioselectivity (figure 3B).   Furthermore, in 2007, Codexis reported an engineered 
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variant of Agrobacterium radiobacter AD1 for the enantioselective synthesis of ethyl 
(R)-4-cyano-3-hydroxybutyrate, the starting material for commercial synthesis of 
atorvastatin (Lipitor), from (S)-4-chloro-3-hydroxybutyrate and sodium cyanide.20 The 
reaction proceeds through two HHDH-mediated steps: initial epoxide formation from the 
chlorohydrin, then subsequent epoxide opening by the cyanide nucleophile. After 18 
rounds of recombination-driven directed evolution using protein sequence-activity 
relationships, mutants were identified that provided an approximately 4,000-fold 
improvement in volumetric productivity compared to the wild-type enzyme. 
Another enzyme that has been found to react with a variety of synthetic 
nucleophiles is O-acetylserine sulfhydrylase, which catalyzes the biosynthesis of cysteine 
from serine and sulfide in nature (figure 3C).21  The enzyme facilitates the elimination of 
acetate from L-O-acetylserine to form an aminoacrylate intermediate that was found to be 
reactive toward nucleophiles such selenol, azide, hydroxylamine, and a few N-containing 
heterocycles in addition sulfide.  Discovery of these transformations has enabled in vivo 
synthesis of a variety of unnatural amino acids in 45%-91% yield. 
Members of the cytochrome P450 enzyme family catalyze myriad oxidative 
transformations involving different bond disconnections, including hydroxylation, 
epoxidation, oxidative ring coupling, oxidative decarboxylation, heteroatom release, and 
heteroatom oxygenation.22 Most transformations encompassed by this broad catalytic 
scope manifest the reactivity of the same high-valent iron-oxene intermediate, compound 
I (figure 4). We hypothesized that P450s could be engineered to catalyze the transfer of 
carbenes and nitrenes from diazoesters and azides, respectively, to C-H and C=C bonds, 
akin to the well-established isoelectronic oxene transfers from iodosylbenzene (figure 
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4A). Ethyl diazocarboxylate (EDA) is a commercially available and highly reactive 
carbene precursor that has been used to generate many transition metal carbenoids for 
cyclopropanation, and we hypothesized this synthetic starting material could be used to 
generate Fe-carbenoids for cyclopropanation.  When we combined EDA with wild-type 
BM3 and styrene alone, no reaction was observed.  However, addition of EDA to BM3 
and styrene in the presence of a reductant led to trace amounts of cyclopropanes (~20 
catalytic turnovers), suggesting that the reduced Fe(II)-heme could access a high 
oxidation state Fe-carbenoid intermediate.  From this starting point, directed evolution 
and site saturation mutagenesis provided variants that “traded” native monoxygenation 
activity for cyclopropanation activity and produced styrenyl cyclopropanes in excellent 
selectivity and high turnover.  Similarly, azides have been known to react with transition 
metal complexes to generate metal nitrenes that can then react with benzylic C-H bonds.  
When wild type BM3 was combined with a benzylsulfonyl azide and a reductant, the 
nitrene insertion product was observed, albeit with 2 total turnovers.  Again, optimization 
of this promiscuous activity yielded variants that could catalyze C-H insertion in good 
yield and selectivity. By exploiting the ability of P450 to accommodate high oxidation 
state iron complexes and identifying analogous relationship of metal-carbenes, metal-
nitrenes and metal-oxenes, we were able to adapt P450 for reaction with synthetic, 
bioorthogonal reagents.  Studies to elucidate the reactive intermediates and catalyst 
resting state in these pathways are ongoing. While the formation of the cyclopropane and 
nitrene C-H insertion products do not preclude the possibility that the reactions proceed 
through mechanisms that do not involve Fe-carbenoid and Fe-nitrenoid complexes, 
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analysis of P450 reaction promiscuity nonetheless led to discovery of two novel 
enzyme-mediated bond connections. 
 
Figure 4: (A) Carbene, nitrene and oxene transfer reagents are isoelectronic. (B) Putative 
intermediates for carbene and nitrene transfers are not isoelctronic to compound I.  
 
Preadaptation   
 Simply put, the principle of preadaptation asserts that a structure can change its 
function radically without altering its form as much.23 Evolutionary biologists use 
preadaptation to address the question: how can selection act on a structure before that 
structure has appeared? That is, how can a structure be selected for before it has acquired 
selective value? For example, preadaptation is often invoked to explain the evolution of 
“perfect” organs by devising adaptive significance for the incipient stages in their 
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development. The question  “what use would 5% of an eye be?” is avoided by 
arguing that the possessor of such an incipient structure did not use it for sight.   
 Biologists use preadaptation to rationalize events in historical time. For instance, 
given the present observation of complex organs, they try to recreate intermediate stages 
that use elements of such structure for different functions. We would like to use concepts 
from preadaptation to engineer synthetic catalytic functions in natural enzymes. Given 
our knowledge of the structure of existing enzymes, can we predict which structures 
would be more suitable or preadapted for the desired novel function? In Biology, 
structures are fortuitously preadapted for new functions because the organism is ignorant 
of future environmental changes. In the lab, however, we can equate environmental 
changes to the introduction of synthetic reagents, which we have complete control of. We 
define a novel function here as the catalysis of a nonnatural bond disconnection that 
results from changes in the amino acid sequence of the enzyme. We illustrate this 
approach using olefin cyclopropanation by cytochrome P450s as an example. 
 Cytochrome c (cyt c), myoglobin (Mb), horseradish peroxidase (HRP), and 
cytochrome P450BM3 all show basal levels (<50 TTNs) of promiscuous catalytic activity 
for olefin cyclopropanation because they all share the heme cofactor, which is also a 
cyclopropanation catalyst on its own (note that other heme enzymes, such as catalase and 
chloroperoxidase, do not catalyze olefin cyclopropanation).24 A single mutant of P450BM3 
(T268A) is able to make hundreds of turnovers of cyclopropananes with 96% 
enantioselectivity and 99% diastereoselectivity for the trans isomer. Are there single 
mutants of the other heme proteins (cyt c, Mb and HRP) that will also efficiently and 
selectively catalyze olefin cyclopropanation? That is, are all promiscuous enzymes 
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equally preadapted for the new function? We argue that the answer is no because the 
native function of those proteins never required them to evolve the ability to catalyze 
asymmetric chemical transformations. 
 Clearly, there are other preexisting elements in BM3-T268A, apart from Ala268, 
that enable the high performance of this catalyst. These preexisting elements evolved 
under selection for the native function, fatty acid monooxygenation, but also happen to be 
useful for olefin cyclopropanation. BM3 monooxygenations are known to be 
stereoselective, and so its uniquely buried active site is endowed with the capability to 
induce asymmetry for both oxene and carbene transfer reactions. Furthermore, axial 
cysteine to serine substitution (BM3-C400S, which we call ABC) enables thousands of 
NADH-driven cyclopropanation turnovers, whilst abolishing the native monooxygenation 
activity. This is similar to the evolution of TriA from AtzA, but in the P450 case a single 
mutation achieves specialization to the new function. An outside observer without 
knowledge of TriA or BM3 would not be able to recreate evolutionary trajectories for 
AtzA and ABC because the intermediates would be virtually nonfunctional for the 
ultimate chlorohydrolase or olefin cyclopropanation activities. The evolution of AtzA and 
ABC is possible because the intermediates were used for a different function (i.e., 
pyrimidine-NH2 hydrolysis for AtzA and C-H monoooxygenation for ABC). Structural 
features that were selected for the old function were then fortuitously adapted for the new 
synthetic function.  
 Let us now reverse the order of this argument. Given TriA, BM3, atrazine, and 
diazoesters. could we have engineered AtzA and ABC? The reason why the answer to 
this question is yes is because the synthetic activities (chlorohydrolase and C=C 
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cyclopropanation) share mechanistic similarities with the native activities (vide 
supra). It is important to realize that a detailed knowledge of the structure of TriA, BM3 
or of the intricate details of the mechanism of the target reactions are not necessary for 
choosing TriA and BM3 as starting points for directed evolution projects. All that is 
required is the formulation of a basic hypothesis based on a simplified view of the target 
mechanism, as shown in figure 5 for carbene transfers. We see that by following the 
mechanism-based approach, we would hypothesize that any enzyme that evolved for 
catalyzing oxene transfers are likely to be preadapted for carbene transfers. Shortlisted 
natural enzymes would include cytochrome P450, α-ketoglutarate dependent 
monooxygenase, diiron monooxygenases, and dicopper monooxygenases. Knowledge 
about the cofactor composition of the active site of these enzymes is not required to 
arrive at this short list. Variants of these enzymes can then be screened against 
diazoesters and olefins to find those suitable for the target reaction. The alternative 
structure-based approach (figure 5) is somewhat more limited because there is often only 
a small overlap between the structure of cofactors used in nature and those used in 
synthetic chemistry. We believe it is more fruitful to focus on the bond disconnections 
involved in the reaction and the necessary mechanistic features that the candidate enzyme 
must have to enable the new function.  
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Figure 5: Mechanism and structure based approaches for finding natural enzymes that can 
be adapted for synthetic reactions. α-KG (α-ketoglutarate); CPO (chloroperoxidase).   
 
 The alternative strategies for creating enzymes with synthetic catalytic functions, 
namely computational design and protein-bound transition metal catalysts, were reviewed 
in the end of chapter 1. Computational design requires a detailed understanding of the 
mechanism of the target reaction and has thus far not been applied for transition-metal 
catalyzed transformations. In protein-bound transition metal catalysts, the new chemical 
capabilities are all enabled by the abiological organometallic cofactor. While the 
approach is highly modular, tethering of the cofactor has only been reported in vitro, and 
it is not clear if the platform could enable in vivo catalysis. The comparative advantages 
of the approach outlined here are that by using existing enzymes one retains several 
features that are desirable for both in vitro and in vivo catalysis such as thermostability 
and functional expression in vivo without the addition of exogenous cofactors. 
Accordingly, the ABC catalyst described in chapter 3 is the first report of efficient 
catalysis of a synthetic bond disconnection in vivo.  
. 
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